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Abstract 
To enter cells, HIV utilises the envelope (Env) protein to engage the CD4 
receptor and a co-receptor, CXCR4 or CCR5. In addition to its role in HIV entry, 
the Env protein also triggers intracellular signalling events. Expression of the HIV-
1 and HIV-2 Env gp41 cytoplasmic tails triggered a significant decrease in 
microtubule acetylation at the single cell level. Since microtubule stability is 
controlled by Rac1, the role of Rac1 in HIV-1 infection was investigated. 
Treatment of TZM-bl cells with a Rac1 inhibitor that blocks its upstream 
activators, Tiam1 and TrioN, inhibited HIV-1 NL4.3 (X4-tropic) but not HIV-1 BaL 
(R5-tropic) suggesting a role for these activators which is possibly, co-receptor 
dependent. Subsequently, an siRNA screen including 145 upstream regulators of 
Rac1, cdc42 and RhoA were investigated in their role in HIV-1 NL4.3 and HIV-1 
BaL infection. As a result, 39 upstream regulators of Rho-GTPases were 
identified of which 5 proteins had effects on both HIV-1 BaL and HIV-1 NL4.3 
infection which suggests a novel role of Rho-GTPase upstream regulators in HIV-
1 infection. Early in infection, HIV-1 also encounters restriction factors such as 
RNA polymerase II-Associated Factor 1 (PAF1). The possible cytoplasmic or 
nuclear role of PAF1 in HIV-1 infection was investigated. Confocal imaging and 
cellular fractionation suggested that endogenous PAF1 is localised mostly in the 
nuclei but also in the cytoplasm.  Overexpression of a murine PAF1 cytoplasm-
localised mutant decreased HIV-1 infection similarly to wild-type overexpression. 
On the other hand, overexpression of a nuclear PAF1 construct decreased 
infection better than the wild-type. This suggests that PAF1 restricts HIV-1 via a 
nuclear function. In addition, infection time-course experiments revealed that HIV-
1 counteracts the effect of PAF1 within 30 minutes of infection. Overall, the 
evidence presented, suggests that PAF1 has a nuclear mechanism and that its 
downregulation could take place in the cytoplasm.  
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1. Introduction 
 
This thesis describes new evidence on the signaling pathways triggered by 
Human Immunodeficiency Virus 1 (HIV-1) envelope (Env) (chapter 3 and 4) and 
on the possible mechanism of RNA Polymerase II-Associated Factor 1 complex 
(PAF1c) restriction factor in HIV-1 infection (chapter 5).  
1.1 Viral taxonomy 
Since Dimitri Ivanovsky, one of the founders of virology, described an infectious 
agent that was smaller than bacteria, the Tobacco Mosaic Virus, our knowledge 
on viruses has widely broadened [1]. For instance, virus classification can be 
performed according to the nucleic acid as defined by Nobel prize-winner 
biologist, David Baltimore. Baltimore classification comprises seven groups which 
include: double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), double-
stranded RNA (dsRNA), positive single-stranded RNA ((+)ssRNA), negative 
single-stranded RNA ((-) ssRNA), single-stranded reverse transcribing (ssRNA-
RT)  and double-stranded reverse transcribing (dsDNA-RT) viruses (Table 1.1) 
[2, 3].  According to the Baltimore classification, retroviruses belong to group six 
of single-stranded RNA-reverse transcribing viruses because their genome 
consists of two copies of single- stranded RNA which is reverse transcribed [3]. 
Group Nucleic acid type Examples 
I dsDNA Adenoviruses, 
Herpesviruses, Poxviruses 
II ssDNA Parvoviruses 
III dsRNA Reoviruses 
IV (+)ssRNA Picornaviruses 
V (-) ssRNA Orthomyxoviruses, 
Rhabdoviruses 
VI ssRNA-RT Retroviruses 
VII dsDNA-RT Hepadnaviruses 
 
Table 1.1. Baltimore classification of viruses according to viral nucleic acid. Viruses 
can have dsDNA, ssDNA, dsRNA, (+)ssRNA, (-) ssRNA, ssRNA-RT and dsDNA-RT. 
Nucleic acid type dictates the replication mechanism by which viruses amplify their 
genome to produce novel virus progeny. Adapted from Sharma et al., [4] 
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1.2 Retroviruses 
This thesis describes studies on HIV-1 which is a retrovirus. According to the 
International Committee on Taxonomy of Viruses (ICTV), retroviruses are part of 
the Retroviridae family which includes the subfamilies of Orthoretrovirinae and 
Spumavinirae [5]. The Orthoretrovirinae subfamily is divided into six genera 
which include: Alpharetrovirus, Betaretrovirus, Deltaretrovirus, Epsilonretrovirus, 
Gammaretrovirus and Lentivirus (Table 1.2) [5]. The first five genera fall into the 
classification of oncoviruses which further divide morphologically into B-, C- and 
D-type particles [6]. The Spumaretrovirinae subfamily is divided into the 
Spumavirus genus [5]. All viruses from the Retroviridae family share in common a 
single-stranded RNA genome which is reverse transcribed by the virally-encoded 
reverse transcriptase enzyme and then, integrated into the host’s genome. 
However, their genomes vary in complexity. For instance, Alpharetrovirus, 
Betaretrovirus, Epsilonretrovirus and Gammaretroviruses have a simple genome 
which is composed of three major coding domains: gag (for group-specific 
antigen, encodes capsid (CA), nucleocapsid (NC) and matrix (MA), pol (for 
polymerase, encodes reverse transcriptase (RT), protease (PR) and integrase 
(IN) enzymes) and env (which encodes the viral surface and transmembrane Env 
glycoproteins) [6, 7]. On the other hand, complex retroviruses such as 
Lentiviruses, Spumaviruses and Deltaretroviruses additionally encode a series of 
accessory proteins which are multiply spliced [6-8].  
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Genera Examples Genome type 
Alpharetrovirus Avian leukosis virus 
Rous sarcoma virus 
Simple 
Betaretrovirus Mouse mammary tumour virus 
Mazon-Pfizer monkey virus 
Simple 
Deltaretrovirus Human T-Lymphotropic virus 
Bovine leukaemia virus 
Complex 
Epsilonretrovirus Walladee dermal sarcoma virus Simple 
Gammaretrovirus Murine leukaemia virus 
Feline leukaemia virus 
Simple 
Lentivirus Human immunodeficiency virus 1 
Human immunodeficiency virus 2 
Simian immunodeficiency virus 
Equine infectious anemia virus 
Feline immunodeficiency virus 
Complex 
Spumavirus Human foamy virus Complex 
  
Table 1.2. Classification of retroviruses by genera and genome type. Simple 
retroviruses have gag, pol and env genes which encode matrix, capsid, nucleoprotein, 
integrase, protease, reverse transcriptase and Env proteins. Complex retroviruses 
additionally have regulatory proteins that enhance their infection and replication abilities. 
Adapted from Fields Virology [9].  
 
Within the Retroviridae family of viruses and Orthoretrovinae subfamily, HIV-1 is 
part of the Lentivirus genera. HIV-1 is further classified into four lineages: group 
M (main), group O (outlier), group N (non M/non O) and group P. These four 
lineages are a result of four cross-species transmission events, being M the most 
prevalent [10]; the M lineage is further divided into 9 subtypes or clades (A,B, C, 
D, F, G, H, J and K) [11]. Similarly, HIV-2 is also subclassified into groups A-H 
[10]. Even though HIV is the best known retrovirus as the causative agent of 
Acquired Immunodeficiency Syndrome (AIDS) in humans, retroviruses can infect 
many other species such as monkeys, fish, and cats [12, 13]. Retroviruses have 
an important economic and agricultural impact causing for example 
leukoencephalomyelitis in goats or leukosis in chickens [6, 14, 15].   
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1.3 Discovery and origin of Human Immunodeficiency Virus  
HIV was first isolated by two independent teams lead by Luc Montagnier’s and 
Robert Gallo [16, 17]. Both teams described a novel retrovirus with great 
similarity in shape to human T-lymphotropic virus (HTLV) which was later 
confirmed as the causative agent of AIDS [18]. HIV-1 arose from cross-species 
transmission events from a chimpanzee SIV in Southeastern Cameroon and HIV-
2 from Sooty Mangabey [19, 20], suggesting that AIDS had resulted from inter-
species infections with related lentiviruses [10]. Exactly how the zoonosis 
emerged is unknown but several studies suggest that it could have been through 
hunters being exposed to ape blood in the context of bush meat hunting [21]. A 
recently published evolutionary study suggests that the HIV epidemic originated 
in the 1920s in Kinshasha, Democratic Republic of Congo, reaching south cities, 
Lubumbashi and Mbuji-Mayi in the late 1930s. Interestingly, the authors believe 
that it was not until 1960s that AIDS started to spread in the general African 
population far from the local initial hotspots due to migration changes triggered as 
a consequence of the Congo Republic independence.  
1.3.1 Genetic variability and epidemiology  
HIV-1 presents extensive genetic diversity for four reasons. Firstly, the HIV 
genome has high replication rates which result in 109 virions produced per day in 
an infected individual [22]. Secondly, reverse transcriptase is highly error-prone 
because it lacks proofreading mechanisms (unlike other DNA polymerases); the 
reverse transcription mutation rate has been estimated to be 1-10 errors per 
replication cycle [23]. The HIV-1 genome undergoes recombination events which 
also contribute to a wide genetic variability [24]. These recombination events give 
rise to genetic forms of the virus known as Circulating Recombinant Forms 
(CRFs) which arise from single patients infected with multiple subtypes [25].  
Additionally, the host immune pressure also plays a role in the high rate of 
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mutation that causes the wide genetic variability of HIV-1 [26].  Altogether this 
gives rise to virus quasispecies which present different phenotypes and antigenic 
responses within an infected person [22, 27]. Mutations that are beneficial for the 
virus under specific environmental pressures are termed escape mutants since 
they are resistant to immune and antiretroviral suppression [28].  
Whilst in sub-Saharan Africa nearly all subtypes of HIV-1 are present, the pattern 
of HIV-1 infection is more specific worldwide [29]. The most prevalent group of 
HIV-1 worldwide is the M or main group which is further divided into clades A,B, 
C, D, F, G, H, J and K [11] . Most HIV-1 infections worldwide belong to clades A, 
B and C; for instance, clade C alone accounts for at least 50% of the cases [25]. 
Clade A HIV-1 infections concentrate mostly in eastern Europe and countries in 
central and eastern Africa [25]. Subtype B is most prevalent in USA, Australia, 
central and western Europe; this form is also prevalent in some Southeast Asian 
countries, Northern Africa and the Middle East. Clade C HIV-1 infection 
concentrate in India and Southern Africa [25]. In Senegal, Guinea Bissau, Ivory 
Coast, Burkina Faso, Ghana and Gambia, HIV-2 is prevalent and within the 9 
HIV-2 clades, clade A is the most predominant [30].  
1.4 Clinical aspects of HIV infection 
1.4.1 HIV transmission 
Report of the first cases of AIDS in the USA were found to be clustered in male 
homosexual that had had high-risk sexual encounters, intravenous drug users or 
within hemophiliac populations which suggested that AIDS was a blood-
transmitted disease that is transmitted horizontally [31].  The link between HIV 
and AIDS caused public interventions by which blood banks were screened to 
prevent further infections through blood-transfusions. HIV-antibody screening 
decreased the incidence from 1 in 1000 infected units to 1 in 40000 infected units 
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at high risk areas [31, 32].  Apart from being transmitted horizontally from cell-
free virus or cell-associated [33], HIV can be transmitted vertically from mother to 
child [6]. Vertical transmission of HIV can occur in utero, post-natally through 
breast-feeding and during birth, the latter being the most common mode of 
vertical transmission [34]. Vertical transmission in utero can be reduced by 
treatment of the mother with antiretrovirals to reduce viral load [35]. In addition, 
discouragement of breast-feeding and recommendation of cesarean section 
during birth have also contributed to decrease the chances of vertical 
transmission [36].   
1.4.2 Clinical manifestations of AIDS 
Between 1980 and 1981, five patients in Los Angeles were treated for 
Pneumocistis carinii and had Cytomegalovirus infection and Candida mucosal 
infection [37]. Three out of five patients had low T-cell numbers. The others were 
not tested. This was the first documentation of patients with what was later 
defined as AIDS.  
The World Health Organization (WHO) has defined four clinical stages: 
asymptomatic, mild, advanced and severe which are symptomatically well-
defined [38]:  
 The initial asymptomatic period which varies in time is characterized by 
the absence of symptoms but enlarged lymph nodes. 
 The mild stage of infection is characterized by diarrhoea, recurrent 
respiratory upper tract infections, herpes zoster, recurrent oral ulceration, 
dermatitis, fungal nail infections, weight loss and fever.  
 The advanced stage is defined by recurring weight loss, chronic diarrhea 
episodes that last longer than a month, oral candidiasis, pulmonary 
tuberculosis, severe bacterial infection (pneumonia, meningitis, bone or 
joint infection bacteraemia), acute necrotizing ulcerative gingivitis or 
periodontitis, unexplained anemia (decrease in red blood cells), 
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neutropenia (low number of neutrophils) or chronic thrombocytopenia 
(decrease of platelet numbers).  
 The severe stage is defined by an HIV wasting syndrome (constant loss 
of weight), recurrent bacterial pneumonia, chronic herpes simplex virus 
infection, oesophagial candidiasis, extrapulmonary tuberculosis, Kaposi 
sarcoma, Cytomegalovirus infection, HIV encephalopathy, mycosis, 
septicaemia, cardiopathies, and invasive cervical carcinoma.  
The common laboratory markers that are used to estimate patient prognosis 
include depletion of cluster of differentiation 4 (CD4)+ T-lymphocyte (T-cell) counts 
[39], elevated serum b2-microglobulin which marks immune activation [40] and 
neopterin (a catalytic product of GTP which marks immune activation) [41].  
1.5 Cell tropism 
HIV infects cells from both the innate and the adaptive immune system. The fastest 
immune response, the innate immunity, comprises: macrophages, dendritic cells, 
mast cells, natural killer cells, basophils, eosinophils, neutrophils and granulocytes 
[42]. The slowest immune response, the adaptive immunity is comprised by B cells, 
T cells (CD4+ T-cells and cluster of differentiation 8 (CD8)+ T-cells) and γδ-T 
cells[42]. HIV is able to infect cells that express CD4 [43] and either C-C chemokine 
receptor type 5 (CCR5) [44, 45] or CXC-chemokine receptor type 4 (CXCR4) [46] 
because these are the main entry receptors to which HIV binds in order to access 
the cell [47]. These includes T-cells, macrophages and dendritic cells [48]. Whilst in 
T-cells and macrophages, it is able to productively infect cells, in dendritic cells the 
current consensus is that they are the initial cells that transfer HIV from the mucosal 
barriers to T-cells in lymph nodes [49].  Since these cell types are at the center of 
the innate and adaptive immune responses, an HIV-infected patient is no longer 
able to fight opportunistic infections giving rise to AIDS.  
Apart from immune cells, HIV-1 is also able to infect cells from other tissues. For 
instance, HIV-1 crosses the blood-brain barrier and infects microglia and 
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perivascular macrophages [50]. This is why HIV-1 patients present cognitive 
impairment which can range in severity from mild to severe [51]. 
1.6 The HIV-1 genome  
Two copies of positive sense unspliced single-stranded and non-covalently linked 
RNAs are found in the viral particles of HIV-1 [52]. They are identical and they are 
able to dimerise through their dimer initiation sites [53].  As shown in figure 1.1A, 
the HIV-1 genome encodes the gag, pol (for polymerase) and env (for envelope) 
genes. The gag polyprotein, also referred to as pr55Gag, due to its total molecular 
weight, is cleaved by protease (PR) to give rise to MA (p17), CA (p24), NC (p7) and 
p6 [54]. The pol gene is synthesized during a rare frameshifting event from 
p160GagPol which encodes the viral enzymes: RT (p51), RNAse H (p15) and INT 
(p31) [55]. Each individual enzyme is cleaved from p160GagPol by PR [56]. Similarly 
the env gene is synthesized as a polyprotein precursor (gp160) which once 
synthesized, is cleaved by the viral PR to produce, gp120 and g41, the two 
components of the viral Env protein [56].  
In addition to env, gag and pol genes, HIV also synthesizes a range of accessory 
proteins which allow HIV to replicate more efficiently. For instance, Tat (for 
transactivator of transcription) increases RNA synthesis rate from the 5’ Long 
terminal repeat (LTR) HIV-1 promoter; tat is synthesized as a two exon RNA [57, 
58].  Rev is also synthesized as a two exon RNA and is required for transport of 
unspliced and partially spliced viral RNAs out of the nuclei into the cytoplasm [59]. 
These RNA species have specific packaging signals which, together with the other 
protein components, allow them to be packaged  efficiently into infectious viral 
particles [60]. In addition, Nef (for negative factor) plays a wide range of functions 
which enhance viral infectivity: 1) it downregulates CD4 surface expression which in 
turn allows HIV to be released from the membrane upon assembly [61], 2) it 
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downregulates major histocompatibility class I proteins (MHC-I) from the cell 
surface [62] and 3) activates signaling pathways [63-65]. Vpr (for viral protein R) is 
a multifunction protein which not only contributes to transport of the preintegration 
complex to the nuclei but is also a co-activator of Tat-mediated transcription and 
exerts G2-cycle arrest [66]. HIV-2 strains lack Vpr but encode Vpx which is 
genetically similar to Vpr [67]. Vpx is packaged into virions and upon release, it 
downregulates SAMHD1, a restriction factor that downregulates the pool of dNTPs 
required for DNA synthesis during reverse transcription. Vpx also contributes to 
nuclear import of the preintegration complex. Vpu (for Viral Protein Unique) is also 
a multifunctional protein that is synthesized from a Rev-dependent bicistronic 
mRNA molecule that also encodes env [68]. Vpu degrades CD4+ in the 
endoplasmic degradation to facilitate release of virion particles and additionally 
degrades tetherin, a cellular protein that anchors exiting virion particles, to avoid 
release of new particles [68, 69]. In addition, viral infectivity factor (vif)-mutant HIV 
strains were shown to have low infectivity rates [70, 71]. It was later shown that Vif 
antagonizes the human cytidine deaminase, apolipoprotein B mRNA-editing 
enzyme, catalytic polypeptide-like 3G (APOBEC3G) to overcome its antiviral 
function [72]. As shown by Stopak et al., Vif physically interacts with APOBEC3G. 
Vif forms a Vif-CBF-β-ElonginB-ElonginC-Cullin5-Rbx (Vif-CBF-β-EloB-EloC-Cul5-
Rbx) E3 complex which tethers APOBEC3G resulting in proteasomal degradation 
[73]. 
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Figure 1.1 The HIV-1 genome and viral proteins. (A) Schematic representation of the 
HIV-1 genome. The HIV genome is 9,7 Kbp in length and the relative locations of each open 
reading frames are described. The gag gene comprises MA (p17), CA (p24), NC (p7) and 
p6. The pol gene comprises RT (p51), RNAse H (p15) and IN (p31). The env gene 
comprises gp120 and g41, the two components of viral Env protein. (B) Schematic 
representation of the HIV-1 viral particle. Each HIV-1 viral particle has a viral membrane 
lined with matrix protein. Inside the matrix protein is the capsid protein which contains the 
viral RNA genomes associated with nucleocapsid, integrase, protease and reverse 
transcriptase. Adapted from Freed O., [56].  
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1.7 HIV-1 replication cycle 
 
Initially, HIV enters the cells by engaging the CD4 [43] receptor and either 
CXCR4 [46] or CCR5 [44, 45]. This engagements trigger fusion with the cell 
membrane (Figure 1.2) [74, 75]. Alternatively, HIV is also able to enter cells via 
clathrin-mediated endocytosis though this entry route has been lessl 
characterized [76]. Clustering of receptors/co-receptors at the plasma membrane 
is a crucial step to trigger membrane fusion upon Env binding, and for that 
instance, HIV utilizes actin cytoskeleton [77]. This process also involves filamin, 
an actin-binding protein which links the CD4+ receptor cytoplasmic tails to actin 
[78, 79]. After receptor binding, HIV has to overcome the cortical-actin barrier and 
to do so, HIV has been shown to upregulate cofilin, a cellular protein which 
severes actin filaments [80]. Reverse transcriptase then transcribes the positive, 
single-stranded RNA molecule to a double-stranded DNA molecule [81]. The 
double-stranded DNA molecule is then transported to the nuclei as part of the 
preintegration complex; the pre-integration complex is composed  of viral DNA, 
MA, RT, Vpr , nucleocapsid and protease [82]. In the nuclei, the double-stranded 
viral DNA integrates in the hosts’ genome. Transcription produces a mix of 
partially spliced and unspliced RNA species which are transported into the 
cytoplasm by the viral protein Rev [56]. The polyprotein precursors, Gag and 
Gag-Pol are synthesized and packaged into the virions, where they are cleaved 
by PR shortly after or during virus release from the plasma membrane giving rise 
to their encoded mature proteins [56]. In addition, at the plasma membrane, the 
RNA viral genomes are packaged into new particles which bud out of the cells 
[83].  
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Figure 1.2 HIV-1 replication cycle. Schematic representation of HIV-1 infection. HIV 
fuses with cells via CD4 and CXCR4 or CCR5 co-receptor engagement and/or clathrin-
mediated endocytosis. Once in the cell, CA uncoats to release the viral genome. The viral 
genome is then reverse transcribed to give rise to double-stranded DNA. This DNA is 
integrated in the cell’s genome where it is transcribed. With the aid of Rev, the partially 
spliced and spliced RNA species are imported to the cytoplasm. Unspliced RNAs are 
packaged into viral particles after protein synthesis of viral components. At the plasma 
membrane, new viral particles are assembled which then bud out of the cell, ready to 
infect new cells. Adapted from Frankel,  [84]. 
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1.7.1. HIV entry and receptor engagement 
HIV enters the target cell via plasma membrane fusion and/or clathrin-mediated 
endocytosis mediated by receptor/co-receptor binding of viral Env [76].  To enter 
cells gp120, a component of the Env glycoprotein, must interact with CD4 [43]. 
The Env glycoprotein also binds to a secondary  co-receptor, CXC-chemokine 
receptor-4 (CXCR4) [46] or CC-chemokine receptor-5 (CCR5)) [44, 45, 48]. HIV-
1 strains that enter via CXCR4 are named X4-tropic whilst HIV-1 strains that 
enter via CCR5 are termed R5-tropic.  In addition to viral entry, engagement of 
Env to cellular receptors also induces signaling events which are the subject of 
chapter 3 and 4. The importance of the co-receptor for HIV-1 infection is 
highlighted by the findings that patients with mutant CCR5 alleles are resistant to 
infection [85].  
The HIV Env protein is a multimeric protein that consists of two components: 
gp120 and gp41, which form homotrimers that are non-covalently associated to 
form heterodimers that can be visualized by electron microscopy as spikes 
(Figure 1.3) [86, 87]. HIV gp120 has five conserved (C1-C5) regions which form 
the core of the protein and interact with gp41 [88].  The constant domains are 
interspersed with five highly glycosylated variable protein domains (V1-V5) which 
lie at the surface of the protein [89]. The third variable loop (V3) determines co-
receptor usage [47]. In its native or pre-fusion state, HIV gp41 has three domains: 
an external, a transmembrane and an intracellular domain. The extracellular or 
ectodomain has three marked regions, two heptad repeats located next to the C- 
and N-terminal regions of the extracellular domain and a fusion peptide located at 
the N-terminus [90]. Binding of HIV gp120 to the target cell’s CD4 causes a 
conformational change in gp120 that enable it’s binding to the co-receptor [91].  
This double interaction exposes the gp41 fusion peptide and triggers a series of 
conformational changes which result in the formation of a gp41 pre-hairpin 
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intermediate that anchors the virus membrane to the cell membrane [92]. These 
conformational changes generate a highly thermostable gp41 conformation which 
is thought to trigger the fusion event between viral and cellular membranes [93]. 
 
 
 
 
 
Figure 1.3. HIV fusion. A. HIV attachment to the cell membrane. HIV anchors the Env 
protein (composed of gp120 and gp41) to the primary receptor, CD4+, and a co-receptor, 
CXCR4 or CCR5. B. Co-receptor engagement. Attachment of the Env protein triggers a 
conformational change in the gp41 portion of the Env protein which brings into close 
proximity the viral and cellular membranes. C. Fusion. The viral and cellular membranes 
fuse to release the viral genome into the cell’s cytoplasm, initiating the replication cycle. 
Adapted from Tomkowicz et al., [94].  
 
After receptor/co-receptor engagement, the viral core is released into the 
cytoplasm. The viral core is composed of the CA protein which encases the viral 
genome and associated proteins including reverse transcriptase, nucleocapsid 
and integrase [95]. Following release into the cytoplasm, the CA protein 
disassembles in a multistep process which requires host factors such as 
cyclophillin A, a peptidyl propyl isomerase [96, 97]. Lack of detection of CA in 
preintegration complexes and reverse transcription complexes initially suggested 
that uncoating takes place prior to or during reverse transcription [95]. However, 
28 
 
more recent in vivo imaging studies suggest that CA uncoating is coupled to 
reverse transcription [98, 99]. 
1.7.2 Reverse transcription 
Reverse transcription of a single-stranded RNA molecule into a double-stranded 
DNA molecule is a unique feature of retroviruses and hepadnaviruses [100]. The 
process of reverse transcription is catalyzed by virally-encoded RT and takes 
place in several steps which involves viral RNA cis-acting sequences; namely 
primer binding site (PBS), short regions of homology or R sequences, polypurine 
tract (PPT), the central termination sequence (CTS) and U3/U5 sequences 
(Figure 1.4) [56]. The U3, R and U5 sequences are part of the 5’/3’ LTR HIV-1 
promoter which binds to Tat to initiate transcription of DNA into RNA after 
integration [56].  
Reverse transcription is a multistep process (Figure 1.4) [56, 95, 101]: 
1. Initiation of reverse transcription takes place by binding of a tRNA to the 5’ 
PBS site. DNA synthesis starts from 3’ and results in the generation of a 
DNA/RNA hybrid. 
2. The RNA fragment of the generated hybrid is degraded by virally-encoded 
RNase H which is part of the RT enzyme. The resulting DNA fragment is 
referred to as the minus-strand strong stop DNA.  
3. The minus-strand strong stop DNA “jumps” from the 5’ end to the 3’ ends 
using the R sequences and this constitutes the first strand transfer.  
4. The minus-strand strong stop DNA serves as a primer for DNA synthesis 
from 3’. 
5. DNA synthesis takes places from other sites including the central PPT 
site, this generates the plus-strand DNA fragment. 
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6. Once PPT-initiated DNA synthesis stops, the tRNA is removed by RNAse 
H giving rise to the plus-strand strong stop product. 
7. Generation of the plus-strand strong stop product allows a second jump to 
take place by annealing to the PBS on the minus-strand DNA. DNA 
synthesis continues. 
8. After generation of the plus-strand strong stop, DNA synthesis continues. 
9. The RT then synthesizes from the PBS and PPT sites. Repair and ligation 
of the generated circular intermediate results in a linear DNA duplex 
which has 5’/3’ LTRs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Reverse transcription of the HIV genome. Reverse transcription is a 
multistep process which involves: 1) Binding of a molecule of tRNA to the PBS. 2) 
Negative strand DNA initiation and elongation. 3) First strand transfer or “jump”, negative 
strand elongation and degradation of positive RNA strand. 4) Positive strand DNA 
initiation and elongation. 5) Additional positive strand initiation and elongation from 
central PPT. 6) Strand synthesis. 7) Removal of RNA primers. 8) Second strand transfer 
or “jump”. 9) Strand displacement and/or repair and ligation to produce a linear double 
DNA molecule. Adapted from Sarafianos et al., [101].  
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1.7.3 Integration 
Following reverse transcription, the reverse transcription complex (RTC) 
composed of the double-stranded DNA viral genome, NC, IN, Vpr and MA, is 
imported into the host’s nucleus [102]. Various proteins involved in cellular import 
pathways have been linked to nuclear import of the RTC including importin 7 
[102],  karyopherin α2 Rch1 [103],  transportin SR-2 [104] and nucleoporins 
Nup98 [105], Nup358/RANBP2, and Nup153 [106]. In addition, MA, Vpr and IN 
have nuclear localization signals (NLS) [102]. The elements involved in nuclear 
import of the RTC are numerous although the exact mechanism is still not clear.  
Once in the nucleus the IN enzyme catalyses integration of the viral genome into 
a cell’s chromosome. IN has two catalytic activities: a 3’ processing activity and a 
DNA strand transfer activity [81]. Using the 3’ processing activity, IN cleaves the 
ends of the LTRs of both viral DNA strands using water a nucleophile [107]. The 
3’ resulting hydroxyl groups are then used by IN to cut and join the viral DNA 
strands to the opposing host DNA strands [107].   
1.7.4 Gene expression, nuclear RNA export and viral protein translation 
Upon integration of the viral genome into the host chromosome, transcription is 
initiated from the LTR HIV-1 promoter; transcription starts from the U3/R junction 
sequence which contains several elements that form a platform to which 
transcription initiator factors bind to [56].  For instance, the viral DNA sequence 
has regulator sequences that include, a TATA element, three tandem Sp1 
binding sites and an initiator sequence [108]; these sequences contribute 
efficiently to cooperative binding of transcription initiator TFIID and other factors 
to TATA [109]. Additionally, viral DNA also contains two NF-ᴋB binding sites 
which act as enhancers of transcription upon binding of NF-ᴋB [110]. However, 
basal transcription from the HIV-1 promoter is low which suggested that 
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additional factor(s) were required [56]. Subsequent studies showed that the 
transcription activation of the HIV genome required the viral accessory protein, 
Tat [111, 112]. The mechanism by which Tat transactivates LTR-driven 
transcription is via binding to an RNA element at the 5′ ends of HIV-1 transcripts, 
the transactivation response region (TAR) [112] and recruits cyclin T1 which in 
turn binds to cyclin-dependent kinase 9 (CDK9) forming a heterodimer [113]. The 
cyclinT1/CDK9 heterodimer recruits human P-TEFb to Tat [114] and this results 
in phosphorylation of the C-terminal domain of RNA polymerase II (RNAPII) 
which is required for transcription elongation [115]. Following transcription, the 
transcription products undergo alternative splicing in the nucleus which gives rise 
to a complex and extensive range of transcripts to produce the complete set of 
mRNAs that encode the viral proteins [109]. In addition, unspliced transcripts are 
also produced. To evade cellular surveillance mechanisms that normally degrade 
unspliced transcripts, HIV-1 utilises the virally encoded accessory protein, Rev; 
Rev binds to an RNA element located in the Env-encoding region, the Rev-
responsive element (RRE), a 350 nt highly-structured cis-acting RNA, which 
enables unspliced mRNAs to be transported to the cytoplasm [109, 116, 117]. 
Rev contains both a nuclear export signal element and a nuclear localization 
signal that enables shutting from the nuclei to the cytoplasm and viceversa. In 
this manner, unspliced and partially-spliced transcripts are transported from the 
nuclei to the cytoplasm by binding of Rev to the RRE (Figure 1.5) where 
transcripts are translated [117] (Figure 1.5).  
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Figure 1.5 Transport of HIV-1 spliced and unspliced/partially spliced transcripts. 
Early in the replication cycle, spliced transcripts are transported from the nuclei to the 
cytoplasm similarly to cellular mRNAs. On the other hand, Rev enters the nucleus via an 
Arg-rich nuclear localization signal to then bind to the RRE of unspliced and partially 
spliced transcripts, which then are transported to the cytoplasm where they are then 
translated (Adapted from [117]).  
 
1.7.5 Viral assembly, budding and maturation 
The viral components required to assemble a fully infectious HIV virus particle 
are two copies of positive single-stranded RNAs which constitute the viral 
genome, the viral Env protein, the tRNALys,3 that initiates reverse transcription and 
the Gag-pol polyprotein which encodes PR, IN and RT and that is translated via 
rare frameshift[56] event [83, 118]. In addition, the Gag polyprotein which 
encodes  MA, CA, NC and p6 is synthesized from an unspliced viral mRNA and 
orchestrates assembly at the plasma membrane by recruiting two copies of the 
viral RNA which constitutes the genomic viral RNA.  The MA domain of Gag is 
responsible for binding to the plasma membrane where assembly takes place 
[118]. The viral mRNA unspliced transcripts to be packaged in the virions, are 
targeted to the plasma membrane where assembly of new virion particles takes 
places via a packaging sequence located in the 5’ end between the LTR and the 
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gag initiation codon [60]. To package and assemble novel virus particles the virus 
hijacks the ESCRT pathway which is normally involved in production of vesicles 
that are then released into multivesicular bodies and abcission cytokinesis [119-
121].  
1.8 Highly Active Antiretroviral Therapy  
Highly Antiretroviral Therapy (HAART) has proven to be efficient at reducing 
morbidity and mortality by suppressing viral RNA and blood viral load; this in turn, 
decreases the risks of transmission [122]. According to the United States 
National Institutes of Health (NIH) and the European AIDS Clinical Society 
(EACS) guidelines, patients presenting less than 350 CD4-T-cells per mm3 are 
strongly recommended to start HAART. However, HAART does not eradicate HIV 
infection completely as it does not eliminate viral DNA reservoirs or immune 
dysregulation as a result of chronic immune activation [123]. Since HIV-1 mutates 
at very high rates, the success of this therapy relies on the use of a combination 
of drugs that target different steps of the virus replication cycle [23]. Based on 
their targets, antiretroviral drugs are classified into 5 different groups: fusion, co-
receptor, nucleoside reverse transcription, non-nucleoside reverse transcription, 
integrase and protease inhibitors (Figure 1.6). 
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Figure 1.6 Viral replication steps targeted by five different antiretroviral groups. 
There are currently five types of antiretrovirals which have different mechanisms. Fusion 
and co-receptor inhibitors, interfere with the Env-receptor/co-co-receptor interactions.  
Reverse transcription inhibitors block reverse transcriptase. Integrase inhibitors block viral 
DNA integration into the host genome. Protease inhibitors block the cleavage of 
polyprotein precursors which give rise to the different viral proteins. Adapted from La 
Bonte et al., [124]. 
 
1.8.1. Nucleoside reverse transcription inhibitors (NRTIs) 
Nucleoside reverse transcription inhibitors (NRTIs) were the first class of 
antiretrovirals approved by the US Food and Drug Administration (FDA) [125]; 
NRTIs are prodrugs that require phosphorylation by cellular kinases to be 
activated [126]. NRTIs are analogues of nucleoside substrates that lack a 5’ 
hydroxyl group and which substitute nucleoside 3’ triphosphates during reverse 
transcription. This causes premature termination of viral DNA synthesis [126]. 
1.8.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
NNRTIs bind non-competitively to a region proximal to the catalytic pocket of RT 
which triggers changes in the conformation of RT, reducing its catalytic activity 
[127]. Importantly, NNRTIs are highly specific compared to NRTIs which can 
interfere with normal cellular processes by binding to DNA polymerases and 
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unlike NRTIs they do not need to be activated to exert their function [128]. 
NNRTIs and NRTIs account for nearly half of the antiretrovirals approved [23]. 
1.8.3 Fusion and co-receptor inhibitors 
Since HIV requires gp120 to interact with CD4 to gain access to the cells, this 
interaction has been an extensively investigated drug target. As a result, BMS-
378806 and TNX-355, have shown clinical promise [23].   BMS-378806 is a small 
molecule inhibitor that binds to gp120 and inhibits binding to CD4 [129]. TNX-355 
is an antibody that binds to CD4 and thus, prevents gp120 attachment [130].  
Current available fusion inhibitors are a peptide-like inhibitor that targets the gp41 
fusion peptide (fuzeon) [131] and a small molecule inhibitor that targets the CCR5 
co-receptor (maraviroc) [132].  
1.8.4 Integrase inhibitors 
As described in section 1.7.3, the HIV-1 IN enzyme has two catalytic activities: a 
3’ processing activity and a strand transfer activity [81]. Raltegravir, the first 
approved integrase inhibitor,  targets the strand transfer activity and most 
molecules investigated so far target this IN activity and so, are referred to as 
integrase strand transfer inhibitors (INSTIs) [133]. However raltegravir has to be 
taken twice a day and resistance has been reported [134, 135] which prompted 
for the development of alternative IN inhibitors. As a result, elvitegravir was 
approved in a daily single tablet format but with a similar resistance profile to 
raltegravir [134]. Most recently dolutegravir, a novel INSTI being reviewed by the 
FDA for marketing, shows an improved resistance profile compared to raltegravir 
and elvitegravir and can be taken once a day [136]. 
 
 
37 
 
1.8.5 Protease inhibitors 
As described in section 1.7.5, PR is responsible of cleaving p160GagPol and pr55Gag 
polyproteins into the individual viral proteins [137]. Protease polyprotein 
processing is essential for viral replication and so, it has been object of numerous 
studies which resulted in the development and approval of a 10 protease 
inhibitors which are commonly used in conjunction to other inhibitors [138]. Apart 
from tripanavir, all of the protease inhibitors mimic protein binding and include 
saquinavir, ritonavir,or darunavir, the latter being the latest approved [139].  
1.9 Prevention strategies and vaccine attempts 
Currently, various strategies are being studied to prevent HIV infection; these 
include microbicides, pre/post-exposure prophylaxis of high-risk populations 
(such as sex workers and injecting drug users) and male circumcision.  
There are various types of microbicides available with different mechanisms of 
action. For instance, some microbicides such as Cyanovirin® act as a barrier 
against incoming virus by blocking the Env glycoprotein which prevents CD4 
engagement and thus, viral entry [140]. Other microbicides aim to acidify the pH 
thus enhancing the mucosal defences such as cellulose sulphate or Acidform®. 
Tenofovir is an antiretroviral formulated in gel form which acts by inhibiting HIV 
replication which is currently being tested in a South African Phase III clinical trial 
[141]. Another antiretroviral drug being currently being tested as a microbicide is 
dapivirine which innovatively, is being marketed as a vaginal ring [142].  
In addition, three phase III randomized clinical trials showed that male 
circumcision has a protective effect against heterosexual HIV transmission of 
60% [143-145] and so, the WHO has recommended its implementation for 
prevention in high-risk areas [146].   
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Despite huge efforts to develop a vaccine that broadly neutralizes HIV, to date 
there are no vaccines against HIV. The main strategies being currently 
investigated are to produce a preventive vaccine and a therapeutic vaccine that 
intensifies the effect of ART, delays treatment initiation or clears viral reservoirs 
[123, 147]. However, numerous attempts have proven unsuccessful due to:  
genetic variability of target epitopes as a result of high mutation rates and the 
structural biology of the Env glycoprotein which includes conserved glycan motifs 
and receptor/co-receptor binding sites [148]. The most recent trials (Figure 1.7) 
include  efficacy evaluation of two recombinant vaccines of gp120 in USA [149] 
and in Thailand [150], VAX 004 and VAX003, which showed no efficacy. Another 
strategy attempted has been using adenoviral vectors as systems for delivery of 
genes. The MRKAd5® HIV-1gag/pol/nef vaccine is an adenovirus-5 based vector 
that delivers gag, pol and nef genes which was trialled in the STEP trial but even 
though it showed promising immunogenicity and safety [151] it was halted due to 
reviews that suggested it was not effective [152]. Similarly, in the HVTN505 trial, 
evaluated the efficacy of an adenoviral vector delivery to deliver DNAs encoding 
HIV-1 clade B gag and pol and env derived from clade A, B and C [153]. 
Unfortunately the trial had to be halted after results showed that it failed to 
prevent infection [152]. Out of the 6 trials so far, only one has showed a modest 
efficacy, the RV144 trial in which the vaccine trialled showed a 31.2% efficacy at 
preventing HIV-1 infection [154]. The trial evaluated the efficacy of a combination 
of ALVAC® (incorporating a canarypox vector, vCP1521) and AIDSVAX® B/E 
vaccine, including the gp120 constructs assayed in the VAX trials. Currently, a 
clinical trial in South Africa is being conducted to improve the RV144 vaccine in 
which HIV-1 clade specificity has been modified to clade C because in South 
Africa HIV-1 clade C is the most prevalent [155].  
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Figure 1.7 HIV efficacy vaccine trials including vaccine components, name of trial and 
trial dates. From Esparza et al, [152]  
 
Despite the efforts in education prevention strategies, the WHO estimates that in 
2013, 2 million people newly enrolled in antiretroviral therapy, the largest annual 
increase ever [156]. 
1.10 HIV restriction  
Host cells have evolved a wide diversity of proteins termed restriction factors that 
constitute a first line of defence against incoming virus. The first evidence of 
restriction factors came from studies with the murine Friend Virus susceptibility 1 
gene (Fv1) [157]. The authors showed that mice cells that encode the Fv1n allelic 
form were susceptible to infection by N-tropic MLV but resistant to B-tropic MLV 
infection [157]. Since then, a number of proteins that inhibit HIV-1 infection have 
been described which vary in potency and mechanism. In an effort to identify 
other proteins that are  involved in HIV-1 restriction, Liu et al., performed a whole 
genome screen which identified additional 114 proteins which significantly inhibit 
HIV-1 infection [158]. I will give a brief overview of the restriction factors that are 
best characterized which differ in the step of the replication cycle they target 
(Figure 1.8).  
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Figure 1.8. Known restriction factors and their viral step targets in the HIV 
replication cycle. Restriction factors that target early steps in the replication cycle 
include TRIM5α, REAF, SAMHD1 and APOBEC3G whilst MX2, SAMHD1, p21 and 
Tetherin all target later stages of the viral replication cycle.  
 
1.10.1 Apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like: 
APOBEC3G. 
Apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like (APOBEC3G) 
was discovered upon characterisation of the HIV-1 virally encoded Vif accessory 
protein. Initially, Vif was shown to be required for viral DNA synthesis [159] and 
for stabilisation of viral nucleocapsid protein complexes [160, 161]. Following 
studies to try and understand the function of Vif showed that in non-permissive 
cells, Vif was absolutely required for HIV-1 replication but in permissive cells, Vif 
was not essential [160]. This supported the hypothesis that there was an innate 
defence mechanism that Vif could overcome, the cellular gene responsible for 
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this defence was APOBEC3G, also known as CEM15 [161]. APOBEC3G restricts 
HIV-1 infection in T-lymphocytes during reverse transcription through its 
deaminase activity that mutates G-A in nascent retroviral DNA and it is also 
effective against other retroviruses such as MLV or SIV [162]. Interestingly, in 
MLV, APOBEC3G is packed into virions where it deaminates the viral genome in 
a destruction mechanism, a strategy overcome by Vif [163]. It was later confirmed 
that APOBEC3G can also mutate viral RNA [164].  
1.10.2 Tripartite-motif-containing 5α (TRIM5α) 
HIV is able to readily enter Old World Monkey cells but upon doing so, it 
encounters a block which happens earlier than reverse transcription[165]. The 
restriction block was found to be Tripartite-motif-containing 5α protein which 
recognises incoming capsid [165]. Owl monkey cells are resistant to TRIM5α 
restriction because a cellular protein, Cyclophillin A, binds to CA and protects HIV 
from TRIM5α [166]. The human equivalent of TRIM5α encodes the human 
restriction factor Ref1 [167].    
1.10.3 The TRIM28 (KAP1)/SETDB1 complex 
Another restriction factor within the TRIM family of proteins, TRIM28, has been 
described to target HIV-1 replication [168]. TRIM28 targets acetylated INT which 
is required to efficiently integrate the viral DNA into the host genome. TRIM28 
forms a complex with HDAC1 which allows deacetylation of integrase [168].  
1.10.4 Tetherin.  
Upon release, virus particles encounter another restriction factor named tetherin. 
Tetherin, also known as BST2 or HM1.24 is a membrane protein that anchors 
budding virus particles and targets them for degradation [69]; it is constitutively 
expressed and interferon (IFN) induced [69]. Tetherin-enriched filaments 
physically link virions to the surface of the plasma membrane as shown by 
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immune-electron microscopy [169]. Unfortunately, tetherin is counteracted by 
Vpu, an accessory HIV protein [69]. It was later shown that Vpu binds to tetherin 
and targets it to the ER-associated degradation (ERAD) pathway and lysosomal 
degradation pathway [170, 171].  As well as HIV-1, tetherin is able to restrict 
other retroviruses such as equine anemia virus (which interestingly counteracts it 
via the viral Env) [172], foamy virus [173] as well as filoviruses such as Ebola 
virus [174].  
1.10.5 SAM domain and HD domain-containing protein 1: SAMHD1. 
Even though dendritic cells play an important role in viral persistence, HIV-1 is 
not able to replicate efficiently in dendritic cells [175]. The explanation could be 
partly due to the restriction exerted by SAM domain and HD domain-containing 
protein 1 (SAMHD1) [176]. Soon after the discovery, Lahouassa et al., showed 
that the mechanism by which SAMHD1 restricts HIV-1 is by depleting the pool of 
deoxynucleosides triphosphates (dNTPs) required for DNA synthesis during 
reverse transcription and can be counteracted by the virion-packed SIV/HIV-2 
accessory protein Vpx [177, 178]. Interestingly, SAMDH1 must be in the nucleus 
to be degraded by Vpx even though its main antiviral function takes place in the 
cytoplasm [179]. The antiviral activity of SAMHD1 is regulated by phosphorylation 
by Cyclin A2/CDK1 [180].  
1.10.6 Cyclin-dependent kinase inhibitor: p21 
The Cyclin-Dependent Kinase 1 inhibitors, (CKI) p21Cip1/Waf1 is known as p21 and 
restricts HIV-1, SIV and HIV-2 infection in macrophages. Importantly, p21 
restricts infection in haematopoietic stem cells [181]. A novel function of p21 has 
recently been described as part of its HIV antiviral mechanism by which p21 also 
depletes the pool of dNTPs impairing reverse transcription [182].  
 
43 
 
1.10.7 Myxovirus resistance 2 (MX2 or MxB) protein  
A recently discovered restriction factor is the human dynamin-like, myxovirus 
resistance 2 (MX2 or MxB) protein [183]. MX2 is interferon-induced and potently 
inhibits X4 and R5 HIV-1 strains, modestly inhibits SIV and has no effect on MLV, 
E1AV or FIV[183]. Specificity of action is determined by CA and causes nuclear 
accumulation and integration defects of viral cDNA [183, 184]. HIV-1 is able to 
escape MX2 restriction through an Alanine mutation in CA which abolishes the 
ability of CA to binding by Cyclophillin A, suggesting a role of Cyclophillin A in 
MX2 restriction [184]. Most recently, Fricke et al., showed that MX2 binds to core 
and prevents uncoating[185]. 
1.10.8 RNA-associated Early-stage Anti-viral Factor: REAF. 
One of the most potent restriction factors discovered recently is the RNA-
associated Early-stage Anti-viral Factor, also known as RPRD2 [186]. RPRD2 is 
a cellular protein with unknown function that is potent against HIV-1, HIV-2 and 
different SIV strains with a restriction potency of >50 fold that occurs during 
reverse transcription. Interestingly, REAF was shown to interact with viral RNA 
and/or DNA so it could be that this is the first restriction factor that actually targets 
the viral genome per se [186]. Viral challenge decreases REAF protein 
expression so it could be that it is counteracted by an HIV viral protein similar to 
Vif against APOBEC3G or Vpu against tetherin [186].  
1.10.9 The Polymerase II-Associated Factor 1 Complex  
The Polymerase-Associated Factor 1 (PAF1) was identified as a potent restriction 
factor against HIV-1 in the same siRNA screen that identified REAF [158]. Since 
PAF1 is subject of chapter 5, a review of the current knowledge on the discovery 
and cellular functions of PAF1 and its involvement in viral infection will be 
outlined here.  
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1.10.9.1 Discovery of Polymerase II-Associated Factor 1 in humans  
 
During gene transcription, initiation factors that recognize gene promoters bind to 
the C-terminal domain (CTD) of RNAPII. The RNAPII CTD has a Y1S2P3T4S5P6S7 
repeat where the Ser5 and Ser7 become phosphorylated by Kin28 which is part 
of the TFIIH initiation factor [187]. As elongation proceeds, Ser2 becomes 
phosphorylated by Ctk1 and Bur1 kinases to allow association of other elongation 
factors with RNAPII [188]. Phosphorylation of Ser2 allows association of RNA 
splicing factors and polyadenylation enzymes which causes the nascent RNA to 
be spliced, polyadenylated and cleaved.  
To understand if additional proteins associate with RNAPII during transcription, 
an antibody directed against the C-terminal domain (CTD) of the Saccharomyces 
cerevisiae RNAPII and the complex was affinity purified [189]. These studies 
revealed that PAF1 (Polymerase-Associated Factor 1) and CDC73 (Cell Division 
Cycle73), two proteins involved in gene expression, interact with RNAPII [190]. 
Subsequent studies showed that in addition, LEO1, CTR9 and RTF1 are part of 
the yeast Polymerase-Associated Factor 1 complex (PAF1c) [191]. CTR9 was 
first described through its link to cell cycle regulation by regulation of G1 cyclin 
genes [192] and RTF1 was shown to be involved in TATA-box site selection and 
transcription elongation [193, 194].  
The PAF1c has also been shown to bind to RNAPII in higher eukaryotes 
including human, Drosophila, mouse and plants such as Arabidopsis thaliana 
[195]. The human PAF1c has an additional component, SKI8/WDR61, which 
together with SKIV2L and TTC37 constitutes the trimeric Superkiller complex 
(SKIc) [196, 197]. The human SKIc is directs RNAs to the exosome which plays a 
role in mRNA surveillance and degradation [198]. Within the PAF1c, chromatin 
immunoprecipitation (CHIP) experiments show that SKI8 is present at 
transcriptionally active genes and that recruitment is PAF1c-dependent 
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suggesting a new role for PAF1 downstream of transcription, in mRNA quality 
control and surveillance [196]. However, there is still no additional structural or 
functional information of the role of SKI8 in the PAF1c functions. Indeed, the 
structural information regarding PAF1c assembly is limited. The crystal structure 
of the C-terminal domain of CDC73 revealed a Ras-like domain that promotes 
recruitment of the PAF1c to chromatin [199]. In addition, Amrich. et al., showed 
that mutations in the C-terminal domain of CDC73 and RTF1, caused a defect in 
transcription elongation suggesting that CDC73 might be the scaffold protein that 
interacts with RTF1 to promote RNAPII association [199]. RTF1 has also been 
shown to have a central domain, the ORF-Association Region also referred to as 
Plus3 domain, which promotes recruitment of PAF1 complex to the chromatin 
[200]. In addition, NMR studies showed that the RTF1 Plus3 domain has a DNA 
binding domain similar to the domain of DNA which unwinds during transcription 
[201] which further reinforces the central role of RTF1 in DNA binding of the 
PAF1c. As to inter-subunit interactions, a recent study mapped the minimal 
regions of direct interaction of  PAF1 and LEO1 and resolved the crystal structure 
of these regions [202]. Through CHIP strategies using human Myc-tagged 
constructs of the PAF1c subunits, Chu. et al., showed that  Myc-LEO1 only co-
precipitated with PAF1 suggesting that LEO1 binds to the PAF1c through PAF1 
[202]. In addition, the authors showed that PAF1 co-precipitated with CTR9, SKI8 
and cdcd73 and that the scaffold linking protein was CTR9. The interaction 
studies obtained thus far allows the following model of PAF1c (Figure 1.9). 
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Figure 1.9 Model of human PAF1c and known cellular functions. Schematic 
representation of the PAF1c which binds to RNAPII. RNAPII is shown bound to DNA 
(black) which is packaged around histones (orange). The known PAF1 function are 
outlined according to the current knowledge. Adapted from [195].  
 
The FACT complex (Facilitates Chromatin Transcription), which has a role in 
transcription elongation, also interacts with PAF1c [203] and in doing so, it 
monoubiquitinates histone H2B, important in displacement of the nucleosomal 
barrier [204]. Apart from histone ubiquitination, PAF1 has also been shown to 
have an influence on other histone modifications which regulate gene expression, 
for example CDC73 is required for H3K36-Me3 and H3K4-Me3 [205]  
Furthermore, PAF1C has a role in RNA 3’ formation. Both yeast and human 
PAF1 component depletions have been shown to decrease polyA mRNA length 
[206, 207]. In addition the hPAF1C has been shown to interact with factors 
involved in RNA processing such as the homologous CPSF (Cleavage and 
Polyadenylation Specificity Factors) [205]. The yeast PAF1C has roles not only in 
processing of polyA mRNA transcripts but also in 3’-end processing of non-
polyadenylated RNAs such as small nucleolar RNAs (snoRNAs) [208]. 
 
 
47 
 
1.10.9.2 The role of PAF1 in viral infection 
As obligate intracellular parasites, viruses have evolved to hijack the cell’s 
machinery in order to replicate. Given the fine mechanisms by which PAF1c 
regulates transcription and gene expression, a role of PAF1c in control of viral 
gene expression has also been reported.  
For instance, to efficiently transcribe the viral genome once integrated, HIV-1 
requires the viral protein, Tat which, according to Sobhian et al., interacts with 
PAF1c and enhances transactivation [209].  Sobhian et al., purified Tat 
complexes and showed that Tat forms two functionally distinct complexes, 
Tatcom1 and Tatcom2. Tatcom1, the complex found to have enhanced CTD-
kinase activity, was found to bind to PAF1, suggesting that it is directly involved in 
transcription elongation. Indeed, knockdown of PAF1 decreased Tat 
transactivation by 2- 5 fold. Importantly, CHIP showed that Tat recruits PAF1 and 
the additional components of the Tatcom1 complex to the TAR promoter region 
and these travel along with RNAPII. This therefore constitutes a first example of 
how HIV-1 may appropriate the transcription elongation function of PAF1c to 
enhance viral transcription. Most recently, in addition to HIV, human adenovirus 
(HAdV) Early Region 1A viral protein (E1A) has also been shown to recruit PAF1 
to stimulate transcription and to regulate transcription-coupled histone 
modifications of HAdV early genes [210, 211]. Interestingly, influenza virus has 
been shown to usurp PAF1 activity [212]. In the search for proteins that bind to 
the influenza non-structural protein 1 (NS1) tail, Marazzi et al., identified a direct 
interaction of PAF1 with methylated and unmethylated NS1 tail.  Importantly, 
PAF1 was shown to increase the expression levels of an array of genes involved 
in antiviral and pro-inflammatory responses upon influenza virus infection and 
IFN-β stimulation suggesting that NS1 might bind to PAF1 in order to halt this 
process.  
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The functions of PAF1 in viral infection so far described here, focus on viral 
hijacking of PAF1 to favour viral replication at late stages of infection. My group 
described the role of PAF1c in restriction of HIV-1 infection [158]. To identify 
novel restriction factors that may be involved in HIV-1 infection, Liu et al., 
performed a genome wide siRNA knockdown screen of 19,121 genes and 
identified 114 factors that significantly decrease HIV-1 infection [158]. Amongst 
the proteins identified were PAF1, LEO1, CDC73, RTF1 and CTR9. Knockdown 
of any of the five components of PAF1c rescued HIV-1 infection. Interestingly, 
knockdown of PAF1 also rescued infection of HIV-2 and SIV virus isolates, 
suggesting that PAF1 is a broad-acting antiviral factor against lentiviruses. In 
addition, overexpression of a PAF1-HA construct inhibited HIV-1 infection further 
confirming the antiviral function of PAF1. Importantly, PAF1 was shown to be 
expressed in primary macrophages and CD4+ T-cells, two of the main cellular 
targets of HIV-1 [47]. Most recently, PAF1, CTR9 and RTF1 have been shown to 
be upregulated upon Peripheral Blood Mononuclear Cell (PBMC) activation [213]. 
Increased levels of PAF1 and RTF1 in activated PBMCs correlated with 
decreased HIV-1 infection which further supports a role of PAF1 as a HIV-1 
restriction factor in primary cells [213].  
Elite controllers are defined as untreated HIV-1 infected patients that control 
viremia to undetectable levels in blood [214]. The mechanisms underlying why 
elite controllers sustain a virological response have been the subject of extensive 
study [215]. A recent comparative study of the expression levels of known 
restriction factors from elite controllers and ART-supressed patients, showed that 
CTR9 is elevated in elite controllers further supporting the role of the PAF1 
complex in control of HIV-1 infection [216]. However the mechanism by which it 
inhibits HIV and other retroviruses is still unknown.  
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Reagent Protocol Brand
Agarose DNA preparation Sigma
Ampicillin Bacterial culture Sigma
AZT Drug-virus assay Sigma
CellTiter 96® 
Aqueous One 
Solution Cell 
Proliferation Assay 
(MTS) 
Cytotoxicity assay Promega
DharmaFECT cell 
culture reagent 
Transfection
Dharmacon, 
Thermoscientific
DharmaFECT 
reagent 1 and 
reagent 4
siRNA screen
Dharmacon, 
Thermoscientific
DMF
p24 staining/β-gal 
staining
Acros Organics 
DMSO Drug diluent Sigma
Dulbecco’s Modified 
Eagle Medium
Cell culture Sigma
ECL Prime Western-blot GEHealthcare 
EDTA Transfection Life Technologies
EHT1864 Drug-virus assay Tocris
Fetal Bovine Serum Cell culture 
Biosera 
Laboratories 
International
G418 Cell culture Fisher Scientific 
Hiperfect Transfection Qiagen
Kanamycin Bacterial culture Sigma
Lipofectamine 2000 Transfection Invitrogen
Luria Bertani buffer Bacterial culture Fisher Scientific 
Maxiprep kit DNA preparation Qiagen
Methanol Imaging Fisher Scientific 
MG132 Drug-virus assay Sigma
Nitrocellulose 
membranes
Western-blot Life Technologies
NP40
Cellular 
fractionation
Pierce
NSC23766 Drug-virus assay Tocris
Optimem-I Transfection Life Technologies
Paraformaldehyde Imaging Acros Organics 
Penicillin-
Streptomycin
Cell culture Sigma
Phosphate Buffer 
Saline
Cell culture Sigma
Polyethylenimine, 
JetPEI
Transfection Polyplus
Pre-plated siRNA 
screen plates 
siRNA screen
Dharmacon, 
Thermoscientific
Protease inhibitors Western-blot
Complete, Roche 
Applied Sciences
Restriction enzymes DNA preparation
New England 
Biolabs 
RNAse-free water siRNA screen Qiagen
RPMI(+)L-glutamine Cell culture Gibco, Invitrogen
Running buffer Western-blot Life Technologies
SDS
Cellular 
fractionation
Pierce
siGLO-red siRNA screen
Dharmacon, 
Thermoscientific
Sucrose
Cellular 
fractionation
Pierce
Transfer buffer Western-blot Life Technologies
 8%-Tris-Bis NuPage 
gel 
Western-blot Life Technologies
Triton X-100 Imaging Sigma
Trypsin-EDTA 
(0.05%), phenol red
Cell culture Life Technologies
Vectashield-DAPI Imaging Vectorlab
X-gal
p24 staining/β-gal 
staining
Melford
X-gal buffer
p24 staining/β-gal 
staining
Melford
2.1 Materials: Reagents and antibodies 
Table 2.1. List of reagents employed classified by protocol and brand.  
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Table 2.2. List of antibodies employed. 
Target
Antibody 
brand
Number 
Acetylated α-
tubulin
SCBT 23950
IgG Alexa 
Fluor®555
Abcam ab150110
IgG 
DyLight®488
Abcam ab98488
GAPDH Abcam 128915
Hemagglutinin Abcam 1208
Histone3 Abcam 1791
p24 NIBSC, UK EVA365 and 366
PAF1 Abcam 20662
Recombinant 
Soluble Human 
CD4 (sCD4)  
NIH AIDS 
Reagent 
Program, 
Division of 
AIDS, 
NIAID, NIH: 
Soluble 
Human 
CD4 from 
Progenics
#4615
α-Tubulin SCBT H-300  
2.2. Methods 
2.2.1 DNA preparations. 
2.2.1.1. DNA production  
DNA was amplified by heat shock transformation of E.Coli DH5-α cells[217]. An 
aliquot of E.Coli DH5-α cells (kindly provided by Kelly Marno) were thawed on ice 
for 5 minutes. 1 ng of DNA (quantified using a NanoDrop 1000 
spectrophotometer) was incubated with 40 µl of E.Coli DH5-α cells on ice for 10 
minutes. Cells were then heat shocked at 42°C for 110 seconds and incubated 
for 10 minutes on ice. The transformed cells were then incubated with 300µl of 
Luria-Bertani (LB) (Fisher Scientific) media at 37°C shaking in an automatic 
shaker for one hour. 150 µl of transformed cells were then plated onto agar 
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plates containing ampicillin at 100 µg/ml for antibiotic resistance selection. Plates 
were incubated overnight at 37°C. Colonies were then picked and incubated in 
5ml of LB-antibiotic and incubated for 8 hours in a room at 37°C. The cultures 
were then diluted into 200ml of LB-antibiotic and incubated overnight in a room at 
37ºC. DNA was extracted using a QIAGEN Maxiprep Kit according to 
manufacturer’s instructions.  
2.2.1.2. Agarose gel electrophoresis and restriction digest of DNA 
Size of DNA was analysed by restriction enzyme digestion using 10 units of 
restriction enzyme (NEB) per reaction with appropriate buffer and Bovine Serum 
Albumin if required, followed by incubation in a water bath at 37°C for 1hr. Digest 
products were visualized on a 0.8% agarose (Sigma) gel which was run for 1 
hour at 100V.   
2.2.2. Cellular fractionation 
To purify the nuclear and cytoplasmic fractions of HeLa-CD4+ cells, cells were 
seeded at 2x105 cells/ml in 6-well dishes (ThermoScientific, Nunclon). 24 hours 
after seeding, cells were washed with Phosphate Buffer Saline (PBS) (Sigma) 
and harvested from the plate using a cell scraper (three wells/fraction). Cells 
were pelleted at 1000 rpm for 5 minutes. Cells were pipette-resuspended and put 
on ice to avoid protein degradation in cold swelling buffer (see table 1) and 
incubated for 5 minutes. 0.1% NP40 (Pierce) was added to lyse the cell 
membrane without lysing the nuclei and incubated on ice for one minute. Lysates 
were then centrifuged at 1000 rpm, 4ºC for 5 minutes.  
The supernatant, containing the cytoplasmic fraction, was then transferred to a 
new Eppendorf tube. The cytoplasmic fraction was centrifuged for 5 minutes at 
1500 rpm to pellet nuclei contamination. 1% sodium dodecyl sulphate (SDS)-PBS 
was added to solubilize cytoplasmic membranes (such as Golgi or endoplasmic 
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reticulum (ER) membranes) and incubated for 5 minutes at room temperature. 
The cytoplasmic fraction was then pelleted and the supernatant was transferred 
to a new Eppendorf and stored at -80ºC until required.  
The pellet of nuclear fraction was resuspended in 1ml of solution 1 (Table 2.3). It 
was then layered onto 1 ml of solution 2. As shown in table 1, solution 2 has a 
higher concentration of sucrose than solution 1 and so together, both solutions 
form a concentration gradient. The purpose of the sucrose gradient is to purify 
the nuclear fraction which is high in molecular weight from the cytoplasmic 
fraction which is lower in molecular weight (Figure 2.1). Cells were then 
centrifuged for 10 minutes at 3500 rpm at 4ºC. Upon centrifugation, the nuclear 
fraction migrates and is pelleted, whilst the cytoplasmic fraction, which is lighter, 
migrates to solution 1.  After centrifugation, solutions 1 and 2 were discarded and 
the pellet with nuclei was resuspended in 1x RIPA buffer ( described in section 
2.2.10.) with protease inhibitors (Complete, Roche). Lysates were then 
centrifuged to pellet nuclear membranes and the supernatant was transferred to 
a new Eppendorf before being stored at -80ºC prior to Western-blot analysis 
(described in section 2.2.10).  
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SWELLING BUFFER 
Stock Volume/ml Final concentration/mM 
1M HEPES, pH 
7.9 0.1 10 
1M MgCl2 0.015 1.5 
2.5M KCl 0.04 10 
1M DTT 0.005 0.5 
dH2O up to 10ml 
 SUCROSE GRADIENT SOLUTION 1 
Stock Volume/ml Final concentration/mM 
2.5M sucrose 1.96 0.25 
1M MgCl2 0.2 10 
dH2O up to 20ml 
 SUCROSE GRADIENT SOLUTION 2 
Stock Volume/ml Final concentration/mM 
2.5M sucrose 5.5 0.35 
1M MgCl2 0.02 0.5 
dH2O up to 40ml 
  
Table 2.3. Buffers used in the cellular fractionation protocol to purify cytoplasmic 
and nuclear fractions.  
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Figure 2.1. Sucrose gradient to purify nuclei from cellular membranes. A sucrose 
gradient is established with the heavier and most concentrated solution lying at the 
bottom of the falcon tube and the lighter and most diluted solution lying at the top portion 
of the falcon tube. After centrifugation, heavy nuclei remain in the most concentrated 
sucrose gradient forming a pellet and the lighter cellular membranes remain at the top 
within the most diluted solution.  
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2.2.3 Cells 
The adherent cell lines that were employed consist of HeLa-CD4+ [218],  TZM-bl 
[219] and 293T cells[220]. Cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma) with 1% penicillin-streptomycin (PAA), 10% fetal 
bovine serum (FBS) (Biosera Laboratories International) at 37ºC and 5% CO2 
conditions. HeLa-CD4+ and TZM-bl cells are derivatives of the HeLa cervical 
cancer cell line. HeLa-CD4+ cells are a derivative of HeLa cells which stably 
express CD4+ after infection with a retroviral vector [221]; HeLa-CD4+ cells 
express CD4 under the control of HIV-1 long terminal repeat and are grown in the 
presence of 1mg/ml of G418 (32). They also express naturally CXCR4 and CCR5 
and since these are the receptors and co-receptors for entry of HIV, they are a 
widely used cell line in the HIV field. TZM-bl express cell surface CD4, CXCR4 
and CCR5 and in addition, have Tat-inducible luciferase and β-galactosidase 
reporter genes. 
The suspension cell lines used in this project were Jurkat,[222] and PM1[223, 
224]   cell lines. Jurkat and PM1 cells are derived from T-cells and naturally 
express CXCR4 and CXCR4/CCR5 respectively. Cells were grown in RPMI(+)L-
glutamine (Gibco, Invitrogen) supplemented with 1%  penicillin-streptomycin 
(PAA) and 10% FBS (Biosera Laboratories International).  
2.2.4 MTS cytotoxicity assays 
EHT1864 (EHT) and NSC23766 (NSC) were diluted to 10mM in 
dimethylsulfoxide (DMSO) (Sigma), aliquoted and stored in dark conditions at -
20°C.  
To characterise the cytotoxic profile of these inhibitors, a cytotoxic assay was 
performed in Jurkat and PM1 cells. For this purpose, 4x103 cells/well were 
seeded in 96-well plates (ThermoFischer, Nunclon). Cells were incubated 
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overnight at 37ºC. Serial dilutions of EHT and NSC from 50µM to 3.125 µM were 
prepared in in RPMI(+)L-glutamine (Gibco, Invitrogen) supplemented with 1%  
penicillin-streptomycin (PAA) and 10% FBS (Biosera Laboratories International) . 
Similarly, in parallel, as a control, serial dilutions of DMSO were prepared. The 
purpose was to assess the toxicity effect of DMSO since the compounds had 
been diluted in 100% DMSO. Cells were incubated at 37ºC for 48 hours post-
addition of drugs/DMSO dilutions. A cytotoxic assay was performed using the 
colorimetric assay, CellTiter 96® Aqueous One Solution Cell Proliferation Assay 
(MTS) (Promega). In this assay, cell viability is proportional to the ability of cells 
of metabolically processing a tetrazolium salt, MTS to formazan, a purple 
compound which can be measured at 490nm [225] using a BMG FLUOstar 
OPTIMA Microplate Reader. Thus, after incubation of cells with DMSO, EHT and 
NSC for 48 hours, 20 µl of Aqueous One solution (Promega) were added to each 
well. Cells were incubated for one hour at 37ºC in dark conditions and 
absorbance was read at 490nm. Previously, the cytotoxic profile of EHT and NSC 
in TZM-bl cells had been characterised (Appendix 2). 
2.2.5 Virus production and HIV-1 detection of infection 
2.2.5.1 Production of single round infectious pseudovirus stocks in 293T cells 
Single round infectious pseudovirus particles were produced by transfection of 
293T cells with a plasmid encoding HIV-1 NL4.3 or HIV-1 BaL envelopes and a 
genomic plasmid, TN6stop [226], which encodes a GFP reporter gene. For this 
purpose, 4x106 cells were seeded in 10-cm dishes. Cells were incubated 
overnight at 37ºC. A total of 1.5 µg of the envelope and the genomic plasmid 
were transfected using polyethylenimine (PEI, Polyplus) in a 1:3 ratio in a total 
transfection volume of 100µl in media. Each transfection reaction was incubated 
at room temperature for 20 minutes and then added to each 10-cm dish. Cells 
were incubated at 37ºC for 48 hours post-transfection. The supernatant was then 
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pelleted at 1,500 rpm, room temperature, aliquoted in cryovials and frozen at -
80ºC. Replication competent HIV virus stocks were prepared using the same 
protocol. Virus titres obtained by this method ranged from 5x103 to 7x105 focus 
forming units per ml (ffu/ml) measured as described in section 2.2.5.3.  
2.2.5.2. Production of replication-competent HIV-1 in C8166 cells 
The human umbilical cord blood lymphocyte cell line, C8166, was used to 
produce HIV-1 89.6 full length, replication competent virus. For this purpose, 
2x106 cells were pelleted at 1000 rpm for 5 minutes. Cells were resuspended at 
1x105 ffu/ml of HIV-1 89.6 virus kindly provided by Kelly Marno and originally 
obtained from the Centre for AIDS Research (NIBSC, UK). Cells and virus were 
incubated at 37ºC for 2 hours, at which time they were seeded upright in a T25 
flask with an extra 5ml of RPMI-10%FCS. Two days after infection, upon 
visualization of syncytia (indicates high titer virus), 2x107 cells were added. 24 
hours after incubation at 37ºC, cells were pelleted in a 50ml falcon at 3,500 rpm. 
The supernatant was aliquoted into 0.5ml aliquots and frozen in liquid nitrogen. 
Full replication-competent HIV-1 NL4.3 and BaL (chapter 5) were kindly provided 
by Kelly Marno. The production protocol was the same as described above in 
PM1 cells. 
2.2.5.3. Detection of infection by in situ staining for β- galactosidase in TZM-bl 
cells 
TZM-bl cells have a HIV Tat-inducible β-galactosidase gene, which provide a 
convenient method to calculate the number of virus particles/ml in a virus stock 
solution. When TZM-bl cells are infected by a single round infectious virus β-
galactosidase expression is induced by HIV Tat and by reaction with its 
substrate, 5-bromo-4-chloro-indolyl-β-D- galactopyranoside (X-gal), β-
galactosidase hydrolyses X-gal into galactosidase (colourless) and 4-chloro-3-
58 
 
brom-indigo which forms a blue precipitate [227], thus allowing the count of 
infected cells.   
A total of 4x103 cells/well were plated in 96-well plates and incubated overnight at 
37ºC. An aliquot of each virus stock was thawed for 5 minutes in a water bath at 
37ºC. Serial dilutions (1:5) were performed and 100 µl of each virus dilution were 
added per well. Cells were then incubated at 37ºC for 48 hours. 
To fix and stain TZM-bl cells, media was discarded from each well. Cells were 
then washed twice with 100 µl 1x PBS (PAA) and fixed with 50µl/well of 3.7% 
formaldehyde for 5 minutes at room temperature. The formaldehyde was 
discarded and cells were washed twice with 100 µl 1x PBS. A 1 mg/ml  solution 
of X-gal  (Melford, MB1001; ) in X-gal buffer (consisting of 5mM Potassium 
Ferricyanide Crystalline, 5mM Potassium Ferricyanide Trihydrate and 2mM 
Magnesium Chloride in PBS) was prepared from a 80 mg/ml stock solution in 
dimethylformamide (DMF) and 100µl/well was added. Cells were incubated for 4 
hours at 37ºC.  Foci of cells were counted and focus forming units/ml were 
calculated for each virus stock. 
2.2.5.4. Detection of infection in Jurkat and PM1 cells  
Pseudovirus stocks have a GFP reporter gene so infection of Jurkats and PM1 
cells is monitored by flow cytometry through the detection of GFP-positive cells. 
Jurkat and PM1 cells were fixed 48 hours-post infection by overlaying cells onto 
2ml of 3.7% formaldehyde, incubating at room temperature for 5 minutes in 10ml 
falcon tubes (BDBiosciences). Cells were then pelleted at 1,500 rpm for 5 
minutes at room temperature, the supernatant discarded and cells resuspended 
in 250µl of 1x PBS. Cells were then analysed by flow cytometry using a Becton 
Dickinson FACScan Analyser fitted with an Argon laser (488nm) and CellQuest 
software, (Becton Dickinson, San Jose, USA).  
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 2.2.5.5. Determination of focus forming units by in situ immunostaining for p24 
antigen 
To calculate the virus infectivity of the HIV-1 89.6 virus stocks HeLa-CD4+ cells 
were seeded at 7x104 cells/ml in 48-well plates. Cells were infected, in duplicate, 
by addition of neat virus and successive 1:5 virus dilutions in DMEM-10% FCS 
(with no antibiotic added). Cells were incubated with the virus dilutions for two 
hours at 37ºC, after which media was replaced with DMEM- 10%FCS. Infected 
cells were incubated for 48 hours at 37ºC. At 48 hours post-infection, cells were 
fixed with a cold 1:1 acetone:methanol solution (stored at -20ºC) for 10 minutes. 
Cells were quickly washed twice with PBS to remove any acetone-methanol 
excess and cells were then incubated with anti-p24 antibody. The monoclonal 
antibodies to p24 (EVA365 and 366) were provided by the EU Programme EVA 
Centre for AIDS Reagents, NIBSC, UK (AVIP Contract Number LSHP-CT-2004-
503487). at 1:50 in 1%FCS-PBS for 1 hour. Cells were then washed three times 
with PBS. Cells were then incubated with anti-mouse β-galactosidase antibody at 
1:400 in 1%FCS-PBS for 45 minutes. Cells were then washed three times with 
PBS. Cells were then incubated with X-galactosidase substrate at 1:80 in 
dimethylformamide (DMF, Acros Organics), overnight at 37ºC. 24 hours post-
incubation, blue focus forming units were counted and virus infectivity per ml of 
virus was calculated. Viruses produced by the method described in section 
2.2.5.2 ranged from 1x104 to 9x104 ffu/ml.  
2.2.6. Drug-virus inhibition assays 
2.2.6.1. Drug-virus assay in TZM-bl cells 
TZM-bl cells were seeded at 4x103 cells/well in 96-well plates and incubated for 
24 hours at 37ºC. EHT and NSC were diluted in DMEM supplemented with 1% 
penicillin-streptomycin (PAA) and 10% fetal bovine serum (FBS) (Biosera 
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Laboratories International) according to the concentrations found not to be 
significantly toxic in the cytotoxic assay (described in section 2.2.4.) Similarly, as 
a control, DMSO was diluted in media. Each drug/DMSO dilution was then added 
in triplicate (100µl/well). Treated cells were incubated for 24 hours.  Virus 
dilutions of pseudovirus stocks HIV-1 NL4.3 and BaL (produced as described in 
2.2.5.1) were prepared in DMEM supplemented with 1% penicillin-streptomycin 
(PAA) and 10% fetal bovine serum (FBS), according to the results of the virus 
titrations (described in 2.2.5.3) to achieve an infection rate of 1000 ffu/ml 
(50µl/well). Cells were incubated for 48 hours at 37ºC. Cells were then fixed and 
an X-gal staining was performed as described in section 2.2.5.3.  
2.2.6.2. Drug-virus assays in Jurkat and PM1 cells 
Jurkat and PM1 cells were seeded at 4x103 cells/well in 96-well plates and 
incubated for 24 hours at 37ºC. EHT and NSC were diluted in RPMI 
supplemented with 1% penicillin-streptomycin (PAA) and 10% fetal bovine serum 
(FBS) (Biosera Laboratories International) according to the concentrations found 
not to be significantly toxic in the cytotoxic assay (described in section 2.2.4) and 
added in duplicate (50µl/well). Cells were incubated at 37ºC for 24 hours. Neat 
HIV-1 NL4.3 and BaL was added (100µl/well). Cells were incubated for 48 hours, 
pelleted at 1,500 rpm, resuspended in PBS and analysed by flow cytometry in a 
Becton Dickinson FACScan instrument. 
2.2.6.3. Virus infection time-course.   
HeLa-CD4+ cells for imaging were seeded directly onto microscope coverslides 
(12mm diameter, VWR), at 7x104 cells/ml. To prepare the microscope 
coverslides before cell seeding, slides were sterilised by immersion in 100% 
industrial methylated spirit (Ranson) and sterile water (Fisher) and placed into 
wells of a 24 well dish (Nunclon). In parallel, cells were seeded for Western-blot 
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analysis at 4x 105 cells/ ml in 6-well dishes. Cells were incubated for 24 hours at 
37ºC. After incubation, cells seeded on coverslides and on 6-well trays, were 
incubated with DMEM media or anti-CD4 antibody (recombinant soluble human 
CD4 (sCD4), #4615**) for one hour. Cells were then infected with full-length 
replication competent HIV-1 89.6 for 30 minutes, 1 hour and 5 hours. To fix cells 
after infection, each time point coverslip was immersed into a 4% PFA for 30 
minutes, after which they were washed with PBS ready for staining as described 
in section 2.2.9.3.  
** Recombinant soluble human CD4 was obtained through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH: Soluble Human CD4 from 
Progenics.  
2.2.7. Transfections  
2.2.7.1 JetPEI DNA transfections of HeLa-CD4+ cells  
HeLa-CD4+ cells were seeded at 3.0x 104 cells/well in a final volume of 0.5ml per 
well, in 8-chamber microscope slides (BDFalcon). Cells were incubated 
overnight at 37ºC. Media was discarded and replaced with 200 µl/well of fresh 
media. Cells were transfected at a 1:3 ratio of DNA:PEI (JetPEI, Polyplus). 
Transfection of 320 ng DNA/ transfection was performed in a final volume of 4 µl.  
Cells were incubated for 48 hours, at which time cells were fixed and stained as 
described in section 2.2.9.2.  
 
2.2.7.2. Lipofectamine DNA transfections of HeLa-CD4+ cells and HIV-1 infection. 
HeLa-CD4+ cells were also transfected with Lipofectamine (Invitrogen). For this 
purpose, a 3µl of Lipofectamine was diluted in 50µl of Opti-MEM I (Life 
Techonologies) in an Eppendorf. In parallel, 1µg DNA was diluted in 50 µl of 
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Optimem-1. After 20 minutes the Lipofectamine and DNA dilutions were 
combined and incubated for 20 minutes at room temperature. HeLa-CD4+ cells 
were plated at 4 x 105 cells/ml in 12-well dishes, a high concentration because 
Lipofectamine is highly toxic. After incubation, the DNA-Lipofectamine complexes 
were added to the cells dropwise and incubated for 4 hours at 37ºC. Cells were 
incubated with 5mM Ethylenediaminetetraacetic acid (EDTA)-PBS to harvest 
them from the plate at 4 hours post transfection and diluted 1:2 into a new 12-well 
to avoid over confluence. Cells were incubated for 24 hours at 37ºC and 5% CO2 
conditions. After incubation, cells were infected with HIV-1 89.6 (100 FFU/well) 
with stocks that had been previously titrated (as described in section 2.2.5.5.). 
Cells were incubated for 4 hours at 37ºC, at which time media was changed. 
Cells were then incubated for 48 hours, before being fixed and p24-
immunostained as described in 2.2.5.5. 
 
2.2.7.3 Transient PAF1-siRNA knockdown 
 
PAF1-small interfering RNA (siRNA) (QIAGEN, cat number 5105107606) was 
diluted in 0.57µl HiPerfect (QIAGEN) and 14.2 µl OPTImem (Life Technologies) 
at a final siRNA concentration of 0.15 µM. The lipid/siRNA mix was incubated at 
room temperature for 30 minutes. Meanwhile HeLa-CD4+ cells were counted and 
diluted to a final concentration of 2.2 x 104 cells/ml. Cells were plated in a 48-well 
plate, 0.2ml/well in DMEM-1%FCS media (Biosera Laboratories International, 
Sigma). The lipid/siRNA mix was added dropwise. Cells were incubated for 4 
hours, at which time media was replaced with DMEM-10%FCS-1%penicillin-
streptomycin. Cells were incubated at 37ºC for 72 hours, when they were fixed 
and stained as described in section 2.2.9.3.  
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2.2.8 siRNA screen  
2.2.8.1. Optimisation of siRNA screen  
To assess the transfection efficiency of siRNA in TZM-bl cells, siGLO Red was 
transfected using two candidate transfection reagents: Dharmafect tranfection 
reagent 1 and Dharmafect transfection reagent 4 (Dharmacon, Thermo 
Scientific). Since siGLO-Red has been modified to have a 557 (excitation 
wavelength) fluorophore attached, detection of fluorescence emission 
wavelength at 570 nm allows it to be conveniently visualized using a fluorescent 
microscope such as the Zeiss 510 confocal microscope. In this manner the 
internalized siRNA is detected and approximate transfection efficiencies can be 
calculated.  
For this purpose, TZM-bl cells were counted and diluted to a cell density of 5 x 
104 cells/ml. siGLO was diluted initially in RNase-free water (QIAGEN) to a 
concentration of 10µM and further diluted to 500nM in antibiotic-free media. 
Transfection reagents were diluted (1:200) in antibiotic-free media. A volume of 
10µl of 500nM siGLO was combined  with 10 µl of diluted transfection reagent 
per transfection, mixed gently and incubated for 20 minutes at room temperature. 
After incubation, addition of 80 µl of media per transfection further diluted siGLO 
to 50nM. The combination of siGLO and transfection reagent (100µl) was added 
per well in a 96-well plate and cells were incubated for 48 hours at 37ºC.  Cells 
were then fixed as described in 2.2.9.2 ready for confocal imaging. Images were 
performed in a Zeiss 510 microscope using 40x/63x lenses and a 561 multi-beam 
splitter (to excite siGLO red) and 405 multi-beam splitter (to excite nuclear 
staining, 4',6-diamidino-2-phenylindole, (DAPI)).  
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2.2.8.2. siRNA knockdown of GAPs and GEFs 
To investigate the role of GTPase Activating Proteins (GAPs) and Guanine 
Nucleotide Exchange Factors (GEFs) in HIV-1 NL4.3 and HIV-1 BaL infection, an 
infectivity assay was performed in TZM-bl cells with individual knockdowns of 145 
genes encoding the Rho GTPase GAPs and GEFs modulators (targets included 
are listed in Appendix 3 and individual sequences of each siRNA employed can 
be found as supplementary material in the electronic version). For this purpose 
custom-made 96-well plates were purchased from Dharmacon Thermo Scientific. 
The plates included 4 single siRNAs per gene screened, pre-seeded into each 
well. In addition, four Dharmacon ON-TARGETplus® Non-Targeting siRNA 
control pools and one Dharmacon ON-TARGETplus® Cyclophilin B siRNA 
control pool were included. Moreover, four single siRNAs against CD4, CCR5 
and CXCR4 were included as positive controls. Initially, the plates were 
equilibrated at room temperature for 20 minutes. Each siRNA was resuspended 
in DharmaFECT Cell Culture Reagent (DCCR) (Dharmacon, Thermoscientific) 
and reagent 1 (50 µl of reagent 1 was diluted in 6 ml of DCCR, 25µl/well). siRNA 
was left to rehydrate for 60 minutes at 4ºC. TZM-bl cells were counted and 
diluted to 5 x 104 cells/ml. 100 µl of the cell dilution were added per well. Cells 
were incubated for 48 hours at 37ºC. For each screen, viruses were diluted to 
1ffu/µl and added into each well (50 ffu/well). HIV-1 NL4.3 HIV-1 NL4.3  was 
obtained from the Centre for AIDS Research (NIBSC, UK) and HIV-1 BaL was 
obtained from For this purpose, viruses had been titrated as described in 2.6.3. 
Cells were incubated for 48 hours post-infection at 37ºC. Cells were then fixed 
and stained using the X-gal assay as described in section 2.2.5.3. Blue cells were 
imaged using INCell machine Analyzer 1000 (GEHealthcare).  
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2.2.9 Imaging techniques 
2.2.9.1. Transfection and imaging of Rac1 and Rac1 CA Raichu probes. 
One of the methods by which spatio-temporal changes in Rho GTPase activity 
can be monitored at the single cell level is through the use of Raichu probes. 
Raichu probes encode the GTPase subject of study, a GTPase binding domain 
and two fluorochromes, yellow fluorescent protein (YFP) and cyan fluorescent 
protein (CFP) (see chapter 3, figure 3.5) [228]. After transfection of Rac1 into 
HeLaCD4+ cells by the method described in 2.2.7.1., cells were fixed by adding 
100 µl of methanol at -20°C for 10 minutes. Cells were then washed twice in 1x 
PBS and mounted on coverslides with Vectashield (Vectorlab). Cells to be 
analysed were chosen on the basis of a normal elongated cytoplasm and intact 
nuclei. Only cells that displayed a strong signal in the YFP channel were 
analysed to avoid false positives. Bleaching parameters were adjusted to achieve 
a 90% bleach using a Zeiss 710 confocal microscope and images pre- and post-
bleach were taken in the CFP and YFP channels using a 405 diode laser line and 
a 488nm Argon laser line respectively.  Image analysis was performed with the 
AccPbFRET plugin v.3.16 [229] in the ImageJ MacBiophotonics (MBF) version 
(Rasband, W.S., ImageJ, U. S.NIH Maryland, USA, http://imagej.nih.gov/ij/, 1997-
2011). 
 2.2.9.2. Immunostaining of HIV gp41 constructs and microtubules. 
After transfection of constructs using JetPEI as described in 2.2.7.1, media was 
discarded and cells were washed once with 1x PBS. Cells were incubated anti-
HA-FITC antibody (100µl/well) (Abcam1208) for 30 minutes at 4ºC at 1:100 in 1x 
PBS-1%FCS. Anti-rabbit FITC conjugated antibody at 1:500 (Abcam, 98488), 
100µl/well was added. Cells were then incubated with the secondary antibody at 
4ºC for 30 minutes. Cells were fixed and permeabilised with 100% methanol for 
10 minutes at -20ºC. Cells were then washed once with 1x PBS-1%FCS. Cells 
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were then incubated with anti-tubulin (1:100), 100 µl/well at 4ºC for 30 minutes. 
Cells were then washed twice with 1x PBS-1%FCS and incubated with anti-
mouse-Alexa 555 conjugated secondary antibody (1:500) for 30 minutes at 4ºC. 
Cells were then washed twice with 1x PBS-1%FCS. Chambers were removed 
from slides and mounted using Vectashield-DAPI stain diluted 1:2 in distilled 
water and sealed with nail varnish. Imaging was performed using a Leica 
DM5000B epi-fluorescence upright microscope keeping exposure and gain 
parameters constant in each experiment. Filter cubes included Rhodamine - 
Band Pass 560nM +/-20nM and DAPI – BandPass 400nM+/-20nM and FITC - 
Band Pass 490nM +/- 20nM. For each experiment, image acquisition settings 
were set with the lowest expression construct to avoid pixel saturation of the 
higher expressing constructs. Image analysis was performed with ImageJ MBF 
version (Rasband, W.S., ImageJ, U. S.NIH Maryland, USA, 
http://imagej.nih.gov/ij/, 1997-2011) using an automated threshold method to 
avoid bias. The cell perimeter of each cell analysed was selected using the free-
hand drawing application of ImageJ MBF and mean integrated density of the 
acetylated tubulin was quantified in untransfected cells and in cells expressing 
the anchor, full length and truncated versions of the cytoplasmic tail constructs. 
2.2.9.3. PAF1 and HIV-1 capsid immunostaining  
Media was initially removed from seeded HeLa-CD4+ cells. Cells were washed 
with 500 µl 1% FBS/PBS.  Cells were fixed with 200 µl 4% Paraformaldehyde for 
30 mins at room temperature. Cells were then washed with 500 µl 1% FBS/PBS.   
Cells were then permeabilised with 100 µl 0.1% Triton X-100/PBS for 5 min at 
room temperature. Triton x-100 was then removed and washed with 100 µl 
1%FBS/PBS. Cells were then blocked with 100 µl 0.25% BSA/PBS for 20 
minutes at room temperature.  Anti-PAF1 primary antibody was added at 1:80 
(rabbit). Cells were then incubated at 4ºC for 1 hour with the primary antibody. 
67 
 
Cells were then washed twice with 1x PBS-1%FCS. Secondary antibody was 
added at 1:500 (anti-rabbit FITC conjugate) for 30 minutes at 4°C. For 
experiments in which double staining was performed including p24, cells were 
then incubated with anti-p24 (1:50) (EVA 365 and EVA366) for 1 hour at 4ºC. 
Cells were then washed three times with 1x PBS-1%FCS. Cells were then 
incubated with anti-mouse 555 (Abcam, 150110) for 30 minutes.  Cells were then 
washed twice with 1x PBS-1%FCS and mounted on a slide using Vectashield-
DAPI. Imaging was performed using a Zeiss 710 confocal microscope using the 
same exposure, gain and pinhole settings for each experiment. Lasers employed 
were a 405 diode laser line for DAPI, a 543 Helium/Neon laser line and a 488nm 
Argon laser line.  
2.2.10. Western-Blot analysis 
Cells to be analysed were harvested using a cell scraper into an Eppendorf. Cells 
were pelleted at 1,100 rpm for 5 minutes at room temperature. Cells were then 
lysed by addition of 100 µM per sample of 1x RIPA buffer (20 mM Tris-HCl (pH 
7.5), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4  with added protease 
inhibitors (Complete, Roche). Cells were incubated for 30 minutes on ice. Cells 
were then shaken in an automatic shaker for 1 hour in a room at  4ºC to ensure 
complete lysis. Lysates were centrifuged at 13000 rpm at 4ºC to pellet cellular 
membranes. Supernatants were then transferred to new Eppendorfs. Protein 
quantification was performed by Bicinchonic acid (BCA) (Pierce) according to 
manufacturer’s instructions. Per well, 20 µg of protein was incubated with 
4xloading buffer (4% SDS, 10% 2-mercaptoethanol, 20% glycerol, 0.0004% 
bromophenol blue and 0.125M Tris-HCl). Lysates in loading buffer were 
incubated at 70ºC for 10 minutes. Meanwhile, a 10-well 8%-Tris-Bis NuPage gel 
was rinsed with distilled water. The pre-cast gel was positioned into the running 
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tank with 1x MOPS-SDS running buffer (Lifetechnologies). Samples were loaded 
and run for 1.5 hours at 110V after which time the gel was set for transfer. The 
gel was positioned between two nitrocellulose membranes (Life technologies). 
Transfer was performed at 40V for 3 hours. The nitrocellulose membrane was 
then washed with 1x TBST (137 mM Tris-HCl, 2.7 mM KCl and 19mM Tris base, 
1% Tween-20). The membrane was then blocked with 5% skimmed milk in 1x 
TBST. Membranes were then washed four times with 1x TBST for 15 minutes 
each at room temperature. The membrane was then incubated with anti-PAF1 
(1:1000) (Abcam 20662) or anti-Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Abcam 128915) antibodies in 5% milk overnight at 4ºC. Membranes 
were then washed four times with 1x TBST for 15 minutes each at room 
temperature. The membrane was then incubated with anti-rabbit-Horseradish 
Peroxidase (HRP) (Abcam 6721) for 1 hour in 5% milk. Membranes were then 
washed four times with 1x TBST for 15 minutes each at room temperature. The 
membrane was then developed using ECL Prime blocking reagent (Amersham) 
which reacts with HRP from the secondary antibody. This reaction between the 
secondary HRP antibody and the ECL reagent is a chemiluminiscent reaction 
which produces light. The light from this reaction is recorded onto a film using a 
CCD camera. 
Band densitometry was measured using ImageJ MBF and results are presented 
as a ratio of integrated density normalized to loading control.  
2.2.11 Statistical analysis 
Each data population was assessed to understand if data points had a normal 
distribution using SPPS IBM software. When the data population followed a 
normal distribution, the statistical test applied to understand whether the 
differences observed were significant was the parametric Student t-test. When 
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the population did not follow a normal distribution, the statistical test employed 
was the non-parametric Wilcoxon Man-Whitney test.  
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
Chapter 3. Investigating the role 
of HIV envelope signalling during 
cellular entry 
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3.1. Introduction 
HIV entry: Env signaling pathways 
To gain access into the cell, HIV-1 utilises the Env protein to bind to a primary 
receptor, CD4 [43] and a co-receptor either CXCR4 [46] or CCR5 [45, 230] (as 
described in section 1.7.1). HIV-1 strains that utilize CXCR4 as co-receptor for 
entry are named X4-tropic and those that utilize CCR5 are termed R5-tropic 
viruses [47]. Apart from binding to CD4 and a co-receptor for entry, the HIV Env-
receptor/co-receptor interaction also serves to trigger signaling cascades that 
benefit the virus at early stages of infection [80, 231-233]. Env signaling can be 
triggered by various mechanisms. 
Firstly, signaling can be induced via the Env protein interacting with CD4. CD4 
has a central role in T-cell mediated immune responses. For instance, CD4 
interacts with regions of class II Major Histocompatibility Complex and the T-cell 
receptor which in turn increases the interaction between the antigen presenting 
cell and the T-cell [78]. In addition, CD4  mediates T-cell receptor activation via 
phosphorylation of the src-tyrosine kinase, Lymphocyte-specific Kinase (Lck) 
[234]; this non-covalent interaction between CD4 and Lck, results in signaling 
pathways that promote T-cell proliferation, interleukin-2 (IL-2) transcription and 
calcium mobilization amongst other pathways (Figure 3.1) [235]. On the other 
hand, incubation of HIV gp120 with T-lymphocytes decreases the amount of Lck 
bound to CD4, impairing T-cell signaling [236, 237]. In addition, to study the 
signaling events triggered upon ligand binding to CD4, Jabado et al., directed an 
antibody against CD4 and found that antibody binding to CD4 and HIV-1 gp120 
interaction with CD4 both trigger a decrease of the DNA-binding ability of 
transcription factors such as NF-kB which in turn, regulate interleukin-2 
transcription [238]. Furthermore, apart from virion-associated and cell-expressed 
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gp120, gp120 complexed with anti-gp120 is found cell-free in serum plasma and 
in lymphoid tissue; binding of these complexes to CD4 negatively affects T-cell 
activation [237, 239].  T-cell signaling impairment and decrease of CD4 T-cell 
count by HIV-1 infection leads to AIDS disease progression [240]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Signalling events upon HIV Env binding to its primary receptor, CD4 and 
co-receptor. HIV-1 Env interacts with CD4, blocking  the CD4-Lck interaction that results 
in T-cell proliferation, calcium mobilization and IL-2 transcription [235-237]. In addition, 
HIV-1 triggers actin rearrangements via the Rac1-PAK-LIMK1 pathway that results in 
actin depolymerisation [80]. Furthermore, actin rearrangements are triggered via Env 
signal transduction of the WAVE2-Arp2/3 pathway [241]. Env-triggered signal pathways 
are depicted in green whilst pathways in black are normal cellular pathways whose role is 
still not well-understood in Env signalling. These include for example the involvement of 
Rho-GTPase upstream regulators, GAPs and GEFs or the role of Env signalling in 
microtubule dynamics. Adapted from [242].  
 
Secondly, Env signaling can be induced via the Env-co-receptor interaction. 
CXCR4 and CCR5 are part of the G-protein-coupled receptor family (GPCRs) 
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which are integral membrane proteins that share in common a seven 
transmembrane  alpha-helix spanning domain [243]. This transmembrane 
architecture serves as a cell signaling platform that coordinates many cellular 
functions. Importantly, GPCRs represent 3% of genes found in the human 
genome amongst which include, receptors responsible for smell, taste, 
metabolism, chemotaxis and blood pressure regulation [243, 244]. Since they are 
involved in many key cellular processes, 30%-60% of the present drugs target 
GPCRs [244]. Activation of GPCRs is triggered by external binding of a small 
molecule, a protein or a photon of light which triggers conformational changes in 
the cytoplasmic domains of the GPCR (Figure 3.2)[245]. GPCRs, as their name 
indicates, are coupled to a G-protein. G-proteins are heterotrimeric proteins 
which have: α, β and γ subunits. Upon activation of a GPCR, the GPCR 
catalyses GTP-GDP exchange in the α- subunit [245].  
α
γβ
G-protein
GPCR
External
Plasma 
membrane
Cytoplasm
GTP GDP
External stimuli 
 
Figure 3.2. GPCR activation mechanism, structure and localization. GPCRs are 
activated by an external stimuli which can be a photon of light or a protein ligand which in 
turn, causes hydrolysis of GTP to GDP in the alpha subunit. Adapted from Cattaneo et 
al., [246].  
 
The natural ligands for CCR5 include CC-chemokine ligand-3 (CCL3) or 
macrophage inflammatory protein (MIP-1α), CCL4 (termed also MIP-1β) and 
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CCL5 (or RANTES) [247]. Addition of the natural ligands to CCR5-expressing 
cells blocks entry of R5-tropic HIV strains [230]. Similarly, binding of the CXCR4 
agonist, the lymphocyte chemoattractant CXCL12/SDF1, prevents entry of X4-
tropic HIV strains but does not prevent infection with R5-tropic strains or dual 
tropic strains [248]. Primary isolates of HIV-2 utilize CCR5 and CXCR4 as well as 
other co-receptors including CCR1, CCR2b, CCR3 and CCR4 [249]. The first 
evidence for signaling events triggered by Env-co-receptor interaction came from 
experiments that showed that cells incubated with recombinant Env, signal 
through CCR5 enhancing T-cell chemotaxis towards HIV Env [250]. In addition, 
Kroemer et al., later described that when HIV-1 Env interacts with CXCR4, the 
interaction mediates ATP release which in turn stimulates HIV-1 fusion [251].  
The cortical actin barrier poses an obstacle for HIV entry. Cofilin is an F-actin-
severing protein which is inactivated in the cell through phosphorylation by LIM 
kinase 1 (LIMK1) (Figure 3.1) [231].  Initial clues to the role of cofilin in HIV entry 
came from Yoder et al., who found that HIV activates cofilin by Env-CXCR4-
mediated signal transduction [80]. Importantly, the amount of active cofilin was 
found to be significantly higher in cells isolated from peripheral blood of HIV-
infected patients compared to non-infected cells [252]. As  shown in Figure 3.1, 
LIMK1 is downstream of cdc42, Rac1 and indirectly of RhoA since RhoA and 
Rac1 regulate each other [253]. In addition to mediating cofilin activation, the HIV 
Env binding has been shown to activate Rac1 specifically [254, 255] and to signal 
through the Gαq signalling pathway which is essential for virus entry in order to 
trigger rearrangements of cortical actin necessary for fusion with the plasma 
membrane [256]. Actin rearrangements by Env-co-receptor signaling are also 
mediated by the WAVE2 complex through Arp2/3 [241].  
Thirdly, upon viral fusion, the Env gp41 cytoplasmic tail (CT) is thought to be 
inserted into the cell’s cytoplasm [257], being therefore a third possible way by 
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which the Env protein induces cell signaling. For instance, Malinowsky et al. 
described that expression of the HIV-1 and HIV-2 Env gp41 CTs, reduces tubulin 
acetylation which is a marker of microtubule stability [258, 259], ie. expression of 
the gp41 CTs, decreases microtubule stability. The signaling mechanism by 
which the gp41 CT reduces tubulin acetylation is unknown. On the other hand, 
HIV-1 utilises microtubules for nuclear import of the preintegration complex [260] 
and for uncoating [261, 262] and for this purpose, it requires stable microtubules. 
Microtubule acetylation has been shown to be upregulated by gp120 [263]. 
Overall this suggests that Env signaling could be involved in regulation of 
microtubule dynamics during HIV-1 infection. Microtubule stability is mediated by 
RhoA through the DIA pathway and by Rac1 via PAK and stathmin [264-266].  
Apart from the importance of Env signaling in T-cell activation via CD4, the 
evidence described, also suggests a role for Rho-GTPases in Env signaling 
through interaction with the co-receptor and possibly through signaling via 
expression of the gp41 CT which modifies the cell’s cytoskeleton. Rac1, RhoA 
and cdc42 are the best characterized members of the Rho family of GTPases 
(Rho GTPases) which have a central role in control of cell cytoplasm dynamics 
including regulation of cell motility, cytoskeleton and vesicular traffic [267].  Rho-
GTPases are controlled upstream by GTPase Activating Proteins (GAPs) and 
Guanine Nucleotide Exchange Factors (GEFs) [267]. However, the role of the 
upstream regulators of Rho-GTPases in HIV-1 Env signaling is largely unknown. 
Since the role of GAPs and GEFs in HIV-1 infection is the focus of chapter 4, 
upstream control of Rho-GTPases will be described in more detail in chapter 4. 
3.2 Aims 
Since Env signaling events are suspected to be essential for HIV-1 replication at 
early steps, my study focuses on enhancing the current understanding on HIV 
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Env signaling. I hypothesized that expression of the HIV-1 and HIV-2 gp41 CTs 
reduce tubulin acetylation at the single cell level and that HIV-1 Env-co-receptor 
signal transduction might control Rac1 through its upstream effectors. The 
proposed aims of this chapter are to: 
 Investigate whether expression of the HIV-1 and HIV-2 gp41 CTs, 
interferes with tubulin acetylation at the single cell level. 
 Determine whether using Raichu probes are an appropriate method to 
measure GTPase activity. 
 Study of the impact of treatment with Rac1 inhibitors EHT and NSC in 
HIV-1 NL4.3 (X4-tropic) and HIV-1 BaL (R5-tropic) infection. 
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3.3. Results  
3.3.1. Expression of HIV-1 and HIV-2 full length gp41 CTs reduces levels of 
acetylated tubulin. 
Microtubules undergo post-translational modifications at the C-terminus that 
produce microtubule subpopulations specific for different functions; these post-
translational modifications enable microtubule-Associated Proteins (MAPs) or 
motors to bind or unbind [268]. Post-translational modifications include 
detyrosination, glutamylation, glycylation, acetylation, phosphorylation, and 
palmitoylation [269]. In particular, tubulin acetylation has been shown to be 
present in microtubules which are less stable and thus, it is a marker for 
stability[259]. Malinowsky et al., described by Western-Blot quantitation that 
expression of  Env tail constructs induced a reduction of acetylated tubulin in 
HeLa-CD4+ cell lysates [258]. The control construct (anchor) comprised a 
transmembrane domain (TMD) derived from the platelet-derived growth factor 
receptor (amino acids 687-841) and a Myc/HA-tag (HA for hemagglutinin) (Figure 
3.2A). The full length constructs consisted of the full length HIV-1 (HIV-1 FL) and 
HIV-2 (HIV-2 FL) gp41 CTs fused to the same TMD and a Myc/HA-tag. Two 
additional constructs were included in the study which consist of two truncated 
versions of the HIV-1  and HIV-2 CTs (HIV-1 tr and HIV-2 tr respectively) which 
also are fused to the same TMD and a Myc/HA-tag and which incorporate C-
terminal deletions (amino acids 687-731 and aminoacids 687-741 respectively 
[258].  
To characterize further the reduction of acetylated tubulin upon expression of 
HIV-1 and HIV-2 Env tails, these results were confirmed at the single cell level. 
Single cell analysis gives more information about the localization of the 
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constructs in the cell and their expression levels. This can later be useful for the 
interpretation of the biological process.  
To confirm the reduction of acetylated tubulin in HeLa-CD4+, I examined this by 
epifluorescent imaging at the single cell level transfecting the HIV-1 and HIV-2 
CT constructs into HeLa-CD4+ cells (Figure 3.3A). After transfection, cells were 
fixed and stained against HA (to visualize constructs since they express an HA-
tag) and against anti-acetylated tubulin. As expected, since all constructs have 
transmembrane domains, the HIV-1 and HIV-2 gp41 CT constructs localize most 
abundantly in the cell membrane but also in the cytoplasm (Figure 3.3B). The 
anchor and truncated constructs are expressed at higher levels than the full-
length construct. Cells that express the full-length constructs and the truncated 
construct have less acetylated tubulin than anchor-control cells. However, 
quantification is required to confirm this visual result. 
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Figure 3.3. HIV-1 and HIV-2 Env CT constructs. (A) Schematic representation of 
anchor-only construct, HIV-1 full length (HIV-1 FL, aa 687-841) and HIV-1 truncated 
version (HIV-1 tr, ∆687-731). The same constructs were used with the HIV-2 sequence, 
an HIV-2 full length CT (HIV-2 FL, aa 697-859) and HIV-2 truncated (HIV-2 tr, aa 697-
741). B) Examples of epifluorescent images of the HIV-1 and HIV-2 CT constructs 
transfected  into HeLa-CD4+ cells,  stained  using an anti-HA-488 antibody for the gp41 
constructs (green) and anti- acetylated tubulin (red). Controls included were 
untransfected cells, immunostained with acetylated tubulin and anti-HA-488 and anchor-
transfected cells. Scale bar is representative of 10µM. N=3. 
A A B 
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Quantitative epifluorescent imaging was then performed to measure the levels of 
acetylated tubulin in single cells expressing the HIV-1 and HIV-2 CT constructs 
using ImageJ MBF. Acetylated tubulin levels per cell were quantified as 
described in chapter 2, section 2.2.9.2. Quantitative results show that upon 
expression of HIV-1 FL there is a significant decrease of acetylated tubulin 
compared to anchor control (p=0.033) (Figure 3.4A).  A decrease in acetylated 
tubulin was also observed upon expression of the HIV-1 tr construct although it 
was not significant (p=0.06). In the same fashion, expression of HIV-2 FL 
reduced the amount of acetylated tubulin significantly (p=0.046) suggesting that 
reduction of acetylated tubulin is a shared feature of lentiviral gp41 CTs (Figure 
3.4B). Expression of the truncated HIV-2 CT did not reduce tubulin acetylation 
significantly (p=0.07) although a decreasing tendency is observed if compared to 
anchor control.  Both these findings concur with those described by Malinowsky 
et al.,[258]. Interestingly, as can be seen in Figure 3.3B, even though the full-
length tail was expressed at lower levels than the truncated construct, the effect 
on reduction of tubulin acetylation is stronger upon expression of the full-length 
than upon expression of the truncated tail construct.   
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Figure 3.4. Expression of HIV-1 and HIV-2 CTs but not truncated, decrease the 
levels of acetylated tubulin in HeLa-CD4+ cells. HeLa-CD4+ cells were transfected 
with A)HIV-1 and B) HIV-2 FL and tr gp41 CT constructs. Cells were then fixed and 
double stained for acetylated tubulin and HA (to visualize the constructs). Single cell 
quantititative image analysis of the integrated mean density of the acetylated tubulin 
staining was performed with ImageJ MBF of cells expressing the tails. Results show a 
representative of 3 experiments; 300 cells in total were analysed. Significance was 
assessed by Wilcoxon Man-Whitney test*p<0.05.
B 
A 
  * 
B 
A 
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3.3.2. Investigating Raichu probes as GTPase activity biosensors  
 
So far in this chapter, my results and those of Malinowsky et al., [258] suggest 
that expression of the HIV-1 and HIV-2 full length Env CTs, reduces acetylation 
of tubulin, which is a marker of microtubule stability [259]. Microtubule stability is 
promoted through activation of RhoA which in turn activates DIA [264]. 
Downstream of DIA, End-binding protein 1 and adenomatous polyposis coli bind 
to the end of the microtubules and promote their stability possibly by forming a 
complex at stable microtubule ends [270]. Microtubule stability is also controlled 
by Rac1 via stathmin which is a downstream effector of Rac1 [265] (see figure 
3.1). Stathmin is a microtubule depolimerising protein that regulates microtubule 
dynamics by changes in phosphorylation; this dynamic regulation allows stathmin 
to, for example, regulate microtubule stability during cell cycle progression[271].  
In addition, Rac1 and RhoA  regulate each other [272] . It could be that HIV 
modulates the activity of Rac1 or RhoA to achieve this reduction of acetylated 
tubulin. Therefore, being able to measure the effect of gp41 cytoplasmic 
expression on the activity of Rho GTPases could shed light on the signaling 
mechanism that HIV Env orchestrates to modulate the cytoskeleton.  
Raichu probes are GTPase activity biosensors that have been described as 
reporters of GTPase activity at the single cell level by confocal microscopy [228].  
Classical methods to measure GTPase activity include biochemical pull down of 
active form (GTP-loaded) with known GTPase effector domains tagged to GTP 
(Glutathion S-transferase) [273]. This method does not give information about the 
localization of the active GTPase.  Nor is it sensitive enough to detect small 
changes. On the other hand, Raichu probes have proven to be useful in the 
understanding of spatio-temporal regulation of Rho GTPases [274-276]. This 
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method in turn, could serve to understand if Rho GTPases are activated upon 
expression of the HIV gp41 CT. 
The chosen method to measure Fluorescence Resonance Energy Transfer 
(FRET) was acceptor photobleaching (Figure 3.5). The Raichu probe, encoding 
Rac1 wild-type (Rac1 WT) or Rac1 constitutively active (Rac1 CA), consisted of: 
the GTPase protein, two fluorochromes: an acceptor, yellow fluorescent protein 
(YFP) (514/527) and a donor, cyan fluorescent protein (CFP) (433/475) and a 
GTP binding domain. GTPase activation brings the YFP and CFP fluorochromes 
into close proximity by a conformational change.  Upon acceptor photobleaching, 
if the GTPase is active,  YFP and CFP are within 5nm and there is an energy 
transfer which results in the excitation of YFP and very low excitation of CFP 
(Figure 3.5A) [277]. On the contrary, if the GTPase is not active, the two 
fluorochromes are more than 5nm from each other and the energy transfer upon 
bleaching does not occur (Figure 3.5B). In this case, the fluorochrome CFP is 
strongly excited. In acceptor photobleaching FRET efficiency is measured as the 
ratio of CFP before and after photobleaching.    
A.    B. 
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Figure 3.5. Schematic representation of the structure and mechanism of Raichu 
probes for the measurement of intracellular Rho GTPase activity. The Raichu probe 
encodes a small Rho GTPase, two fluorophores: YFP and CFP and a GTPase binding 
domain. A. If the Rho GTPAse is active (GTP-bound), upon bleaching, there is a 
Fluorescent  Resonance Energy Transfer (FRET) that results in excitation of YFP. B. If 
the GTPase is not active (GDP-bound), upon bleaching, there is no energy transfer and 
the YFP fluorochrome is not excited; the CFP is the fluorochrome excited. 
           ACTIVATION 
      INACTIVATION 
GAP: 
Inactivation 
GEF: 
Activation 
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I first tested the validity of using Raichu probes to measure GTPase activity. 
Rac1 WT and Rac1 CA Raichu probes were transfected into HeLa-CD4+ cells, to 
optimize photobleaching conditions.   
Images show that Rac1 WT (Figure 3.6A) and CA (Figure 3.6B) are expressed in 
HeLa-CD4+ cells as shown by the YFP expression. Pre-bleach, YFP is bright and 
post-bleach, YFP is not detectable, which suggests that bleaching parameters 
were set correctly. Their activity is shown in images where upon photobleaching, 
YFP is excited and CFP is detected (FRET efficiency). Importantly, activity of 
both Rac1 WT (Figure 3.6A FRET efficiency panel) and CA (Figure 3.6B FRET 
efficiency panel) is at its highest at the cell membrane which is where GTPases 
are mostly active. This suggests that Raichu probes are functional in HeLa-CD4+ 
cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Confocal imaging of Rac1 WT and Rac1 CA Raichu probes during FRET. 
Confocal images show HeLa-CD4+ cells transfected with (A) Rac1 WT and (B) Rac1 CA 
Raichu probes.  FRET efficiency or GTPase activity, which is the ratio of CFP emission pre 
and post-bleach, is represented in (orange/yellow) mostly at the cell membranes.YFP in green 
channel is bright pre-bleaching and is absent post-bleach. Red arrows indicate cells that were 
bleached with the parameters set. Purple arrows indicate cells that have lost the characteristic 
HeLa-CD4+ morphology. Image scale bar is representative of 10µM. Pseudocolor 16-bit 
grayscale gradient where warm colours indicate high FRET efficiency.  
65536 
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Once the photobleaching parameters were optimized (chapter 2, section 2.2.9.1), 
HeLa-CD4+ cells were transfected with Rac1WT or Rac1 CA. The purpose was 
to assess whether the Raichu probes were sensitive enough to measure Rac1 
WT and Rac1 CA changes in activity. Additionally, as a control, cells transfected 
with Rac1WT were treated with a Rac1 inhibitor, EHT. EHT is an inhibitor that 
binds directly to Rac1 [278] (Figure 3.7A). The cytotoxicity of both EHT and 
NSC23766 (NSC) (another Rac1 inhibitor employed further on as described in 
section 3.3.3) was assessed (Figure 3.7B and 3.7C). EHT and NSC showed no 
significant cytotoxicity upon treatment at 25µM and 12.5µM respectively.  
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Figure 3.7. Mode of action of EHT and NSC Rac1 inhibitors and FRET efficiency of Rac1 
WT, Rac1 WT in EHT-treated cells and Rac1 CA. (A) Schematic representation of inhibition 
targets of NSC and EHT. (B) Cytotoxic profile of TZM-bl cells treated with NSC for 48 hours as 
measured by MTT cytotoxicity assay. (C) Cytotoxic profile of TZM-bl cells treated with EHT for 
48 hours as measured by MTT cytotoxicity assay. (D) Cells were transfected with Rac1 WT 
and Rac1 CA constructs and treated or non-treated for 48 hours, time at which they were 
photobleached and readings of CFP before and after photobleaching were taken from the 
images in Figure 3.5 to calculate the ratio or %FRET efficiency using the AccPbFRET plugin 
from ImageJ MBF. In total, 21 cells were analysed, n=1. Error bars represent Standard 
Deviation, STDEV. Cytotoxicity assays were performed by Dr. Aysegul Tosun.  
(C) 
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Quantification of 15 cells of the ratio of CFP before and after photobleaching 
(Figure 3.7D) pre- and post-bleach showed that Rac1 WT has a FRET efficiency 
(GTPase activity) of 13% and Rac1 CA of 12%. In EHT-treated cells, FRET 
efficiency decreased to 9% which is only 4% and 3% compared with untreated 
Rac1 WT and Rac1 CA.  Typically, Rac1 WT and Rac1 CA differ in a 2-fold 
FRET efficiency difference [274]. Since the differences were not very strong 
compared to what others have reported, it was agreed that acceptor 
photobleaching of Raichu probes was not suitable for measuring changes in 
GTPase activity in HeLa-CD4+ cells. In addition, it was observed that Raichu 
probes were toxic since transfected cells did not look very healthy; for example 
cell cytoplasm was rounded and had lost the HeLa-CD4+-characteristic 
elongated cytoplasm (see cells with purple arrows in Figure 3.6). Since the 
objective was to double transfect the gp41 constructs and the Raichu probes, it 
was thought that this could additionally affect cell viability and so, the use of the 
probes was discontinued. 
3.3.3. Treatment with Rac1 inhibitor, NSC, decreases infection of HIV-1 NL4.3 
but not HIV-1 BaL. 
Results in section 3.3.1 indicate that expression of the HIV-1 and HIV-2 gp41 FL 
CT in HeLa-CD4+ cells reduces acetylated tubulin. Tubulin acetylation is a 
marker of microtubule stability [259]; apart from RhoA, microtubule stability is 
also regulated by Rac1 via PAK and stathmin [265, 266]. It could be that, to 
modulate the cytoskeleton via Env, HIV requires Rac1. I therefore hypothesized 
that Rac1 could have a role in HIV-1 infection.  
Two Rac1 inhibitors, EHT [278] and NSC [279], were employed to investigate 
their effect on HIV-1 infection. These inhibitors target Rac1 through different 
mechanisms (Figure 3.7A). For instance, EHT targets Rac1 by binding directly to 
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Rac1 [278] whilst NSC targets Rac1 by specifically binding to its GEF upstream 
activators, Tiam1 and TrioN [280].  
Rac1 has been shown to promote microtubule stability through PAK and stathmin 
(Figure 3.1) [265, 266]; it is therefore expected that inhibiting Rac1 decreases 
microtubule stability. Previously, others have shown that EHT and NSC treatment 
causes alterations in normal microtubule organization [281]. To determine if 
treatment with EHT and NSC have an effect on microtubule stability of TZM-bl 
cells as an indirect measure of Rac1 inhibition, cells were treated with EHT and 
NSC at 25 µM and 12.5µM respectively for 24 hours and microtubules were 
immunostained. Results (Figure 3.8), show that upon DMSO treatment, 
microtubules have a fibrous morphology characteristic of microtubules. However, 
upon treatment with EHT, the microtubules morphology and organisation is 
diffuse and microtubule length is disturbed as would be expected upon inhibition 
of Rac1 since it controls microtubule stability. In addition, treatment with NSC, 
also disrupts microtubule organization and length as can be seen by the uneven, 
diffuse and irregular shape of the microtubules compared to untreated control. 
Altogether, results therefore suggest that treatment with EHT and NSC affect 
microtubule structure and since Rac1 has been shown to promote microtubule 
stability [265, 266], this could be an indirect measure of inhibition of Rac1 by EHT 
and NSC.  
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Figure 3.8  Microtubule disassembly after treatment with EHT and NSC. TZM-bl cells 
were treated with EHT and NSC at 25µM and 12.5µM for 24 hours, time at which they 
were fixed and stained with anti-tubulin-555 (orange) and DAPI (blue) to visualize nuclei. 
Scale bar represents 10 µM, n=1.  
 
I then assessed the effect of treating cells with EHT and NSC on infection of HIV-
1 NL4.3 (X4-tropic) and HIV-1 BaL (R5-tropic) which differ in co-receptor usage. I 
therefore hypothesized that the effect of treatment with EHT and NSC on 
infection could differ on the virus strain employed and so, that the effect could be 
co-receptor dependent. TZM-bl cells were pre-incubated with EHT and NSC at 
decreasing concentrations from 25µM and 12.5µM respectively and challenged 
with HIV-1 NL4.3 and HIV-1 BaL pseudotype virus. β-gal staining was performed 
to detect infected cells as described in section 2.2.5.3. Results show that 
Tubulin DAPI Overlay
+NSC23766
+ EHT1864
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treatment with EHT did not have an effect on HIV-1 BaL or HIV-1 NL4.3 infection 
in TZM-bl cells compared to DMSO-treated infected cells (Figure 3.9A). On the 
other hand, treatment of TZM-bl cells with 12.5µM of NSC inhibited 99% of HIV-1 
NL4.3 (Figure 3.9B) in a dose-dependent manner. Treatment with NSC had no 
effect on HIV-1 BaL infection suggesting that the effect observed is strain-
dependent and could depend on co-receptor usage. 
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Figure 3.9. Effect of EHT and NSC treatment on HIV-1 NL4.3 and HIV-1 BaL infection 
in TZM-bl cells. Cells were treated for 24 hours with (A) EHT at 25,  12.5 and 6.5 µM  
and (B) NSC at 12.5, 6.5 and 3.1 µM, then challenged with HIV-1 NL4.3 and BaL for 48 
hours and foci of infection determined. A representative of three independent 
experiments in triplicate is presented. Error bars represent STDEV. 
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3.3.4. Effect of EHT and NSC treatment on HIV-1 infection in T-cell lines.  
I next investigated the effect of NSC and EHT treatment in T-cell lines, PM1 and 
Jurkat cells which are more relevant cell lines in HIV-1 infection since T-cells are 
a primary infection target of HIV-1. 
Initially, the level of toxicity of EHT and NSC in PM1 and Jurkat cells was 
measured. Cells were incubated with EHT and NSC in serial drug dilutions from 
50µM to 3µM for 48 hours and cell viability was assayed with an (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt) (MTS) cytotoxic assay. In an MTS cytotoxicity assay, cell 
viability is proportional to the ability of cells to metabolically processing a 
tetrazolium salt, MTS [225].  
Cytotoxicity assay of NSC in Jurkat cells (Figure 3.10A) showed that at the range 
of NSC concentrations assayed there was 100% cell viability compared to DMSO 
which suggests that the inhibitor is not toxic at these concentrations. In PM1 
cells, treatment with NSC (Figure 3.10B) at concentrations higher than 25µM 
caused cell viability to decrease to 70% compared to DMSO. It was therefore 
decided to treat both Jurkat and PM1 cells with 12.5 µM, a concentration in which 
cell viability was of 100%. 
Cell viability of Jurkat cells upon treatment with 25 µM or higher (Figure 3.10C) 
was of 80% compared to DMSO alone.  Cell viability of PM1 cells, upon 
treatment with EHT from 3.125µM-12.5µM, was of 80-90% compared to DMSO 
(Figure 3.10D). However treatment with EHT concentrations higher than 12.5µM, 
caused PM1 cell viability to decrease to 60 and 40% compared to DMSO. For 
these reasons, it was decided to assay EHT at 12.5 µM for both cell lines.  
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Figure 3.10. Cytotoxic profiles of NSC and EHT in  Jurkats and PM1 cells. Top row, 
A representatitive cytotoxic profile of (A) Jurkats and (B) PM1 cells upon treatment with 
NSC at a range of drug concentrations from 3.1-50 µM 48 hours post-treatment. Bottom 
row, a representative cytotoxic profile of (C) Jurkats and (D) PM1 cells upon treatment 
with a range of drug concentrations from 3.1-50.0 µM, 48 hours post-treatment. 
Percentage of cells alive was normalised to DMSO-treated controls. Jurkats, n=3 and 
PM1, n=2. Per experiment each condition was done in triplicate. Error bars represent 
STDEV. 
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Having determined the concentrations of EHT and NSC which are not toxic for 
PM1 and Jurkat cells, I next determined the effect of these inhibitors on HIV-1 
infection. Since Jurkat cells only express CXCR4 and not CCR5, only HIV-1 
NL4.3 was assayed in Jurkat cells. PM1 cells express both CXCR4 and CCR5 
and so, HIV-1 NL4.3 and HIV-1 BaL were assayed. Infection with HIV-1 BaL and 
HIV-1 NL4.3 was measured by flow cytometry since these pseudotypes express 
GFP (described in chapter 2, section 2.2.5.4).  
PM1 cells treated with EHT for 48 hours were then challenged with HIV-1 NL4.3 
or BaL. Treatment with EHT in PM1 cells increased infection with HIV-1 NL4.3 
and HIV-1 BaL by 2% and 10% respectively (Figure 3.11A and 3.11B) compared 
to DMSO control. On the other hand, treatment of PM1 cells with NSC (Figure 
3.11A and 3.11B) decreased HIV-1 NL4.3 infection by 2% and had no effect on 
HIV-1 BaL infection (Figure 3.11B) compared to DMSO control.  
Treatment of Jurkat cells with EHT and NSC increased HIV-1 NL4.3 infection 2% 
and 6% respectively compared to DMSO (Figure 3.11C) control.  
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Figure 3.11. Effects of EHT and NSC treatment on HIV-1 NL4.3 and HIV-1 BaL 
infection in T-cell lines.  PM1 cells were treated with 12.5 µM EHT and NSC for 24 
hours and infected with (A) HIV-1 NL4.3 or (B) HIV-1 BaL for 48 hours. (C) Jurkat cells  
were treated with 12.5 µM EHT and NSC for 48 hours and infected with HIV-1 NL4.3. 
Flow cytometry was performed to measure the percentage of GFP-positive cells 
compared with DMSO treated in duplicate, N=1.  
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3.4. Discussion 
Consistent with the requirement of Rac1 activation for HIV-1 infection [241, 255, 
256, 282, 283], three independent experiments showed that treating cells with 
Rac1 inhibitor NSC, inhibited HIV-1 NL4.3 (X4-tropic) infection in TZM-bl cells 
(Figure 3.9). On the other hand, treatment with NSC had no effect on HIV-1 BaL 
infection. This pattern was similar upon treatment with NSC in a T-cell line, PM1 
cells, although the effects were smaller than in TZM-bl cells (Figure 3.11A and 
3.11B). This concurs with that of Zoughlami et al., who found that NSC-treated 
U87.CD4.CCR5 cells decreased HIV-1 HxB (X4-tropic) infection but had no effect 
on HIV-1 BaL (R5-tropic) infection [254]. Since, NSC targets Rac1 via its 
upstream regulators, Tiam1 and TrioN [279], this suggests that Tiam1 and TrioN 
have a role in HIV-1 infection which could be CXCR4-dependent and it could be 
confirmed by including other X4-tropic viruses. Importantly, it has previously been 
described that Rac1 inhibition causes a decrease of CXCR4 surface expression 
and most interestingly, Rac1 and CXCR4 are interacting partners [254]. It could 
therefore be that NSC treatment causes a decrease of CXCR4 which in turn 
decreases CXCR4 surface expression which would explain why this phenotype is 
observed for NL4.3 (X4-tropic) but not for HIV-1 BaL (R5-tropic). In contrast to my 
results and those of Zoughlami et al., Harmon et al found that NSC treatment 
inhibited an R5-tropic virus, HIV-1 ADA. It is possible that the opposing results 
could be explained by cell type differences.  Harmon et al.,  used U87 
astroglioma cells whilst I used TZM-bl cells, a cervical cancer cell line, and so 
phenotypes could be cell-specific; however, Zoughlami et al., also employed U87 
cells so it is possible that the observations made by Zoughlami et al and me, are 
HIV-1 BaL-specific rather than R5-specific. This could be tested by including 
other R5 strains such as ADA and YU2. Since sequence of V3 loops in Env 
determines co-receptor usage [284], an additional method to confirm these 
results would be by generating virus mutants with swapped V3 loops.   
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The step affected by Rac1 inhibition is an early step since the HIV-1 NL4.3 strain 
included in my experiments was a single-round infection virus which is not able to 
go through a full-replication cycle and is only integrated. The role of Rac1 in HIV-
1 has been suggested to modulate actin rearrangements for virus entry [241, 
255, 256]. It is possible that Env binds to CXCR4 and in doing so, recruits Rac1 
regulators, Tiam1 and TrioN, which then mediate actin rearrangement. On the 
other hand, a Tiam1/TrioN-mediated Rac1 activation could also have an effect on 
microtubules. For instance, Rac1 regulates microtubule stabilization [266] which 
is required for virus pre-nuclear integration[260, 285-287]. It could therefore be 
that Tiam1 and TrioN activate Rac1 which in turn, have an effect on both actin 
rearrangements for virus entry but also, stabilize microtubules for nuclear import. 
Whilst discrepancies lie on the virus strains assayed, altogether, results highlight 
a new role for Rac1 activators, Tiam1 and TrioN in Env-mediated signalling.   
Intriguingly, whilst blocking Rac1 via Tiam1 and TrioN significantly decreased 
HIV-1 NL4.3 infection, inhibiting Rac1 had no effect on NL4.3 nor BaL in TZM-bl. 
There is a possibility that EHT did not work. However, even though microtubule 
stability is an indirect measure of Rac1 activation, treatment with EHT caused a 
strong microtubule disassembly (Figure 3.8) which suggests that EHT is inhibiting 
Rac1 and thus, causing the expected effect on microtubule organization. EHT 
binds directly to Rac1 which blocks binding of Rac1 regulators [278]. A more 
plausible explanation could be that blocking Rac1 directly, has a strong effect 
that is counteracted by RhoA, since crosstalk between RhoA and Rac1 has been 
reported [288]. This is supported by the fact that EHT also has high affinity with 
Rac1b, Rac2 and Rac3 isoforms [278] and this general Rac1 inhibition might 
induce RhoA activation. Therefore, by inhibiting Rac1 directly, RhoA is 
upregulated and this has a knock on effect on Rac1 whose activity is unaffected 
by EHT. It could be that in Jurkats and PM1 cells, Rac1 regulation is very tightly 
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regulated and inhibition of Rac1 has an even stronger knock on effect that 
activates Rac1 and this is why an increase of NL4.3 infection is observed (Figure 
3.11A and 3.11C). Another explanation could be that EHT treatment actually 
targets different pathways in TZM-bl cells and the T-cell lines assayed, that affect 
HIV-1 infection differently. Furthermore, treatment with NSC increased HIV-1 
NL4.3 and BaL infection in Jurkats (Figure 3.11C), an opposing result to that 
observed in TZM-bl and PM1 cells; it could be that in Jurkats, Rac1 is regulated 
differently or that Jurkats do not express Tiam1 and TrioN and actually NSC non-
specifically targets another signalling pathway that is beneficial for the virus. 
Another possibility could be that Jurkats do not express Rac1 and so, that the 
increase in NL4.3 and BaL infection is an off-target effect. It is possible that 
measuring the levels of expression of Rac1, TrioN and Tiam1 in all cell types 
could help to further understand the results. 
It would therefore have been interesting to measure the activation status of Rac1 
and RhoA using Raichu probes upon treatment with NSC and EHT during HIV-1 
NL4.3 infection as this would have helped to understand the results. However, as 
shown in Figure 3.6, differences between Rac1 CA and Rac1WT were not very 
strong compared to what others have reported (2-fold) [274] and there was also 
some associated toxicity upon expression of the probes; therefore the use of this 
technique was discontinued. It could be that the more traditional methods to 
measure GTPase activity such as protein pull downs, could yield further clues to 
the mechanism by which HIV Env regulates Rho GTPases.  
Interestingly, quantitative fluorescent imaging of three independent experiments 
showed that expression of the HIV-1 and HIV-2 full length CTs, significantly 
decreased microtubule acetylation at the single cell level (Figure 3.4). The effect 
of expression of the FL HIV-1 and HIV-2 gp41 CTs was stronger than the effect 
of the truncated CTs despite being expressed at lower levels; this suggests that 
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the deleted domain absent in the truncated constructs is important for mediating 
the observed phenotype. In addition to Rac1 [266], microtubule stability is also 
regulated by RhoA via the DIA signaling pathway (Figure 3.1) [264, 289]. It is 
possible that the FL gp41 CT binds to an activator of RhoA and sequesters it, 
preventing RhoA activation which in turn, destabilizes microtubules. Others have 
reported that the gp41 CT binds to and activates P115-RhoGEF  and inhibits, 
viral replication [290]. Malinowsky et al, showed that expression of the gp41 full 
length reduces viral-cell fusion so both results concur [258].  Further studies in a 
stable cell line that has P115-RhoGEF knockdown followed by transient 
transfection of the CTs could help elucidate this phenotype; if loss of phenotype 
was observed in the cell line that has knockdown of P115-RhoGEF upon 
expression of the full length tail, this would support the hypothesis that the Env 
tail interacts with P115-RhoGEF. It could be confirmed doing protein pull-down 
assays to characterize this interaction together with confocal imaging 
colocalisation studies. It would also be interesting to see the effect of expression 
of the HIV-1 Env CT on actin structure to understand whether it might have a role 
in Env-mediated actin rearrangements. Altogether, these results suggest that the 
HIV-1 and HIV-2 Env CTs have a signaling role that triggers microtubule 
deacetylation; since expression of the HIV-1 Env CT has been shown to reduce 
virus-cell fusion [258], the Env CT and its possible interacting partners could be 
potential new therapeutical targets against HIV.  
Results described in this chapter situate Rac1 and perhaps RhoA in a central role 
in HIV-1 infection and their regulation, if further confirmed, could be different 
depending on co-receptor usage. Various studies describe the phenotypic switch 
from HIV R5-tropic viruses to X4-tropic viruses, as a marker for disease 
progression to AIDS concomitant with a rapid CD4 T-cell depletion [291-293]. 
Therefore identifying the specific pathways that are activated upon CXCR4 or 
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CCR5 engagement could be crucial for the design of novel drugs that block the 
phenotypic switch, highlighting the importance of increasing the current 
understanding of these pathways in the HIV context. Since a role for Tiam1 and 
TrioN was described, I went on to investigate whether other upstream regulators 
of Rac1, RhoA and cdc42 might have a role in HIV-1 NL4.3 and BaL infection 
which is the subject of chapter 4. 
3.5. Principal findings 
To summarise, in this chapter the following main findings were made: 
 In agreement with Malinowsky et al., expression of HIV-1 and HIV-2 FL 
CTs reduced tubulin acetylation significantly at the single cell level 
compared to control. Expression of truncated versions of HIV-1 and HIV-2 
tail (with deletions at amino acids 697-859 and 697-741 respectively), 
resulted in less tubulin acetylation suggesting that this domain may at 
least partially explain the phenotype observed. 
 In TZM-bl cells, treatment with Rac1 inhibitor NSC, which targets 
upstream regulators of Rac1, TrioN and Tiam1, inhibited 99% HIV-1 
NL4.3 infection but not HIV-1 BaL compared to control. This pattern was 
also observed in the PM1 T-cell line.  
 EHT treatment which targets Rac1 had no effect on NL4.3 or HIV-1 BaL 
infection in TZM-bl cells. On the other hand, EHT-treatment enhanced 
HIV-1 NL4.3 infection in both Jurkats and PM1 cells.   
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Chapter 4.  Role of Rho 
GTPase regulators in HIV-1 
infection 
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4.1 Introduction 
The Rho family of GTPase proteins (Rho GTPases) are part of the Ras super 
family of GTPases of which Rac1, RhoA and cdc42 are the best characterized 
[294].  Since they have a pivotal role in the cell, Rho GTPases are ubiquitously 
expressed across species with 20 Rho GTPases identified in humans [295]. A 
number of studies show that Rac1, RhoA and cdc42 regulate the actin 
cytoskeleton which maintains cell shape, motility, and polarity [296-299]. 
Furthermore, RhoA and Rac1 mediate microtubule stability [264-266]. In addition 
to their role in the cytoskeleton, Rho GTPases also participate in other key 
cellular processes such as gene transcription and cell survival [300]. Rho 
GTPases localize to many cellular compartments including endosomes, cytosol, 
multivesicular bodies, actin and nuclei  which reflects the many functions these 
proteins have in the cell [301]. Initially synthesized in the cytoplasm, their 
localization depends on post-translational modifications at the C-terminus such 
as prenylation, carboxyl methylation and AAX tripeptide proteolysis [302].  
Rho GTPases  weakly bind GTP and slowly hydrolyse GTP to GDP by breaking 
the GTP γ-phosphate bond [267]. In this manner, Rho GTPases cycle from their 
active GTP-bound form to their inactive GDP- form upon hydrolysis of GTP to 
GDP (Figure 4.1) [303]. In their active GTP-bound form, Rho GTPases can bind 
to downstream effectors that trigger signalling cascades [267] (for examples, see 
Figure 3.1). Cycling between their active and inactive forms is controlled 
upstream by three types of modulators: GTPase activating proteins (GAPs), 
guanine nucleotide exchange factors (GEFs), and guanine dissociation inhibitors 
(GDIs) [304]. Firstly, binding of GAPs stimulates and accelerates their hydrolytic 
activity, thus inactivating them [305]. On the other hand, GEFs bind to the Rho 
GTPase and force release of GDP , allowing GTP to bind to the Rho GTPase in 
an activation process [267]. Finally, since Rho GTPases are only active when 
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bound to the cell membrane, an additional regulation mechanism is provided by 
GDIs which, through interaction with the Rho GTPases, inhibit  Rho GTPase 
membrane localization [306].  
 
Figure 4.1. Regulation of Rho GTPases by GEFs, GAPs and GDIs. Schematic 
representation of the general mechanism of Rho GTPase (in blue) regulation. Rho 
GTPases are activated by displacement of GDP by GEFs which allows GTP to bind. Rho 
GTPases are inactivated by GAPs which accelerate hydrolysis of GTP to GDP with the 
release of inorganic phosphate (Pi). GDIs bind to the inactive form of GTPases, the GDP-
bound state, preventing GTPases from binding to the membrane and thus, preventing 
activation. Modified from [305]. 
 
As described in chapter 3 (section 3.1), studies have suggested that the HIV Env-
co-receptor interaction triggers signalling events inside the cell that aid virus 
infection. Briefly, HIV-1 activates Rac1 via Env-co-receptor signal transduction 
through activation of the Gα(q) signalling cascade [255, 256]. Moreover, the HIV-
1 Env upregulates the levels of active cofilin which causes breakdown of the actin 
barrier [80]; cofilin is controlled upstream by cdc42, RhoA and Rac1 [231, 253]. In 
addition, HIV-1 has also been shown to activate RhoA via Tat in neurons in an 
actin-dependent mechanism  [255, 307]. Recently, Wollard SM et al., showed 
that human brain tissues infected with HIV-1 have higher levels of activated Rac1 
Plasma membrane 
Cytoplasm 
104 
 
and that this activation is likely to be mediated by Env-CCR5 interaction [283]. 
The relevance of this finding lies on the fact that there are no antiretroviral targets 
that are able to prevent infection of the brain, one of the main latency reservoirs 
of HIV-1; an interesting therapeutic strategy could therefore be by targeting Rac1 
activity. 
In addition, results presented in chapter 3 showed that treatment with NSC which 
inhibits upstream regulators of Rac1, Tiam1 and TrioN, inhibited HIV-1 NL4.3 
(X4-tropic) which suggests that these upstream effectors have a role in HIV-1 
infection (Figure 3.9A). Interestingly, treatment with NSC had no effect on HIV-1 
BaL (R5-tropic) (Figure 3.9B). There may be different signalling pathways 
transduced depending on the Env/co-receptor combination or virus strain. In 
addition, expression of the full-length Env cytoplasmic tail caused a significant 
decrease in microtubule acetylation which is a marker of microtubule stability 
(Figure 3.4); microtubule stability is controlled by Rac1 and RhoA (chapter 3, 
figure 3.1) [258, 264, 308]. Upon deletion of the C-terminal domain (110 amino 
acids) of the cytoplasmic tail, the decrease in tubulin acetylation was not 
significant which suggests that this domain is important for the observed 
phenotype. This domain has been described to be necessary for interaction of 
the tail with P115-RhoGEF, an upstream regulator of RhoA [290]. 
Both, evidence from the literature and results presented in chapter 3 suggest  
that Rho GTPases play a role in HIV-1 infection. However, not much is known 
about the role of upstream regulators of Rho GTPases in HIV-1 infection. 
Understanding more about these proteins could shed light onto novel therapeutic 
cellular targets that mutate less easily than viral targets  (cellular DNA 
polymerases have proof-reading mechanisms whilst the HIV RT does not [309]) 
and are a less toxic option than targeting Rho GTPases directly since Rho 
GTPases are key cellular proteins. I hypothesized that GAPs and GEFs that 
105 
 
regulate Rho GTPases might play a positive or negative role in HIV-1 infection 
and that these roles might be different depending on viral co-receptor usage. 
 
4.2 Aims: 
 To determine if any of the known 145 upstream regulators of Rho 
GTPases have a role in HIV-1 infection. 
 To determine if the role of upstream effectors of Rho-GTPases is different 
in NL4.3 (X4-tropic) or HIV-1 BaL (R5-tropic) infection.  
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4.3. Results  
To identify if Rho GTPase upstream effectors affect HIV-1 BaL and HIV-1 NL4.3 
infection, a siRNA screen was performed which included knockdown of the 145 
known upstream regulators of Rho GTPase including GAPs and GEFs. 
Subsequently, a set of pre-seeded siRNAs on 96-well plates were purchased 
from ThermoDharmacon which included 4 single siRNAs against each of the 145 
GAPs and GEFs included per well (the list of targets is included in Appendix 2 
and the details of the sequences for each siRNA employed are included in the 
electronic version as a supplementary file).  
4.3.1. Optimisation of siGLO-transfected TZM-bl cells  
To optimise siRNA transfection of TZM-bl cells I tested two transfection reagents 
(Dharmacon reagent 1 and reagent 4). Dharmacon’s siGLO-Red transfection 
indicator was used to determine transfection efficiency. siGLO-Red has a 
fluorescent red tag (557/570nm) that can be detected using a confocal or 
epifluorescent microscope. Transfected cells were imaged by confocal 
microscopy: i) to estimate the transfection efficiency using both reagents in TZM-
bl cells and ii) to determine whether siGLO-Red was inside the cells as opposed 
to adhering to the external cell membrane. Control cells (untransfected) were 
cells incubated with siGLO-Red but with no added transfection reagent. 
Images show that there is no red signal in the untransfected cells compared to 
the cells transfected with siGLO-Red and reagent 1 or reagent 4 (Figure 4.2A). 
Some cells transfected with siGLO-Red and reagent 1 or reagent 4 appear to 
have a punctuated fluorescent signal in the cells’ cytoplasm and nuclei (yellow 
arrowheads). Quantification of cells that presented the punctuated red signal 
(siGLO-Red positive) versus those that did not present such staining (siGLO-Red 
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negative) (Figure 4.2B) showed that transfection efficiency with reagent 1 is of 
70% whilst transfection efficiency with reagent 4 is of 20%.  
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
Figure 4.2. Transfection efficiency of Dharmacon reagent 1 and Dharmacon reagent 
4 in TZM-bl cells. (A)TZM-bl cells were transfected with siGLO-Red using reagent 1 and 
reagent 4 and incubated for 48 hours, then fixed and imaged by confocal microscopy. 
DAPI (blue) was used to stain the nuclei. Size bar indicates 10µm. Yellow arrows indicate 
SiGLO-Red staining. (B) siGLO-Red positive cells compared to total cells in image. A 
total of 223 cells were analysed from two independent experiments.  
Cells onl 
Cells+ siGLO (no transfection reagent) 
0
10
20
30
40
50
60
70
80
Untransfected Reagent 1 Reagent 4
%
s
iG
L
O
-p
o
s
iti
ve
 c
e
lls
 c
o
m
p
a
re
d
 
to
 t
o
ta
l
108 
 
TZM-bl cells transfected with siGLO-Red, show a punctuated red signal close to 
the nuclei and in the cytoplasm which is absent in the control. However, these 
images are not sufficient to determine whether the siRNA is internalized in the 
transfected cells or adhered to the cell membrane. To confirm this, z-stack 
confocal imaging of cells transfected with siGLO-Red was performed. Z-stack 
confocal imaging allows image acquisition of optical slices of a cell which 
provides information on the localization of fluorescent signals detected in outer 
and inner planes of the cells analysed.  
A total of 29 optical sections of 0.3 µm in width were taken of two cells 
transfected with siGLO-Red; figure 4.3A shows the 29 images for the optical 
sections taken. As can be seen the punctuated red signal (yellow arrow) 
becomes into focus in the middle planes of the cell where the nuclei (DAPI) is at 
its brightest. As the nucleus comes out of focus in the more external planes of the 
cell (stacks 0-4.22 µm and stacks 8.44-9.08 µm onwards), the red signal also 
goes out of focus. This therefore suggests that siGLO-Red is internalized in the 
cell. In addition, the orthogonal view (Figure 4.3B) shows that the siGLO-Red 
signal is present, at the marked intersection through the XY and XZ planes that 
is, across the different optical slices of the cell which confirms that the siRNA is 
inside the cells.  Altogether, evidence shows that siGLO-Red becomes 
internalized in the cell when transfected into TZM-bl cells with reagent 1.  
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Figure 4.3. siGLO-Red is internalized in TZM-bl cells. Confocal 3D microscopy was 
performed of TZM-bl cells transfected with siGLO-Red and nuclei (DAPI, blue). A) Z plane 
confocal images of each Z-stack taken. Numbering on top left corner indicates the depth 
of the Z-stack; each Z-stack was of 0.32 µm. Yellow arrows indicate siGLO red. B) 
Orthogonal view of the red signal (punctuated staining) after transfection with siGLO-Red 
at the marked intersection (white lines) across the XZ and YZ planes.  Size bars indicate 
10µm.  
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4.3.2. siRNA screen of TZM-bl cells infected with HIV-1 BaL and HIV-1 NL4.3 
Once the transfection conditions were optimised, the siRNA screen was 
performed to investigate if known GAPs and GEFs that control Rho GTPases 
have an effect on HIV NL4.3 (X4-tropic) or HIV-1 BaL (R5-tropic) infection. The 
pre-plated siRNAs were rehydrated in transfection reagent 1 and TZM-bl cells 
were seeded in each well of the 96-well plates (two plates per screen: one for 
GAPs and one for GEFs) as described in 2.2.8.2. After incubation for 48 hours, 
cells were infected with replication-competent HIV-1 NL4.3 (X4-tropic) and HIV-1 
BaL (R5-tropic). Infection was detected by β-gal staining since TZM-bl cells have 
integrated β-galactosidase which is under control of the HIV-1 promoter 
(described in 2.2.5.3) [310]. Images of the control wells were taken using the 
INCell machine which includes a Nikon microscope able to take wide field 
images, appropriate to record virus-infected cells which after β-gal staining 
should present a characteristic dark blue staining. Using the images taken, 
quantification of virus-infected cells was performed by counting focus forming 
units per ml of virus added (FFU/ml).   
As described at the beginning of section 4.3, each target protein was knocked 
down with 4 different single siRNAs against each of the 145 known GAPs and 
GEFs per well. siRNAs were distributed across two 96-well plates (one for GAPs 
and one for GEFs) per screen. Moreover, each plate included a set of negative 
siRNA controls which consisted of four Dharmacon ON-TARGETplus® Non-
Targeting Control Pools (5 wells in total) which are not expected to interfere with 
HIV-1 infection. Additionally, 4 single siRNAs against CD4, CXCR4 and CCR5 
each were included as positive controls for siRNA knockdown. Since 
CD4/CXCR4 are required for HIV-1 NL4.3 infection (X4-tropic) and CD4/CCR5 
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are required for HIV-1 BaL infection (R5-tropic) it is expected that down-
modulation positively interferes with infection of either viruses.  
At the end of the screens, cells in some wells covered approximately 80-100% of 
the well and had the characteristic elongated cytoplasms of TZM-bl cells, ie. had 
a healthy normal morphology as previously observed in the laboratory. However, 
in other wells, cells presented irregular monolayers, ie. cells had detached 
possibly due to cell death and cell morphology of the remaining cells had a round 
shape which normally suggests cytotoxicity. In order to exclude false positives 
and to be able to compare results from different wells before performing the 
infected cells count, each well was assessed in terms of monolayer coverage 
(Figure 4.4, HIV-1 NL4.3 screen and Figure 4.5 HIV-1 BaL screen). For this 
purpose at the time of cell fixation, each well was visualized under a light 
microscope and assigned a score. The score was assigned to each well 
depending on the percentage of cells that covered the well as observed under a 
light microscope (raw data in appendix 3); a score of 1 was assigned when the 
monolayer coverage was of over 80% and a score of 0 was assigned when the 
monolayer coverage was lower than 80%. Wells with a 0 score were not included 
in the analysis. Importantly, results show that cells from the CXCR4, CD4 and 
CCR5 controls included in each screen were covered 100% of the well. The 10 
non-targeting controls of the BaL screen (5 per plate) also covered 100% of the 
well. In the NL4.3 screen, the 5 non-targeting controls of plate 1 covered 100% of 
the well whilst in plate 2, 3 non-targeting controls had 0% membrane integrity 
possibly due to contamination of those specific wells. However, since the other 7 
wells of non-targeting controls presented 100% monolayer coverage, the mean 
control count was performed of the 7 non-targeting controls. Interestingly, some 
of the knockdowns such as SYDE1 or ARGHAP10 seemed to affect monolayer 
coverage importantly in the NL4.3 screen whilst in the BaL screen, monolayer 
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coverage was of 100%. It could be that NL4.3 is more cytopathic than BaL and 
this is why differences in cytotoxicity are seen for a same knockdown in both 
screens.  
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Figure 4.4. Scores (0/1) of wells after siRNA knockdown of GAPs and HIV-1 NL4.3 infection (green) and HIV-1 BaL infection (red) according to 
monolayer coverage of cells. Each well was assessed according to the percentage of cells that covered well (monolayer coverage) through observation 
with a light microscope. Wells that presented 80-100% monolayer coverage were assigned a score of 1 and cells that presented under 80% of monolayer 
coverage were assigned a score of 0.  
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Figure 4.5. Scores (0/1) of wells after siRNA knockdown of GEFs and HIV-1 NL4.3 infection (green) and HIV-1 BaL infection (red) according to 
monolayer coverage of cells. Each well was assessed according to the percentage of cells that covered well (monolayer coverage) through observation 
with a light microscope. Wells that presented 80-100% monolayer coverage were assigned a score of 1 and cells that presented under 80% of monolayer 
coverage were assigned a score of 0.  
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Images of the control wells for the HIV-1 NL4.3 screen (Figure 4.6A, top row) 
show that in the CD4 and CXCR4 siRNA knockdowns, the number of HIV-1 
NL4.3 foci of infection  (dark β-gal staining) is lower compared to the number of 
infected cells in the cells alone and non-targeting siRNA controls. A decrease of 
foci of infection of 98% and 96% for CD4 and CXCR4 is confirmed quantitatively 
(Figure 4.6B) which suggests that the siRNA knockdowns are efficient.  HIV-1 
NL4.3 infection is unaffected by CCR5 knockdown and this is confirmed at the 
quantitative level whereby the number of FFU/ml of non-targeting siRNA and 
CCR5 are similar. This was expected since HIV-1 NL4.3 only uses CXCR4. The 
non-targeting and cells alone control should be similar.  
Images of the control wells of the HIV-1 BaL screen show that upon knockdown 
of CD4 and CCR5, infection is reduced compared to cells only and non-targeting 
siRNA controls as expected since these two receptors are required for HIV-1 BaL 
(R5-tropic) entry (Figure 4.6A, bottom row). A reduction of foci of infection of 98% 
and 76% for CD4 and CCR5 is confirmed at the quantitative level (Figure 4.6B) 
suggesting that the siRNA knockdowns are efficient. HIV-1 BaL-infected cells that 
had CXCR4 knockdown are visually slightly higher in number to non-targeting 
siRNA control and cells only control and this is confirmed quantitatively. Since the 
primary co-receptor of HIV-1 BaL is CCR5, it was expected that knockdown of 
CXCR4 had no effect on infection. The fact that it is slightly higher could be due 
to an effect of downregulation of CXCR4 on CCR5 expression levels. 
Overall the evidence presented, suggests that siRNA knockdown controls, 48 
hours after transfection efficiently block HIV-1 infection as expected. Therefore, I 
analyzed the rest of the targets. 
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Figure 4.6. siRNA knockdown controls of HIV-1 NL4.3 and HIV-1 BaL screens. TZM-
bl cells were transfected with non-targeting siRNA, anti-CD4, anti-CXCR4 and anti-CCR5 
siRNA using Dharmacon transfection reagent 1 for 48 hours and infected with (A) HIV-1 
NL4.3 (upper row) or BaL (bottom row) foci of infection 48 hours post infection. Cells 
were then fixed and infection was visualized by staining of β-galactosidase which is under 
the control of the HIV-1 promoter. (B) Mean number of infectious virus was calculated as 
focus forming units in each well containing non-targeting siRNA, cells only, anti-CD4, 
anti-CXCR4 and anti-CCR5 siRNA for each of the screens. N=1. FFU=Focus forming 
units.   
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In order to identify potential hits, an arbitrary threshold was established in which 
positive hits were those that increased or decreased infection by ±50%. Following 
this method, knockdown of GEFs and GAPS and subsequent infection with HIV-1 
NL4.3 or HIV-1 BaL revealed a set of proteins that upon knockdown, increased or 
decreased infection compared to non-targeting siRNA controls Figure 4.7 and 
Figure4.8. 
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(B) 
(A) 
Figure 4.7. HIV-1 NL4.3 siRNA screen results. (A) Number HIV-1 NL4.3 infected cells upon siRNA knockdowns of GEFs. B) Number of HIV-1 NL4.3 
infected cells upon siRNA knockdowns of GAPs hits. Infection is measured as foci of infection or focus forming units, FFU/ml. N=1.  
(A) 
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Figure 4.8. HIV-1 BaL siRNA screen results. (A) Number HIV-1 BaL infected cells upon siRNA knockdowns of GEFs. B) Number of HIV-1 BaL infected cells 
upon siRNA knockdowns of GAPs hits. Infection is measured as foci of infection or focus forming units FFU/ml. N=1. 
(B) 
(A) 
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In particular, knockdown of proteins found to increase infection of HIV-1 NL4.3 by 
2-fold were: DOCK8, ARHGEF9 and SNX26 (Figure 4.9A and 4.9B). On the 
other hand, knockdown of proteins found to decrease infection by 2-fold were: 
SWAP70, SGEF, ARHGEF10L, FGD6, ARHGEF4, ARHGEF9, FGD1 and 
PLEKH7 (Figure 4.9A and 4.9B).  In addition, knockdown of GAPs, RICH2, 
KIAA1688, FA13A1, PIK3R1, RALBP1 and SRGAP2 decreased NL4.3 infection.
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Figure 4.9. Effect of potential GEFs and GAPs on HIV-1 NL4.3 infection. (A) Number 
of HIV-1 NL4.3 infected cells upon siRNA knockdowns of GEFs. B) Number of HIV-1 
NL4.3 infected cells upon siRNA knockdowns of GAPs hits. Infection is measured as 
FFU/ml. N=1 
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On the other hand, all the proteins identified in the HIV-1 BaL screen had a 
decreasing effect on HIV-1 BaL infection upon knockdown (Figure 4.10A and 
4.10B). These included GEFs from the DOCK family of proteins: DOCK5, DOCK8 
and DOCK2. In addition knockdown of GEFs ARHGEF3, PLEKHG2, NET1, were 
found to decrease infection. Two GEFs, ITNS1 and ITNS2, members of the 
Intersectin family of proteins were found to decrease HIV-1 Bal infection upon 
knockdown. In addition, ARHGEF12 and ARHGEF5 decreased HIV-1 BaL 
infection upon knockdown. Furthermore, SOS1, VAV3 and PLEKHG7 were also 
GEFs that decreased infection upon knockdown. Remarkably, a number of 
members from the ARHGAP family of proteins had all a decreasing effect on HIV-
1 BaL infection including: ARHGAP11A, ARHGAP15, ARHGAP17, ARHGAP20, 
ARHGAP21, ARHGAP26, ARHGAP4, ARHGAP29, ARHGAP5, ARHGAP8. In 
addition, knockdown of GEFs FAM13B1, CDGAP, ARAP2, ARAP1, CHN2, 
FLJ32810, GRLF1, FAM13A1, OCRL, OPHN1, PIK3R1, SNX26, SRGAP1 and 
STARD8 were also found to decrease HIV-1 BaL infection. 
Interestingly the pattern of proteins found to increase/decrease HIV-1 BaL or HIV-
1 NL4.3 is different but there are also some common hits identified in both 
screens. 
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Figure 4.10. Effect of potential GAPs and GEFs on HIV-1 BaL infection. (A) Number 
HIV-1 BaL infected cells (FFU/ml) upon siRNA knockdowns of GAP hits. B) Number of 
HIV-1 BaL infected cells upon siRNA knockdowns of GEFs hits. N=1. Infection is 
measured as FFU/ml. 
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4.4 Discussion  
At early stages of infection, HIV-1 Env interacts with a main receptor, CD4 and a 
co-receptor, CXCR4 or CCR5 [48]. These interactions result in 1) access into the 
cell and 2) signalling events [80, 232, 242, 255, 283, 311, 312], that change the 
cell’s environment for replication advantage. The first objective has been well 
characterized in an effort to develop inhibitors which block viral entry and so, viral 
infection [313]. These efforts have contributed to the development of entry 
inhibitors which are widely used as part of the HAART drug regime such as 
maraviroc  [139, 313], a CCR5 antagonist or fuzeon, a gp41 fusion peptide [131]. 
However, Env signaling and its downstream consequences for HIV-1 infection is 
one of the aspect of HIV biology that it is still not well understood.  
Results presented in chapter 3 suggested that upstream effectors that control 
Rac1, Tiam1 and TrioN, have a role in HIV-1 infection since, treatment with NSC, 
an inhibitor designed to inhibit these proteins, reduced HIV-1 NL4.3 infection 
(Figure 3.9). Interestingly, treatment with NSC had no effect on HIV-1 BaL 
infection. I therefore hypothesized: i)that there could be other upstream 
regulators of Rho GTPases that may be involved in HIV-1 infection and 2)that it 
could be that there are differences between signaling events elicited by the Env 
protein of an X4-tropic virus (HIV-1 NL4.3) and an R5-tropic virus (HIV-1 BaL). 
Screening of 145 GAPs and GEFs that regulate Rho GTPases identified 31 
proteins in total which can be divided into three classes: 1) proteins that had a 2-
fold effect on HIV-1 NL4.3 infection, 2) proteins that had a 2-fold effect on HIV-1 
BaL infection and 3) proteins that had a 2-fold effect on both HIV-1 NL4.3 and 
BaL infection (Figure 4.11A). To identify signalling pathways involved, each hit 
was searched in PubMed, NCBI Gene and UniProt EMBL databases (Figure 
4.11B and 4.11C).  
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(B) (C) 
Figure 4.11. (A) Summary of GAPs and GEFs hits identified in siRNA upon HIV-1 NL4.3 and HIV-1 BaL infection. (B) HIV-1 NL4.3 and (C) HIV-1 BaL hits are 
organized based on an increase or decrease effect on infection upon knockdown and on the basis of Rho GTPase known target. A database search was done using 
PubMed, NCBI Gene and UniProt EMBL to identify the Rho GTPase target of each hit and references are included.   
 
(A) 
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The screen was performed, having previously optimized the best transfection 
conditions in TZM-bl cells by trialling the efficiency of two different transfection 
reagents (Figure 4.2) and after confirmation that the siRNA was internalized at 
the chosen conditions (Figure 4.3). In the screens performed, each GAP and 
GEF protein was knocked down with 4 single siRNAs per well. In addition, 5 non-
targeting siRNAs per plate were included and 4 single siRNAs per target against 
CD4, CXCR4 and CCR5 were included in each plate. Although Western-Blot 
analysis of the knockdowns was not performed, siRNA knockdowns against CD4, 
CXCR4 and CCR5 proved to be efficient robustly across the 4 plates since there 
was a decrease of HIV-1 NL4.3 infection upon knockdown of CD4 and upon 
knockdown of CXCR4 and a decrease of HIV-1 BaL infection upon knockdown of 
CD4 and upon knockdown of CCR5 as expected (Figure 4.6).  
Results support the first hypothesis formulated in this chapter: that GAPs and 
GEFs not previously described for HIV, may have a role in HIV-1 infection since 
upon knockdown of these genes the levels of infection are altered compared to 
controls. In fact, the majority of proteins that had an effect on HIV-1 NL4.3 or BaL 
infection are different.  These results therefore also support the second 
hypothesis formulated: that it could be that the signal transduction pathways 
elicited by the Env protein of HIV-1 NL4.3 (X4-tropic) and HIV-1 BaL (R5-tropic) 
are different. Interestingly, DOCK8, PIK3R1, PLEHGH7, FAM13A, VAV3 and 
SNX6 were found to have effects on both HIV-1 NL4.3 and BaL infection which 
also suggests that there are common signalling pathways triggered by both HIV-1 
virus strains. Unfortunately the Rho-GTPase target for PLEHGH7, FAM13A and 
SNX6 is unknown so further conclusions cannot be made.  
Knockdown of the GEF protein DOCK8, inhibited HIV-1 BaL infection. From a 
mechanistic point of view, HIV-1 BaL inhibition of infection by knockdown of 
DOCK8 is reasonable. DOCK8 is an activator of Rac1 [342] and HIV-1 Env has 
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been shown to activate Rac1 to rearrange the actin cytoskeleton for cell entry 
[254-256]; therefore it would be expected that targeting Rac1 activation causes a 
decrease in infection since actin is not depolymerised, preventing efficient HIV 
internalization. Supporting this rationale, other members of the DOCK family, 
DOCK2 and DOCK5, also decreased BaL infection since they also activate Rac1 
[325]. In particular, DOCK2  has been shown to form a complex with HIV-1 Nef 
that activates Rac1 and this in turn, inhibits T-cell chemotaxis [282] ; it could 
therefore be that knocking down DOCK2 prevents Nef-DOCK2 activation of 
Rac1. Intriguingly, knockdown of DOCK8 results in enhancement of HIV-1 NL4.3 
as opposed to the decreasing observation of HIV-1 BaL infection. An explanation 
could be that knock down of DOCK8 affects an additional pathway to Rac1 
activation that is important for HIV-1 NL4.3 infection.  For instance, DOCK8 has 
also been shown to target cdc42 activation [343] and so, it is possible that this 
pathway is involved in HIV-1 NL4.3 infection specifically.   
The role of Rac1 activation in HIV-1 infection is further supported by the fact that 
knockdown of all of the GEF hits identified in both screens (ARHGEF4, VAV3, 
PLEKHG2, SOS1..) that activate Rac1 (Figure 4.9A and 4.9B) have a decreasing 
effect on HIV-1 BaL and HIV-1 NL4.3 infection; other than the identified common 
hit DOCK8, all of the other GEFs identified are different suggesting that this 
pathway could be differentially regulated by NL4.3 and BaL Env proteins through 
engagement of CCR5 or CXCR4. It would be interesting to further confirm this 
with other R5/X4 strains to understand whether this differential regulation is 
X4/R5-tropic specific or only strain-specific.  
Cdc42 is upstream of LIMK1 which inactivates cofilin by phosphorylation [231]. 
On the other hand, Env signaling via CXCR4 activates cofilin which allows HIV to 
overcome cortical actin restriction [80]; It would therefore be expected that 
knockdown of cdc42 activators, enhances HIV-1 NL4.3 infection and knockdown 
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of inactivators, decreases HIV-1 NL4.3 infection. Following this rationale, 
knockdown of ARHGEF9, an activator of cdc42, increased HIV-1 NL4.3 infection 
and knockdown of RICH2, an inactivator of cdc42 decreased HIV-1 NL4.3. It 
could be that the reason behind why HIV-1 patients have active levels of cofilin 
upregulated [252], is due to an Env-triggered activation of cdc42 that is through 
viral regulation of ARHGEF9 or RICH2 and so, understanding further this 
pathway may enlighten the road to novel therapeutic targets that block the 
aberrant Env-triggered cofilin activation. Unexpectedly, knockdown of an activator 
of cdc42, FDG6, decreased HIV-1 NL4.3 infection. This protein has been shown 
to associate with filamin [344] which in turn, is required for actin-dependent 
CXCR4 clustering to aid virus entry [79], so it could that knockdown of FDG6 
affects this pathway negatively. 
In the HIV-1 BaL screen a different set of cdc42 regulators were identified 
suggesting that HIV-1 BaL and HIV-1 NL4.3 Env, trigger different cdc42 signalling 
pathways. The differences are not only in the proteins identified but possibly also 
in the mechanism. For instance, whilst knockdown of cdc42 activator ARHGEF9 
increased NL4.3 infection, knockdown of cdc42 activators, ITSN1 and ITSN2, 
decreased HIV-1 BaL infection. Apart from their role in signaling via cdc42 
activation [330, 331], intersectins have been shown to have a role in clathrin and 
caveolin-mediated endocytosis as scaffold proteins [345]. HIV-1 has also been 
shown to enter the cell via endocytosis [76]. Interestingly, knockdown of two 
proteins from the Intersectin family of proteins, ITSN1 and ITSN2, were found to 
decrease HIV-1 BaL infection. It would therefore be interesting to further 
characterize this phenotype by comparison with a virus pseudotyped with 
Vesicular Stomatitis Virus (VSV-G) Env, a virus that enters cells via endocytosis 
[346]; this would contribute to understand whether upon knockdown of ITSN1 
and ITSN2, the endocytic pathway or the cdc42 signalling pathway is affected.  
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The role of RhoA in the HIV context is complex. Firstly, RhoA activation increases 
microtubule stability via mDIA [264]  and stathmin [265, 266] which is required for 
efficient nuclear import of the HIV-1 preintegration complex [286, 287]. On the 
other hand, RhoA is also involved in actin reorganization through the ROCK-
LIMK-cofilin [347] pathway which HIV subverts to overcome cortical actin 
restriction upon entry [80]. Therefore, RhoA activation might negatively or 
positively influence HIV-1 replication. In the screen it was observed that no matter 
whether the protein identified was an activator or inactivator of RhoA, the effect 
upon knockdown is a decreasing effect which might reflect these complexities. 
Interestingly, even though RhoA has these multiple roles that affect HIV-1 
replication, only one RhoA GEF, SWAP70, was identified in the NL4.3 screen as 
opposed to a number of RhoA GAPs and GEFs identified in the BaL screen, 
suggesting that RhoA might play a more central role in BaL infection than in 
NL4.3. 
There is no evidence for the role of GTPases other than Rac1, RhoA and cdc42 
in HIV-1 infection. Interestingly, knockdown of SGEF, a GEF that regulates RhoG 
and RALBP1, a GAP that regulates RaI respectively, decreased HIV-1 NL4.3 
which could suggest a novel role for these GTPases in HIV-1 replication. 
Finally, whilst inhibiting Tiam1 and TrioN via treatment with NSC, inhibited HIV-1 
NL4.3 (chapter 3), I observed that knockdown of Tiam1 increased NL4.3 infection 
(Appendix 4) and knockdown of TriO caused a small decrease of HIV-1 NL4.3 
infection ; the decrease/increase observed did not reach 2-fold and this is why 
they are not included in the main body of the chapter but as part of the 
appendices; however, since chapter 3 had experiments that included these 
proteins I deemed appropriate to comment them. The differences observed 
between siRNA and inhibitor phenotypes could be explained possibly by a 
difference in the viruses employed in both assays; whilst in the inhibitor 
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experiments, the viruses employed were single-round infection viruses, viruses 
employed in the screen were full-replication competent viruses. It could therefore 
be that early stages of HIV infection, present in the single round assay are 
affected by NSC treatment. This possibility could be confirmed by including full-
replication viruses in the inhibitor assays. It is also possible that whilst the siRNA 
specifically targeted Tiam1 or Trio, the Tiam1/TrioN combination that NSC 
targets, affects negatively NL4.3 virus replication.  
Altogether these results, if further confirmed by assaying other X4 and R5-tropic 
viruses, shed light on the differential signalling pathways activated upon different 
HIV Env-receptor engagement. Their importance in infection could yield novel 
therapeutic targets.  
4.5 Principal findings   
The following findings have been described: 
 Knockdown of 39 proteins encoding Rho-GTPase regulators had an effect 
on HIV-1 BaL or HIV-1 NL4.3 suggesting that Rho-GTPase regulators 
play a role in HIV-1 infection. 
 Importantly, the set of proteins identified in the BaL and HIV NL4.3 
screens were majorly different which suggests differences in the signaling 
pattern elicited by HIV-1 BaL and HIV-1 NL4.3 viruses. 
 All the activators of Rac1 identified in the screen had a decreasing effect 
on both HIV-1 BaL and NL4.3 infection highlighting the importance of 
Rac1 activation on HIV-1 infection and a possible novel role of these 
proteins in HIV-1 replication.  
 Interestingly, three members of the DOCK family inhibited HIV-1 BaL 
infection which could suggest a new role of these proteins with 
therapeutic potential. 
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Chapter 5. HIV-1 antiviral 
activity of PAF1 
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5.1 Introduction 
As reviewed in chapter 1 (section 1.10.9) Liu. et al., showed that upon 
knockdown of PAF1, there is an increase of HIV-1 early viral transcripts within 
two hours of infection [158].  As previously discussed the majority of the known 
cellular functions of PAF1 are mostly involved in control of transcription and gene 
expression (Chapter 1, section 1.10.9).  Interestingly the effects of PAF1c 
knockdown, enhanced viral reverse transcription, manifest within an hour of viral 
challenge.  I hypothesised 3 different models of how PAF1 could be blocking HIV-
1. Firstly, PAF1 could be restricting HIV-1 infection through its known nuclear 
functions. Secondly, PAF’s action may shuttle from the nucleus to the cytoplasm 
[348] upon detection of incoming virus. This hypothesis is reasonable since HIV 
restriction occurs at a very early stage of infection prior to integration  [158]. A 
third model, is an indirect mechanism by which upon HIV-1 entry, an unidentified 
protein signals to PAF1 which triggers effects of PAF1 from the nuclei resulting in 
expression of inflammatory genes. I therefore tested for evidence to support any 
of these three models. 
5.2 Aims 
The proposed aims for this chapter are: 
 To understand whether the nuclear localisation of 
PAF1 is required for HIV-1 infection. 
 To investigate whether PAF1 changes its cellular 
localisation upon HIV-1 infection. 
 To understand whether HIV-1 counteracts PAF1. 
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5.3 Results 
5.3.1 Quantitation of PAF1 mean integrated density in nuclei and cytoplasm 
To analyse PAF1 levels in nuclei and cytoplasm, the periphery of each cell was 
drawn using the free-hand drawing application of ImageJ MBF. This selection or 
region of interest (ROI) is defined as the total amount of PAF1 per cell. DAPI 
staining defines the limit of the nuclei (Figure 5.1). Since staining of PAF1 is 
stronger in the nuclei than in the cytoplasm, the nuclei were purposely drawn 
larger than their actual size. This is to prevent high intensity readouts from the 
nuclei being attributed to the cytoplasm. The cytoplasmic regions are defined as 
the difference between total and nuclear regions. An intensity threshold was set 
according to the staining in which black pixels correspond to background and red 
pixels correspond to foreground (or pixels to be analysed). The same intensity 
threshold was applied across each experiment. Integrated density levels of the 
thresholded images (corrected total fluorescence) were then determined for each 
cell in total, nuclear and cytoplasmic regions and mean integrated density levels 
were calculated. 
 
 
Figure 5.1. Example of the method of quantification of integrated density levels of 
PAF1. ROIs are selected (white lines) for the whole cell’s contour (total), nuclear regions 
are selected using DAPI and cytoplasmic regions are defined as the difference between 
total and nuclear. Equal thresholds (red) in the green channel are set for all images 
analysed. Scale bar represents 10 µm. *Since the staining was not very strong in the 
cytoplasm, contrast is increased to be able to visualise the cell’s periphery.   
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5.3.2. Characterisation of PAF1 cellular localisation.  
Immunostaining was performed to visualise where endogenous PAF1 was 
located in HeLa-CD4+ cells. Confocal images (Figure 5.2) show that PAF1 is 
localised mainly in the nuclei as shown by co-localisation with DAPI. The staining 
is continuous throughout the nucleus which suggests that PAF1 is present in all 
compartments of the nuclei, including the nucleoli; In addition, images also show 
that PAF1 is present in the cytoplasm. The cytoplasmic staining is weaker than in 
the nuclei, indicating that PAF1 is considerably less abundant in the cytoplasm; 
both these results are in agreement with previously published data by Zhu et al., 
who report a strong signal of PAF1 throughout the nuclei and a weak signal in the 
cytoplasm of HeLa cells [196]. Importantly, there is no observable fluorescent 
signal in cells stained with the secondary antibody alone in either cellular 
compartment. 
 
Figure 5.2. Endogenous PAF1 in Hela-CD4+ cells. Example of confocal images of 
HeLa-CD4+ cells stained for PAF1 (green). DAPI (blue) was used to visualise nuclei 
followed by anti-rabbit 488 secondary antibody, which was also used alone as negative 
control. Size bars represent 10µm. 
 
Quantification of mean integrated density was determined for total, nuclear and 
cytoplasmic regions of 120 cells from three independent experiments were 
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performed as described in section 5.3.1. Treatment with secondary antibody 
alone was included as a control. Importantly, the signal detected in negative 
control cells was found to be negligible compared to total PAF1 staining (Figure 
5.3A). Concordant with what was observed in the confocal images, quantitative 
image analysis showed that PAF1 is mainly localised in the nuclei (80%) and to a 
lesser extent in the cytoplasm (20%) (Figure 5.3B and 5.3C).  
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Figure 5.3. Endogenous PAF1 is expressed in nuclei and cytoplasm of HeLa-CD4+ 
cells. A. Mean integrated density quantification of endogenous PAF1 immunostaining in 
total HeLa-CD4+ cells stained for PAF1 and with secondary antibody (negative) alone. B. 
Mean integrated density quantification of endogenous PAF1 immunostaining in total, 
nuclear and cytoplasmic regions of HeLa-CD4+ cells. C. Mean percentage of PAF1 in 
nuclear and cytoplasmic regions compared to total. Data is representative of three 
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independent experiments. A total of 40 cells were analysed per experiment. Error bars 
represent SEM. 
To visualise more accurately the cellular distribution of endogenous PAF1, a 
confocal z-stack of a HeLa-CD4+ cell stained for endogenous PAF1 was 
performed.  For this purpose, a total of 33 confocal optical sections with a width 
of 1µm each were taken. In the orthogonal view of the PAF1 confocal z-stack, a 
representative optical slice is shown (Figure 5.4A). At the marked intersection, 
PAF1 is present in the cross section through the XY and XZ planes, that is, 
across the different optical slices of the cell.  Analysis of the integrated density of 
PAF1 in each optical slice was performed to make a more accurate measurement 
of the amount of PAF1 in the cytoplasm and nuclei in the different sections of the 
cell.  Figure 5.4B shows the quantification of the PAF1 fluorescent signal in nuclei 
and cytoplasm across different optical slices. The fluorescent signal intensity 
(integrated density, y-axis) is measured in each optical slice where each optical 
slice is 1µm in width. Results show that PAF1 is more abundant in the nuclei than 
in the cytoplasm across the optical slices. Maximum integrated density in nuclear 
and cytoplasmic compartments is present in the mid planes of the cell. Image 
acquisition was therefore performed in all experiments by focusing on the mid 
planes of the cell to ensure maximum fluorescent signal of both compartments 
was recorded.  
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Figure 5.4. Endogenous PAF1 is present in nuclei and cytoplasm throughout the 
cell’s volume.  A. Orthogonal view of a Z-stack confocal image of a HeLa-CD4+ cell 
immunostained for PAF1, scale bar represents 10 µm. B.  Integrated density levels of 
PAF1 measured for each optical slice in total, nuclear and cytoplasmic regions. 
 
To confirm the presence of PAF1 in the cytoplasm, HeLa-CD4+ cells were 
fractionated by sucrose gradient centrifugation to purify the nuclear and 
cytoplasmic fractions (method in section 2.2.2). Since GAPDH and Histone3 are 
found mainly in the cytoplasm and in the nuclei respectively [349, 350], they were 
included as controls to assess the purity of the cytoplasmic and nuclear fractions 
respectively. Protein concentration was calculated by BCA reagent assay (see 
Methods 2.2.10). Equal amounts of protein were loaded in each lane. Western-
Blot analysis shows that GAPDH (expected size of 36 kDa) (the original Western-
Blot is included in Appendix 4) is absent in the nuclear fraction and that Histone3 
(expected size of 15 kDa) is absent in the cytoplasmic fraction, suggesting that 
the fractions were relatively pure (Figure 5.5A).  In both cytoplasmic and nuclear 
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fractions a band of approximately 80 kDa can be observed, which is the expected 
size of PAF1. This suggests that PAF1 is located in the nuclei and in the 
cytoplasm specifically. Additionally, a band around 60 kDa was also detected 
which again could possibly be a degradation product according to manufacturers. 
Densitometric analysis of the PAF1 bands (method in section 2.2.10) shows that 
PAF1 is localised 80% in the nuclei and 20% in the cytoplasm, a result which 
correlates with the single cell analysis data (Figure 5.5B). Altogether, both 
quantitative confocal imaging and cellular fractionation results suggest that 
endogenous PAF1 is localised in the cytoplasm and nucleus of HeLa-CD4+ cells. 
This is in agreement with Moniaux et al., who showed that were fractionated and 
Western-Blot analysis showed that PAF1 was present in both the nuclear and 
cytoplasmic compartments of Panc1 cells [351]. 
A   B  
 
 
 
 
 
 
 
Figure 5.5. Endogenous PAF1 is present in nuclear and cytoplasmic fractions of 
HeLa-CD4+ cells. A. Western blot analysis of PAF1 expression levels in nuclear and 
cytoplasmic fractions of HeLa-CD4+ cells. GAPDH and histone3 were included to monitor 
cytoplasmic and nuclear fraction purity respectively. B. Western-Blot densitometric 
analysis of PAF1 bands in nuclear and cytoplasmic fractions compared to total. The 
percentage of PAF1 in nuclear and cytoplasmic fractions compared to total was 
calculated by densitometry analysis using ImageJ MBF software. 
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5.3.3 siRNA knockdown of endogenous PAF1 results in a decrease of PAF1 in 
the nuclei and cytoplasm of HeLa-CD4+ cells.  
The specificity of the PAF1 antibody was tested. HeLa-CD4+ cells were treated 
with 10nM of a control non-targeting siRNA, cyclophilin B (CB) control, and 
siRNA specific for PAF1 for 72 hours (method in section 2.2.9.3). Cells were then 
fixed and stained for endogenous PAF1 and DAPI was used to visualise nuclei. 
Confocal images (Figure 5.6A) show that the fluorescent signal in PAF1-siRNA 
knockdown cells is strongly decreased compared to CB control cells. Importantly, 
there is no detectable fluorescent signal in the green channel in cells incubated 
with anti-rabbit488 secondary antibody only. These results confirm the specificity 
of the antibody.  As can be seen, the PAF1 siRNA knockdown effect is variable 
from cell to cell; some cells present a strong downregulation evidenced by a 
steep decrease of fluorescent signal especially in the nucleus (cells marked with 
arrowheads) whilst other cells have a more modest decrease in fluorescent signal 
which suggests that the knockdown was not 100% efficient. This result is in 
agreement with Western-Blot analysis of cell lysates (Figure 5.6B) that had been 
treated with siRNA against PAF1 whereby the levels of PAF1 are the lowest in 
the PAF1 knockdown cells (as expected) compared to cells only and CB control 
but PAF1 can still be detected. Western-Blot analysis (method in section 2.2.10).  
using the PAF1 antibody detects three bands: a band of approximately 80 kDa, 
which is the expected size of PAF1, a band at around 60 kDa, which has been 
described by the manufacturers as a possible degradation product, and a band at 
around 160 kDa. Nevertheless, even though the siRNA knockdown was only a 
50-70% efficient, confocal images and Western-Blot analysis show a decrease in 
the levels of PAF1 which support the notion that the antibody is specific.  
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5.6. PAF1 siRNA knockdown downregulates PAF1 protein levels. Cells were treated 
with siRNA against CB (control) and PAF1 for 72 hours. HeLa-CD4+ cells were then fixed 
and stained for endogenous PAF1. A. Example of confocal images of HeLa-CD4+ cells 
stained for PAF1 (green) after treatment with siRNA against CB and PAF1 (PAF1 KD). 
DAPI (blue) was used to visualise nuclei. Anti-rabbit 488 secondary antibody was used as 
negative control.  Arrow heads indicate cells with a strong decrease of PAF1 expression 
levels. Scale bar represents 10 µm. B. Western-Blot analysis of cell lysates from cells 
treated with siRNA against PAF1 (PAF1 KD) and CB. Number represents the ratio of 
PAF1 (band at ~80kDa) normalised to GAPDH. Cells only control was also included. CB= 
Cyclophillin B.  
 
To characterise whether the decrease of PAF1 upon knockdown occurs in total 
cells and nuclear and cytoplasmic compartments, ie. whether the staining is 
specific, quantification of the integrated density levels of PAF1 in knockdown cells 
was performed compared to CB control.  
Confocal zoom images (Figure 5.7A) of single cells treated with CB and PAF1 
siRNA show that there is a strong decrease of the fluorescent signal of PAF1 in 
the nucleus. The fluorescent signal of an immunostain can vary in different 
experiments. To compare results of different experiments and to analyse them 
statistically, integrated density levels of CB control and siRNA knockdown cells 
were normalised to average CB control integrated density (Figure 5.7B) in each 
142 
 
 
experiment. Results from three experiments show that there is a decrease of 
60% of total PAF1 upon PAF1 siRNA knockdown compared to CB control at the 
single cell level. 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Effect of PAF1 siRNA knockdown on total, nuclear and cytoplasmic 
endogenous PAF1 levels. Cells were treated with siRNA against cyclophillin B (control) 
and PAF1 for 72 hours. HeLa-CD4+ cells were then fixed and stained for endogenous 
PAF1. A. Example of confocal images of a HeLa-CD4+ cells stained for PAF1 (green). 
DAPI (blue) was used to visualise nuclei after treatment with siRNA against CB and 
PAF1. B. Total endogenous PAF1 integrated density levels. C. Nuclear mean percentage 
of PAF1 in CB and PAF1-siRNA treated cells compared to CB control.  D. Cytoplasmic 
PAF1 in siRNA- to PAF treated cells compared to CB control.  Data is representative of 
three independent experiments. A total of 220 cells were analysed. Scale bar represents 
10 µm. Error bars represent SEM. Significance was assessed by Wilcoxon Man-Whitney 
test ,**P<0.01. Error bars represent SEM.  Size bars represent 10µm. 
 
Having confirmed by Western-Blot (Figure 5.6B) and at the single cell level 
(Figure 5.7B), that upon siRNA knockdown, total PAF1 protein levels are 
B 
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downregulated, the next step was to understand if there is a loss of PAF1 
fluorescent signal in the cytoplasm as well as the nucleus whether the 
cytoplasmic and/or nuclear staining is specific. A decrease of PAF1 in the 
cytoplasm and nuclei of PAF1 knockdown cells compared to CB control is 
observable (Figure 5.7B) but the decrease in the cytoplasm is less convincing 
visually possibly because cytoplasmic PAF1 is already low in CB control cells. 
So, quantitative analysis was performed of each cell compartment. Mean 
integrated density levels were measured in nuclei and cytoplasm and normalised 
to the average CB control (Figure 5.7C and Figure 5.7D). Results show that both 
nuclear and cytoplasmic PAF1 levels are reduced more than 50% upon PAF1 
knockdown compared to CB control.  Since there is a loss of the fluorescent 
signal in the nuclei and in the cytoplasm upon knockdown of PAF1, this suggests 
that PAF1 is reduced by equal amounts in both cellular compartments.  
5.3.4 Effect of overexpression of murine PAF1 constructs on HIV-1 infection.  
In 2013, Kim et al., generated a series of murine PAF1 (mPAF1) constructs with 
the aim of understanding the functional domains that are involved in its role in the 
transcriptional repression of genes induced by interleukin 1β (IL-1β) [352]. These 
constructs were kindly provided by Kim et al., A schematic representation of 
these constructs (Figure (5.8A) shows that murine wild type PAF1 (mPAF1WT) is 
535 amino acids in length, the mPAF1ΔNLS deletion mutant has a deletion of 
amino acids 255-284 and the deletion mutant that abrogates its chromatin 
binding function has a deletion of amino acids 285-355 (mPAF1(Δ285-355). 
Sequence alignment of the murine and human PAF1 sequences was performed 
by ClustalW2 software to understand how conserved the NLS and chromatin 
binding regions are (Figure 5.8B). Results show that the nuclear localisation 
signal and chromatin binding domain described by Kim.N. et al. in the murine 
model is 100% conserved in human PAF1. They could therefore, be useful tools 
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to further understand the relationship between the HIV-1 antiviral function and 
cellular localisation of PAF1. 
To confirm the cellular localisation in HeLa-CD4+ cells of the murine constructs, 
HeLa-CD4+ cells were fixed and stained 24-hours post-transfection with the 
PAF1 murine constructs. Since the constructs have a Myc-tag, cells were stained 
for Myc for epifluorescent imaging. Images show that mPAF1WT and 
mPAF1Δ(285-355) are located mostly in the nuclei (Figure 5.8C and Figure 
5.8D). On the other hand, mPAF1ΔNLS is located mostly in the cytoplasm of 
HeLa-CD4+ cells as expected.    
To study the effect of overexpressing these constructs on HIV-1 infection, 
transfection of mPAF1WT, mPAF1ΔNLS and mPAF1(Δ285-355) was performed 
24 hours prior to HIV-1 89.6 viral challenge, alongside Myc-empty vector as 
control. Focus forming units or foci of infection (FFU) were quantified (method 
described in 2.2.5.5). Results show that overexpression of mPAF1WT results in a 
20% reduction in infection (Figure 5.8E). Similarly, overexpression of 
mPAF1ΔNLS also decreased HIV-1 infection by 20%. However, overexpression 
of mPAF1(Δ285-355) which is impaired for chromatin binding decreased infection 
by 40%.  Overexpression of mPAF1(Δ285-355) restricts HIV-1 infection better 
than mPAF1WT and mPAF1ΔNLS, suggesting that a nuclear function of PAF1 is 
responsible for its antiviral activity. 
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nuclear/cytoplasmic 
ratio
mPAF1WT 2,9
mPAF1ΔNLS 5,1
mPAF1Δ285-355 2,4
 
 
 
 
    
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. Effect of overexpression of murine PAF1 constructs. A. Schematic diagram of wild type 
mPAF1, mPAF1∆NLS and mPAF1∆285-355. B. Sequence alignment (ClustalW2) of the murine nuclear 
localisation signal and chromatin binding domain with the human PAF1 sequence.  C. Localisation of wild 
type mPAF1, mPAF1∆NLS and mPAF1∆285-355 in HeLa-CD4+ cells. Cells were transfected for 24 
hours and subsequently fixed and stained for anti-Myc. Untransfected cells were stained with anti-Myc as 
negative control. D. Mean nuclear/cytoplasmic ratio of cells expressing wild type mPAF1, mPAF1∆NLS 
and mPAF1∆285-355. (E) Effect of overexpression of wild type mPAF1, mPAF1∆NLS and mPAF1∆285-
355 upon HIV-1 89.6 infection. Cells were transfected with Myc-vector, wild type mPAF1, mPAF1∆NLS 
and mPAF1∆285-355. After 24 hours, cells were challenged with HIV-1 89.6 for 48-hours. FFU were 
quantified. Data is representative of three independent experiments. Significance was assessed by 
Wilcoxon Man-Whitney test ,**P<0.01. 
E 
D 
E 
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5.3.4 Effect of HIV-1 viral challenge on PAF1 expression levels at early stages of 
infection. 
To determine if PAF1 expression is altered after viral challenge, HeLa-CD4+ cells 
were incubated with replication-competent HIV-1 89.6 (obtained from the Centre 
for AIDS Research (NIBSC, UK)) at a MOI of 1, for 30 minutes, 1 and 6 hours 
then fixed and stained for PAF1.  To identify infected cells, cells were stained for 
HIV-1 CA (method in 2.2.9.3).  Cells were also lysed for Western-Blot 
densitometry analysis (methods in section 2.2.10). Confocal images (Figure 5.9A) 
show the initial basal level of endogenous PAF1 in uninfected HeLa-CD4+ cells 
with a negative signal in the CA red channel. Within 30 minutes after viral 
challenge, there is a decrease in endogenous PAF1 compared to unchallenged 
cells as seen by a reduction in fluorescent signal in the green PAF1. Levels of 
PAF1 at one hour post-infection are similar to unchallenged cells. At 6 hours 
post-infection, endogenous PAF1 fluorescent signal is stronger than in uninfected 
cells. CA staining is characterised by a punctuated particle-like morphology that 
accumulates at the cell’s membrane and in the cytoplasm and gets stronger over 
time. As previously observed in the lab, Western-Blot analysis of lysates from 
cells infected for 30 minutes, 1 hour and 6 hours (Figure 5.9B) show that there is 
a downregulation of PAF1 within 30 minutes of infection compared to uninfected, 
similar to observations made by confocal imaging. Protein levels of PAF1 
increase at 1 hour post-infection compared to the levels of PAF1 at 30 minutes 
post-infection; however, at 1 hour post infection, PAF1 levels are lower than 
uninfected.  At 6 hours post-infection there is a strong increase of PAF1 protein 
expression levels compared to uninfected.  
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Figure 5.9. PAF1 is downregulated during early stages of HIV-1 infection. HeLa-
CD4+ cells were challenged with HIV-1 89.6 for 0.5, 1 and 6 hours.  A. Example of 
confocal images of HeLa-CD4+ cells stained for PAF1 (green) and HIV-1CA (red) N=3. 
DAPI was used to visualise nuclei. Anti-rabbit Alexa 488 and anti-mouse Alexa 555 
secondary antibodies were used as negative controls. Scale bars represent 10 µm. B. 
Western-Blot analysis of the levels of PAF1 in HeLa-CD4+ cells at 0, 0.5, 1 and 6 hours 
post-infection N=1. Proportional band density (was measured using ImageJ MBF 
software.  
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Having observed that there is a change in the expression levels of PAF1 upon 
different time points of infection, I next quantified these changes at the single cell 
level as described in 2.2.9.3. As can be seen in figure 5.9A, not all cells are 
infected at 30 minutes and 1 hour of virus incubation. To analyse only the cells 
that were infected, a quantification method of infection was established using CA 
as a marker of infection. This method was established to distinguish between 
cells with internalised CA and cells that are negative for CA and also to quantify 
the number of cells infected per field of view taken at the different time points. 
In this quantification method (Figure 5.10A) endogenous PAF1 staining is used to 
mark the cell’s periphery. In the CA image, a threshold was set to exclude 
possible background pixels or CA aggregates. With this threshold, only CA 
particles that are within an area of 0.17-2.61 µm2 are included as positive. The 
threshold was kept constant across each experiment; using the set thresholds a 
mask was generated showing the CA particles that fall within the set parameters. 
Figure 5.10A shows an example of the method from an image of an endogenous 
PAF1 staining infected for 1 hour. Initially, the contour of the four cells was 
selected using the PAF1 staining to delimit the cell. Particle analysis in ImageJ 
MBF was performed and the ROIs were overlaid and the particles detected. In 
the image analysed, 3 out of 4 cells (75%) have detected internalised CA. Longer 
challenge times with virus should increase the number of CA particles detected 
because more time is allowed for virus to enter cells. Figure 5.10B shows an 
example of endogenous PAF1 immunostaining at 0, 0.5, 1 and 6 hours post 
challenge with a multiplicity of infection (MOI) of 0.1. MOI is the ratio of infectious 
HIV-1 particles per cell which is quantified for every virus stock produced by in 
situ p24 immunostaining (see section 2.2.5.3 for method). As can be observed in 
the mask showing the cells selected and particles detected by this method, no 
CA particles are detected in the unchallenged control. On the other hand, the 
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number of detected particles in each challenge time point increases with time. 
Figure 5.10C shows the mean percentage of cells with intracellular CA each time 
point of three independent experiments at an MOI of 0.1.  Within 30 minutes of 
virus incubation, 50% of the cells contain CA. Percentage of intracellular CA 
increases to 80% upon one hour of virus incubation and within 6 hours of virus 
incubation, 100% cells have intracellular CA. Since the number of cells with 
internalised CA increases with time robustly across experiments this suggests 
that this method of detection is valid.  In addition, infecting with a higher MOI, 
should increase the number of CA particles detected by the designed 
quantification method. Figure 5.10D shows the percentage of cells with 
internalised CA detected at 0, 0.5, 1 and 6 hours post infection with an MOI of 0.1 
and 1. Results show that, 30 minutes post-infection, the percentage of cells with 
intracellular CA with an MOI of 1 is two times higher than the percentage of cells 
with intracellular CA with an MOI of 0.1. Altogether, these results further validate 
the quantification method described, as a measure of internalised CA.  
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Figure 5.10. Intracellular CA levels upon incubation with HIV-1 89.6 for 0, 0.5, 1 and 
6 hours by quantitative confocal imaging. A. Method of quantification of CA particles. 
Top: Endogenous PAF1 (green), HIV-1 CA (red) and merged confocal images of 
HeLaHeLa-CD4+cellsinfected with HIV-1 89.6 for 1 hour. Bottom: cell selection mask 
(left), CA mask showing CAs detected (centre) and overlay mask of CAs detected in the 
selected cell regions (right). B. Confocal images of endogenous PAF1 (green) at different 
time points of infection (left column) and their corresponding masks generated (right 
column). Scale bars represent 10 µm. C. Mean percentage infection at 0, 0.5, 1 and 6 
hours post-infection. Data is representative of three independent experiments. D. Mean 
percentage HIV-1 infection of HeLa-CD4+ cells infected for 0, 0.5, 1 and 6 hours with 
MOIs of 0.1 and 1, n=1.  
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Using this method to define cells that have or not intracellular CA, the integrated 
density levels of PAF1 in infected cells were analysed at the different time points 
of infection. A total of 320 cells were analysed from three independent 
experiments. Total mean integrated density levels for each cell were measured 
and mean percentage PAF1 was calculated compared to uninfected cells. 
Results show that there is a significant decrease of PAF1 (40%) at 30 minutes 
after viral challenge compared to uninfected (Figure 5.11A). At one hour post-
infection, PAF1 expression levels are 110% expression levels in uninfected cells. 
At 6 hours post infection, integrated density levels of PAF1 are 1.8 fold higher 
than basal PAF1 levels in uninfected cells. Altogether, these results suggest that 
PAF1 is downregulated within 30 minutes of infection and that PAF1 expression 
levels then recover at one hour post-infection, increasing to levels higher than 
basal at 6 hours post-infection.  
Earlier I proposed a nuclear role in the mechanism for PAF1 restriction of HIV-1. I 
investigated if there was a change in localisation of PAF1 between the nucleus 
and cytoplasm, at different times of infection. PAF1 expression levels were 
analysed by quantitative confocal imaging as performed in the earlier studies 
presented in this chapter. consistent with what was observed by eye in 5.9A, the 
levels of PAF1 expression decrease within 30 minutes of infection, are similar 
within one hour of infection and are higher than uninfected PAF1 basal levels 
within 6 hours of infection (Figure 5.11A). In addition and similarly to what was 
previously observed (Figure 5.3C), results show that initially, in unchallenged 
cells, PAF1 localises 78% in the nuclei and 22% in the cytoplasm as previously 
observed (Figure 5.11B) .  Upon 30 minutes of infection, there is a small but 
significant change (p>0.05 as analysed by Wilcoxon Man-Whitney test) in PAF1 
distribution in which 72% of PAF1 localises in the nuclei and 28% localises in the 
cytoplasm. At one hour post infection, levels of PAF1 in nuclei and cytoplasm are 
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similar to unchallenged cells where PAF1 is present 76% in the nuclei and 24% in 
the cytoplasm. At 6 hours post infection 72% of PAF1 is present in the nuclei and 
28% is present in the cytoplasm (p=0.041). These results suggest that although 
small, there are changes in the cellular distribution of PAF1 upon infection.  
 
 
 
Figure 5.11. Effect of HIV-1 challenge on total, nuclear and cytoplasmic PAF1 
expression levels. A. Percentage of total PAF1 expression levels compared to 
uninfected in cells infected for 0, 0.5, 1 and 6 hours. Mean integrated density levels per 
cell were normalised to mean average integrated density levels in uninfected cells. B. 
Nuclear and cytoplasmic mean percentage PAF1 expression levels at 0, 0.5, 1 and 6 
hours post-infection compared to uninfected. 320 cells were analysed in total. Data is 
representative of three independent experiments. Error bars represent SEM. Significance 
was assessed by Wilcoxon Man-Whitney test *P<0.05 
 
5.3.5. HIV-1 requires viral entry to downregulate PAF1. 
PAF1 is downregulated within 30 minutes of HIV-1 infection as previously 
observed by confocal imaging and Western-Blot. To further investigate whether 
HIV infection might require entry to downregulate PAF1, HeLa-CD4+ cells were 
treated for 1 hour with anti-CD4 antibody prior to challenge with HIV-1 89.6 for 30 
minutes and 1 hour. Cells were then fixed and stained for endogenous PAF1 and 
HIV-1 CA. 
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Initially, to understand whether the anti-CD4 antibody is effective at blocking virus 
entry, CA quantification of confocal images (Figure 5.12A) was performed and 
the mean percentage of cells with detected intracellular CA for each time point 
was calculated as described in figure 5.10. Quantification of intracellular CA 
(figure 5.12B) shows that that at 30 minutes of challenge, 40% of cells have 
intracellular CA whilst in anti-CD4+-treated cells only 20% of cells have 
detectable CA. At 1 hour post challenge, 50% of untreated cells have intracellular 
CA whilst 25% of anti-CD4+ treated cells have intracellular CA. This therefore 
suggests that anti-CD4+ treatment partially decreases internalised CA levels by 
2-fold compared to untreated. 
 
 
 
 
 
 
Figure 5.12. Effect of anti-CD4+ treatment on PAF1 downregulation by HIV-1 in 
Hela-CD4+ cells. A..Mean percentage intracellular HIV-1 89.6 capsid in untreated and 
anti-CD4+ treated cells per field taken. B. Mean percentage total PAF1 integrated density 
levels normalised to uninfected in DMSO and anti-CD4+ treated cells, infected for 30 
minutes and 1 hour with HIV-1 89.6, N=1. Error bars represent SEM.MOI=0.6.  
 
Confocal images of control untreated cells, show that there is a decrease of 
PAF1 within 30 minutes of infection as previously characterised and that PAF1 
further decreases within one hour of challenge compared to uninfected (Figure 
5.13). On the other hand, in anti-CD4 treated cells, the decrease in PAF1 
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expression within 30 minutes is less strong than the decrease observed in 
untreated cells. Having confirmed that treatment with anti-CD4+ decreases viral 
entry, quantification of PAF1 integrated density levels was performed in cells, 
treated/untreated with anti-CD4 and challenged with HIV-1 for 30 minutes and 
one hour (Figure 5.13B). In untreated cells, there is a decrease of PAF1 of 40% 
compared to uninfected. In contrast, in cells treated with anti-CD4+ there is a 
decrease of only 15% of total PAF1, 30 minutes post-infection compared to 
unchallenged cells. One hour post-infection, levels of PAF1 in anti-CD4-treated 
cells, are similar to the levels of PAF1 in uninfected cells. Therefore, 
downregulation of PAF1 is stronger in untreated cells than in cells treated with 
anti-CD4 in which, there is less incoming virus compared to untreated. These 
results suggest that downregulation of PAF1 requires HIV-1 virus entry.  
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Figure 5.13. Effect of HIV-1 challenge on PAF1 on untreated/anti-CD4-treated cells. A. 
Confocal images of untreated cells infected with HIV-1 89.6 for 0, 0.5 and 1 hour stained for 
endogenous PAF1 (green) and HIV-1 CA (red). Anti-rabbit 488 and anti-mouse 555 secondary 
antibodies were used as negative controls. B. Confocal images of cells pre-treated with anti-CD4+ 
for one hour before infection with HIV-1 89.6 for 0, 0.5 and 1 hour stained for endogenous PAF1 
(green) and HIV-1 CA (red). Capsid is represented in white/black scale for ease of view. N=1. Scale 
bars represent 10 µm. 
B 
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5.4 Discussion 
Since PAF1 restriction of HIV-1 occurs at a very early stage of infection [158], I 
hypothesised that PAF1 could be acting via one or two of three mechanisms to 
inhibit HIV-1 infection: i) from the nuclei, ii)from the cytoplasm upon detection of 
incoming virus, iii) through an indirect mechanism via a signalling molecule in the 
cytoplasm that then signals to nuclear PAF1.  
After confirming the specificity of the PAF1 antibody by siRNA knockdown (Figure 
5.3), quantitative image analysis of three independent experiments showed that 
80% of PAF1 is located in the nuclei whilst 20% PAF1 is located in the cytoplasm 
(Figure 5.5); this result was confirmed by cellular fractionation (Figure 5.7). The 
presence of PAF1 mainly in the nuclei but also in the cytoplasm is concordant 
with other studies performed in different cell lines [196, 353, 354]. It would be 
interesting to siRNA knockdown other components of the PAF1c complex such 
as SKI8 [198] which has been shown to shuttle between the cytoplasm and the 
nuclei, to see if upon knockdown, PAF1 expression is lost in the cytoplasm. This 
would be a strategy to show that SKI8 might be involved in the localisation of 
PAF1 in the cytoplasm.  The presence of PAF1 in the nucleoli (Figure 5.4) was 
expected since, apart from the nuclear functions described, in yeast, PAF1 also 
binds ribosomal RNA and influences the rate of RNA pol I, involved in ribosome 
biogenesis which takes place in the nucleoli [355, 356]. In addition, yeast PAF1 
has a role in 3’ end formation of snoRNAs) through interaction with Nrd1 and 
Nab3 [208]. Altogether, results show that PAF1 is located in the nuclei and 
cytoplasm which does not exclude any of the initial hypothesis formulated.  
However, overexpression of the PAF1ΔNLS mutant has a similar effect to 
overexpression of mPAF1WT which inhibits 20% HIV-1 replication (Figure 5.8D). 
This suggests that having more PAF1 in the cytoplasm does not inhibit more 
efficiently HIV-1 replication; therefore its restriction function might not be exerted 
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from the cytoplasm but rather from the nucleus. Interestingly, overexpression of 
mPAF1∆285-355, the mutant that affects the chromatin binding ability of PAF1 
and that was found to be mainly nuclear (Figure 5.8C), restricts 40% of HIV-1 
infection, two times more potently than mPAF1wt. This suggests that PAF1 might 
restrict HIV-1 through a function that is nuclear but not necessarily through 
chromatin binding. Additionally, it could be that overexpression of the 
mPAF1∆285-355 changes the PAF1c stoichiometry and releases other 
components which may have a function in restricting HIV-1. For instance, Liu et 
al., showed that the individual components of the PAF1c also restrict HIV-1 
infection [158]. Overall the evidence presented suggests that PAF1 could be 
acting from the nuclei rather than from the cytoplasm.  
Results show that overexpression of mPAF1wt reduced HIV-1 infection by 20% 
whilst overexpression of a PAF1 human construct, inhibits over 50% infection 
suggesting that human PAF1 is more potent [158]. This could be due to a low 
transfection efficiency of the murine construct (Figure 5.8C). On the other hand, a 
Clustal W2 sequence alignment was performed and it showed that murine and 
human PAF1 differ in 5 amino acid residues which are all concentrated in the C-
terminal domain of PAF1 (Figure 5.8A). These substitutions of for example a non-
polar residue such as Alanine for a polar residue such as Threonine (in position 
386) are quite significant in molecular terms. It could be therefore, that these five 
amino acid changes in the murine and human PAF1 versions affect the PAF1 
HIV antiviral potency. It has been reported that the C-terminal domain of human 
PAF1 (residues 376-531), where these key amino acids are located, is a region 
involved in H3 binding [202]  which might be  important for HIV-1 restriction; this 
would favour a model whereby PAF1 could be restricting HIV-1 from the nuclei 
through regulation of H3 modifications and gene expression. In fact Marazzi et 
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al., showed that PAF1 directly interacts with H3 [29] which together with my 
results would further support a nuclear role of PAF1 in HIV-1 restriction.  
Confocal imaging and Western-Blot analysis of cell lysates supported the 
observation that challenge of cells with HIV-1 89.6 caused a decrease of 40% 
total endogenous PAF1 levels (Figure 5.9). These results suggest that PAF1 is a 
restriction factor that HIV-1 counteracts. Downregulation occurs within 30 minutes 
of virus challenge. It could be that the rapid down regulation is in fact mediated by 
Env signalling. Further studies with a VSV-G pseudotyped virus could help to test 
this. Alternatively, it could be that gp120 activates an indirect signalling pathway 
which in turn, results in PAF1 degradation. For example, gp120 has been shown 
to upregulate the macrophage colony-stimulating factor (M-CSF) which induces 
activation of pro-apoptotic pathways to avoid macrophage death [357]. However, 
Env signalling mediation is unlikely because the decrease in PAF1 expression is 
not as strong in cells treated with CD4+ than in untreated cells (Figure 5.13) 
which suggests that to downregulate PAF1, HIV-1 needs to be inside of cells.  
The CD4 observation better supports a model in which the very rapid 
downregulation of PAF1 could be mediated by a protein that enters the cell with 
HIV, a protein that is enclosed in the virus particle. It is known that upon viral 
assembly and release, HIV particles take up passively, a series of cellular 
proteins, mainly glycoproteins which are membrane-bound [358]. It could be that 
the HIV-1 viral particle enters with a cellular protein that upon entry, sequesters 
PAF1 and downregulates it. For example, the HIV particle is known to sequester 
ubiquitin[359]; ubiquitin ligase targets proteins to degradation pathways [360]. 
HIV-1 is also known to incorporate members of the endocytic pathway such as 
Rab5a [361] or clathrin [362] which could also target rapidly PAF1 for 
degradation. It could be that instead of a cellular protein, HIV utilises an 
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accessory viral protein to downregulate PAF1. For example Vpu counteracts 
tetherin by binding to it and targeting it to a lysosomal degradation pathway [171].  
Analysis of nuclear and cytoplasmic levels of PAF1 at the different time points, 
suggest that there is a significant change of the levels of PAF1 at these 
compartments (8%). Although significant, these changes are very small to 
conclude that it is the virus that actually changes PAF1 localisation, especially 
since PAF1 subcellular localisation depends on cell cycle [37]. Live cell imaging 
experiments with synchronised cells expressing a fluorescently-labelled PAF1 
construct and subsequent viral challenge could help understand better the spatio-
temporal changes of PAF1.  
A hurdle to current antiretroviral therapies is the ability of HIV-1 to rapidly mutate 
due to its high error-prone reverse transcriptase. On average, every three cycles 
of replication, an error is introduced in the HIV genome [363]. As a consequence, 
resistance to current treatments has been reported [364-366]. In addition, current 
treatments available are combination drug regimes that aim to inhibit multiple 
viral targets and limit resistance but pose toxicity problems [367, 368].  From a 
therapeutic point of view, targeting early stages of HIV viral infection is 
advantageous because it decreases the chances of mutagenic evolution during 
reverse transcription and of establishment of latency  [369]. Liu et al,, showed 
that restriction of HIV-1 resulting from the action of PAF1 occurs in steps prior to 
integration [158] therefore investigating further the mechanism of PAF1 is 
interesting from the therapeutical point of view. 
5.5 Principal findings 
To summarise, in this chapter the following findings were described: 
 Endogenous PAF1 is located in the cytoplasm and nuclei.  
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 Overexpression experiments with murine PAF1 mutants suggest that 
PAF1 exerts its antiviral function from the nucleus and this nuclear 
function might not require chromatin binding.   
 On the other hand HIV-1 counteracts PAF1 by downregulating PAF1 upon 
30 minutes of viral challenge suggesting that early events in viral 
replication need to be protected.  
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6. General discussion 
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6.1 HIV-1 Env signalling significance and possible mechanisms 
Since viruses have small genomes compared to multicellular organisms, in order 
to survive and economise their genomes, virus proteins often have multiple 
functions. For instance, the viral envelope serves various purposes for the virus. 
Firstly, viral envelope proteins are antagonists of cellular receptors and so, it is 
via the envelope protein that viruses recognise and bind to cellular receptors in 
order to gain access into the cell. Secondly, numerous studies have described 
that viral envelope proteins also serve the virus to evade the immune 
response[370]. Some examples of viral glycoproteins that modulate the immune 
response include: Herpes Simplex virus type 1 glycoprotein C [370], Ebola virus 
glycoprotein [371, 372] or the Hepatitis C Virus E1/E2 glycoproteins [373] to 
name a few. In addition to entry and immune evasion, binding of viral 
glycoproteins can mediate signalling events that modulate the cell’s environment 
[374, 375]. In chapter 3 and 4, I aimed to increase the current knowledge in HIV-1 
Env signalling pathways. 
Microtubules are one of the major components of the cytoskeleton and perform 
crucial cellular functions including cell migration, cell polarization and vesicle 
transport [376]. Stable microtubule subsets are highly post-translationally 
modified (by for example, tyrosination and acetylation [377]) whilst less stable 
microtubule subsets have reduced post-translational modifications, are highly 
dynamic and explore the cells environment in a “search and capture” mode [287]. 
McDonald et al., described in 2002 that HIV-1 hijacks the microtubule network in 
order to traffic the reverse transcription complex from the cytoplasm to the nuclei 
[260]; Since then, more recent studies have revealed a physical interaction 
between the viral capsid and microtubule-associated protein 1A (MAP1A) 
required for efficient nuclear translocation [285] and requirement of microtubules 
and dynein, a microtubule-associated protein that pulls cargo along the 
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microtubules in the cell [378] during uncoating [261, 262]. In addition, HIV-1 has 
been shown to induce stable microtubules via a microtubule end-binding protein 
1 regulator, Kif4, [287]. Interestingly, induction of microtubule acetylation has also 
been shown to be induced by Env gp120 incubation [263]. These observations 
would support a requirement for stable microtubules to which the pre-integration 
complex binds to in order to not only shuttle to the nuclei but also protect the viral 
DNA from cytoplasmic degradation [261].  In contrast, I found that expression of 
the Env cytoplasmic gp41 domain decreases microtubule acetylation, possibly via 
a not yet described, signalling mechanism. Malinowsky et al., showed that 
microtubule deacetylation by gp41 CT expression, decreases virus-cell fusion 
[258]. This result would suggest that the gp41 CT signals solely to negatively 
affect virus replication. However, it could be that microtubule deacetylation, has 
an additional function that was not measured in the virus-cell fusion assay 
performed by Malinowsky et al.,that positively affects virus replication. This would 
lead to a model in which both microtubule stabilisation and destabilisation occur. 
It could be that initially, right after the Env cytoplasmic domain is inserted in the 
cytoplasm, the gp41 destabilises the microtubules by deacetylation in order to 
increase the subset of dynamic microtubules which through their search and 
capture dynamic, search and capture incoming HIV-1 particles from the plasma 
membrane. Interestingly, Vaccinia virus has been shown to increase the 
dynamics of microtubules by reducing the levels of acetylation of peripheral 
microtubules which enhances the frequency at which the microtubules reach the 
cell cortex; the mechanism involves inhibition of RhoA by the vaccinia virus 
protein F11L [379]. My results also showed that to decrease microtubule 
acetylation, the full length cytoplasmic tail is required because expression of the 
truncated versions had a weaker effect on tubulin acetylation. It is therefore 
possible that the deleted portion of the tail involves a domain like that of vaccinia 
F11L which interacts with a protein that results in RhoA inhibition and triggers 
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microtubule destabilisation. Zhang et al., described that the C-terminal domain of 
the cytoplasmic tail that includes the deleted portion of the truncated version, 
interacts with P115-RhoGEF, an activator of RhoA. It would therefore be 
interesting to investigate whether knockdown of P115-RhoGEF abolishes the 
microtubule deacetylation observed upon CT expression as well as to measure 
by live cell imaging whether there is more incoming virus in CT-expressing cells. 
Destabilisation (as reported in the present thesis) and stabilisation of 
microtubules (as shown in the literature) could both be exerted through different 
mechanisms and for different functions that benefit viral replication. Therefore, a 
model by which the cytoplasmic tail signals to decrease microtubule stability and 
facilitate virus capture from the membrane, is not exclusive with a model whereby 
microtubule stability is then required for shuttling of the pre-integration complex to 
the nuclei (Figure 6.1).  
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Figure 6.1. Model of possible Env signalling in HIV-1 infection through Rho-
GTPases. This model includes two mechanisms that are not exclusive as a result of my 
results and those of others [254-256, 283]. In (1), the Env protein binds to CD4 and 
CXCR4 which triggers activation of downstream Gα1,2 protein. This in turn, activates and 
signals to GAPs and GEFs that activate Rac1, cdc42 and RhoA; this then, triggers 
activation of cofilin to break down the actin barrier and stabilise microtubules for shuttling 
the pre-integration complex to the nuclei.  In (2), the Env cytoplasmic tail could hijack a 
Rho-GEF that activates Rac1 or RhoA and trigger the observed microtubule 
destabilisation via inactivation of either or both Rac1 or RhoA. The objective of this 
destabilisation could be to increase the microtubules instability and promote the search 
and capture of incoming virus from the membrane cortex. 
 
RhoA is a known regulator of microtubule dynamics via the RhoA-DIA pathway 
[264] and of actin polymerisation through the ROCK-LIMK1-cofilin pathway [347]. 
The role of RhoA in HIV-1 infection has not been described even though HIV 
requires stable microtubules early in infection [260, 261, 287] and overcomes 
cortical actin restriction for entry via Env-triggered cofilin activation [80]. It is also 
known that RhoA and Rac1 can regulate each other [272]. Rac1 is involved in 
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actin polymerisation by PAK-LIMK1 [231] and in microtubule stability via stathmin 
[266]. Env activation of Rac1 has been described [254-256, 283]. Both the mutual 
Rac1-RhoA regulation together with the fact that both Rac1 and RhoA control 
functions that affect negatively (actin polymerisation) and positively (microtubule 
stabilisation) HIV replication, suggest that the role of RhoA and Rac1 in HIV is 
complex. This is possibly why, results from the screen did not show a uniform 
conclusion as to whether knocking down an activator or inactivator of for example 
RhoA had a positive or negative effect on HIV infection. However, independently 
of being an activator or inactivator of RhoA, knockdown of RhoA upstream 
regulators caused an inhibition effect on HIV-1 replication especially for HIV-1 
BaL and in the case of Rac1, knockdown of identified activators of Rac1 majorly 
caused inhibition of HIV-1 infection. Their multiple relevant functions in HIV 
makes both Rac1 and RhoA interesting therapeutical targets and so, it is 
therefore important to further confirm and understand the role of the upstream 
effectors identified. 
The screen also revealed a novel role for upstream regulators of cdc42 in HIV-1 
infection, not previously characterised which were different depending on the 
HIV-1 virus strain assayed. Since cdc42 is upstream of cofilin, known to be 
activated through Env-signalling via CXCR4 [80, 252], it would be interesting to 
understand further the consequences of knockdown of specific GAPs and GEFs 
that control cdc42 upon infection to understand whether Env-mediated cofilin 
activation is triggered specifically via these proteins upon receptor engagement. 
Taking into account the array of GAPs and GEFs that showed an effect 
specifically on NL4.3 and BaL, one question is whether at the physiological levels 
of expression of Env in HIV-1 infected patients, these signalling pathways are 
relevant since it is possible that the levels of expression in in vitro models are 
much higher than in patients [242, 380]. As argued by Wu et al., much of the 
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reservoirs of HIV-1 are found in lymphatic tissue and so, it is difficult to measure 
based only on plasma viral load[242]. However, a study performed by Melar et 
al., suggested that at physiological levels Env is able to trigger signalling events 
[381].  
Targeting GEFs and GAPs offers an advantage over targeting for example, actin 
or the actual Rho GTPases: they are oftenly tissue-specific [382]; it would 
therefore be interesting to evaluate whether these proteins are expressed 
specifically in T-cells and/or macrophages. Understanding further the differences 
in signalling events upon infection by X4 and R5-tropic viruses, could be 
determinant in finding novel therapies that aim to target the co-receptor usage 
switch from R5 to X4 that has been described previous to AIDS development 
[292] and which are more strain-specific. 
6.2. The role of PAF1 in HIV-1 infection 
Since its discovery, as part of the PAF1 complex [189, 190], increasing evidence 
on the role of PAF1 has revealed multiple nuclear functions. For instance, PAF1 
is found associated with nuclear proteins that control transcription initiation [187], 
transcription elongation [189, 203, 383] and post-transcriptional processing of 
mRNA [206-208]. In addition to these functions, PAF1 also has an additional 
nuclear role in gene regulation which is regulation of histone modifications [212, 
384, 385]. However, PAF1 has also been shown to be expressed in the cell’s 
cytoplasm [196, 351] and its role in the cytoplasm has not been described. My 
results showed that PAF1 localises mainly in the nuclei and to a lesser extent in 
the cytoplasm, which agrees with the evidence so far, regarding its localisation. In 
addition, PAF1 has been described to have a role not only in HIV-1 infection 
[158, 209] but also in adenovirus [210, 386] and influenza virus infection [212]. 
Both Marazzi I et al., and Fonseca et al., describe a role of PAF1 in influenza and 
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adenovirus infection that involves the recruitment of PAF1 for viral transcriptional 
activation, ie. a positive role for the virus. Liu.L et al., described a novel role of 
PAF1 that restricts HIV-1 virus infection at a step post-entry but previous to 
integration, ie. a negative or inhibiting role against the virus [158]. Therefore, the 
PAF1 mechanisms described for influenza virus or adenovirus are different to the 
mechanism of PAF1 in HIV-1 restriction. However, the Marazzi et al. study 
described that whilst influenza virus infection elicits a strong upregulation of a 
number of genes that include inflammatory and immune response genes, in 
PAF1 knockdown cells the response was reduced, suggesting that PAF1 is 
involved in upregulation of possible antiviral genes against influenza virus [212]. 
It is possible that PAF1 also regulates transcription of antiviral genes upon HIV-1 
infection. For instance, results of the overexpression of murine cytoplasmic PAF1 
(PAF1ΔNLS) had a similar effect on HIV-1 89.6 infection compared to PAFWT, 
suggesting that the role is not a cytoplasmic but a nuclear role. Interestingly, 
overexpression of a PAF1 mutant that is not able to bind to chromatin, decreased 
infection more potently than the murine wild-type PAF1 suggesting that the role of 
PAF1 in infection could be a nuclear role that is not directly related to chromatin 
binding. For instance, to regulate histone methylation, PAF1 binds to 
chromohelicase DNA-binding protein I[385]; it could be that to exert its antiviral 
function against HIV-1, PAF1 regulates gene expression by control of DNA 
methylation via other proteins such as chromohelicase DNA-binding protein as 
mediators thus, avoiding the chromatin binding function. 
Interestingly, upon 30 minutes of incubation with HIV-1, PAF1 is downregulated 
and the levels of PAF1 recover to basal levels within one hour. This rapid 
counteraction of PAF1 by HIV-1 supports a model (Figure 6.2) whereby HIV-1 
enters into the cell with a protein that targets PAF1 for degradation.  
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Figure 6.2. Model of possible mechanism by which HIV-1 counteracts PAF1 and 
PAF1 restricts HIV-1.  In the proposed model, PAF1 has a nuclear role that does not 
involve chromatin binding but that could possibly involve gene expression regulation. On 
the other hand, HIV-1 counteracts PAF1 early in infection in a step previous to reverse 
transcription that could involve a protein (in red) that the virus releases upon uncoating. 
 
Results from the final experiment, support this model since the downregulation 
effect was less prominent in cells that had been treated with CD4 (and as a 
consequence had less internalised capsid) than in untreated cells. Counteraction 
of restriction factors by HIV-1 has previously been described. For example, 
tetherin is counteracted by Vpu which targets tetherin to an ER-associated and 
lysosomal degradation pathway [170, 171]. The influenza virus NS1 protein has a 
histone mimic domain that is able to bind to PAF1 [212]. It would be interesting to 
investigate whether any of the accessory proteins of HIV-1 has a similar histone 
mimic domain that could enable PAF1 binding. The HIV-1 restriction factor, 
SAMHD1 is downregulated by SIV-encoded Vpx [177, 178]. Interestingly, 
SAMHD1 restricts HIV-1 through a cytoplasmic function but actually is 
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downregulated in the nuclei by Vpx [179]. It could be that, oppositely to SAMHD1, 
since PAF1 is degraded so fast upon viral challenge, it is degraded in the 
cytoplasm although it has a nuclear antiviral function.  
As to how the effect of PAF1 could translate to a patient situation it is worth 
mentioning that PAF1 is expressed in primary human T-cells, monocytes and 
macrophages and that it also acts to neutralise HIV-2 and SIV  isolates which 
highlights its physiological relevance not only in the HIV-1 context but also as a 
broad-acting antiretroviral. Since PAF1 is involved in crucial cellular functions, it 
could be that the major therapeutical  benefits arise from its mechanism and the 
possible other proteins implicated rather than as a direct target, which is why 
further characterisation of this mechanism is required. 
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Appendix 2. List of GEFs and GAPs included in siRNA screen (chapter 4) 
 
 GEF/GAP Gene name   
1 GEF SWAP70 
2 GEF  SGEF 
3 GEF PREX1 
4 GEF GEFT 
5 GEF ARHGEF10 
6 GEF FLJ10521 
7 GEF FGD6 
8 GEF DNMBP 
9 GEF MCF2 
10 GEF MCF2L 
11 GEF DOCK4 
12 GEF DOCK5 
13 GEF DOCK6 
14 GEF DOCK7 
15 GEF DOCK8 
16 GEF NGEF 
17 GEF FGD2 
18 GEF SPATA13 
19 GEF MCF2L2 
20 GEF DEF6 
21 GEF FGD4 
22 GEF ARHGEF19 
23 GEF FGD3 
24 GEF DOCK10 
25 GEF PLEKHG5 
26 GEF DOCK9 
27 GEF AKAP13 
28 GEF LOC351864 
29 GEF ECT2 
30 GEF FARP1 
31 GEF FARP2 
32 GEF ABR 
33 GEF ALS2 
34 GEF ARHGEF3 
35 GEF ARHGEF4 
36 GEF ARHGEF10 
37 GEF ARHGEF15 
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38 GEF BCR 
39 GEF PLEKHG2 
40 GEF DOCK1 
41 GEF DOCK2 
42 GEF DOCK3 
43 GEF FLJ10665 
44 GEF NET1 
45 GEF C9ORF100 
46 GEF     FLJ20148 
47 GEF ITSN1 
48 GEF ITSN2 
49 GEF ARHGEF12 
50 GEF ARHGEF2 
51 GEF KIAA1639 
52 GEF ARHGEF18 
53 GEF ARHGEF1 
54 GEF ARHGEF17 
55 GEF ARHEGF11 
56 GEF ARHGEF9 
57 GEF ARHGEF6 
58 GEF ARHGEF7 
59 GEF RASGRF1 
60 GEF RASGRF2 
61 GEF SOS1 
62 GEF SOS2 
63 GEF TIAM1 
64 GEF TIAM2 
65 GEF ARHEGF5 
66 GEF TRIO 
67 GEF VAV1 
68 GEF VAV2 
69 GEF VAV3 
70 GEF FGD5 
71 GEF PLEKHG1 
72 GEF RGNEF 
73 GEF FLJ10357 
74 GEF PLEKHG4B 
75 GEF PLEKHG7 
76 GEF DOCK11 
77 GEF FGD1 
78 GEF KALRN 
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79 GEF PLEKHG4 
80 GEF PLEKHG3 
81 GAP 7H3 
82 GAP ARHGAP1 
83 GAP ARHGAP10 
84 GAP ARHGAP11A 
85 GAP ARHGAP12 
86 GAP ARHGAP15 
87 GAP ARHGAP17 
88 GAP ARHGAP18 
89 GAP ARHGAP19 
90 GAP ARHGAP20 
91 GAP ARHGAP21 
91 GAP ARHGAP22 
93 GAP ARHGAP23 
94 GAP ARHGAP24 
95 GAP ARHGAP25 
96 GAP ARHGAP26 
97 GAP ARHGAP28 
98 GAP ARHGAP4 
99 GAP ARHGAP5 
100 GAP ARHGAP6 
101 GAP ARHGAP8 
102 GAP ARHGAP9 
103 GAP BNIP2 
104 GAP C5ORF5 
105 GAP CDGAP 
106 GAP CENTD1 
107 GAP CENTD2 
108 GAP CENTD3 
109 GAP CHN1 
110 GAP CHN2 
111 GAP DEPDC1 
112 GAP DEPDC1B 
113 GAP DLC1 
114 GAP FKSG42 
115 GAP FLJ13815 
116 GAP FLJ30058 
117 GAP 37 FLJ32810 
118 GAP GMIP 
119 GAP GRLF1 
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120 GAP HA-1 
121 GAP INPP5B 
122 GAP KIAA0672 
123 GAP KIAA1688 
124 GAP LOC201176 
125 GAP LOC257106 
126 GAP LOC389211 
127 GAP MYO9A 
128 GAP MYO9B 
129 GAP OCRL 
130 GAP OPHN1 
131 GAP PARG1 
132 GAP PIK3R1 
133 GAP PIK3R2 
134 GAP RACGAP1 
135 GAP RALBP1 
136 GAP RICS 
137 GAP SH3BP1 
138 GAP SNX26 
139 GAP  SRGAP1 
140 GAP SRGAP2 
142 GAP SRGAP3 
143 GAP STARD13 
144 GAP STARD8 
145 GAP TAGAP 
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Appendix 3. Observed monolayer coverage after siRNA knockdown and HIV-1 NL4.3 and BaL infection (raw data) 
(A) Observed cell monolayer coverage in each well after GEFs siRNA knockdown and HIV-1 NL4.3 infection.  
 
(B) Observed cell monolayer coverage in each well after GEFs siRNA knockdown and HIV-1 BaL infection.  
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(C) Observed cell monolayer coverage in each well after GAPs siRNA knockdown and HIV-1 NL4.3 infection. 
 
(D) Observed cell monolayer coverage in each well after GAPs siRNA knockdown and HIV-1 BaL infection. 
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Appendix 4.Western-Blot of the cellular fractionation of PAF1 
 
Hela-CD4+ cells were treated with 0.1% NP40 in PBS for 1 and 4 minutes. Cells 
were fractionated into nuclear (Nuc) and cytoplasmic (Cyto) fractions and PAF1, 
GAPDH (cytoplasmic marker) and histone 3 (nuclear marker) were analysed by 
Western-Blot.  
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Appendix 5. PAF1 staining quantification repeats 
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